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Abstract 
 In fungi, the iterative, non-reducing polyketide synthases (NR-PKSs) are 
responsible for the biosynthesis of aromatic polyketide products. While the modular type 
I PKSs have been extensively studied for 20 years, the biochemistry of NR-PKS is only 
now beginning to be elucidated. The NR-PKSs share a common domain architecture that 
is intrinsically linked to their function. The mode of biosynthesis is analogous to that of 
fatty acids by animal fatty acid synthases (FAS), but simplified. The three N-terminal 
domains, the starter unit:acyl-carrier protein transacylase (SAT), ketosynthase (KS) and 
malonyl acyl transferase (MAT) domains are responsible for the initiation and polyketide 
elongation phases. The SAT domain selects a precursor or starter unit substrate as an acyl 
thioester while the MAT domain introduces ketide extender units from malonyl-CoA. 
The KS works in collaboration with the acyl-carrier protein (ACP) to catalyze the 
decarboxylative Claisen condensation of these substrates generating a linear, ACP-bound 
β-ketone intermediate. The C-terminal domains of NR-PKSs control the final stage of 
biosynthesis, which includes regiospecific aldol cyclizations/aromatizations by the 
product template (PT) domain and product release by the thioesterase (TE) domain. In 
this way, the four factors governing chemical diversity in aromatic polyketides are 
entirely controlled by the enzyme, with the N-terminal half determining starter unit 
selection and chain length, and the C-terminal half controlling the cyclization pattern and 
mode of product evolution. Our lab has innovated the use of enzyme deconstruction in 
NR-PKSs to determine the catalytic program of these enzymes. The enzyme 
deconstruction approach requires the dissection of an individual NR-PKS into its 
constituent domains or multidomain fragments. Mono- and multidomain fragments are 
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expressed and purified individually and then recombined in vitro, reconstituting wild-
type activity. 
 Using the enzyme deconstruction approach, the catalytic activity of CTB1—the 
NR-PKS of cercosporin biosynthesis in the fungal plant pathogen Cercospora 
nicotianae—was determined. The CTB1 TE domain was demonstrated to catalyze an 
unprecedented enol-lactonization to form the naphthopyrone nor-toralactone—
representing an expansion of known TE chemistry. The formation of nor-toralactone was 
unexpected and in conflict with the accepted cercosporin biosynthetic pathway. Using a 
combination of gene knockout strains and in vitro enzymology, a new cercosporin 
biosynthetic pathway was identified. Of particular interest was the activity of an unusual 
didomain enzyme CTB3. The flavin-dependent monooxygenase domain of CTB3 was 
identified to catalyze a unique oxidative aromatic ring cleavage—expanding the chemical 
repertoire of these ubiquitous proteins. Enzyme deconstruction served as the basis of an 
NR-PKS engineering project in which homologous domains from non-cognate parent 
NR-PKSs were swapped in vitro to produce non-native polyketide products. Using a 
systematic approach to domain-swapping, several rules governing rational engineering of 
NR-PKS were codified. Domain-swapping of deconstructed NR-PKSs facilitated rational 
engineering of intact, chimeric NR-PKSs. A library of chimeric NR-PKSs was prepared 
and selected members were assayed for activity. Combining the rules of engineering 
gleaned from deconstructed NR-PKS domain-swapping and the construction of the 
chimeric NR-PKS library, an attempt to rationally design a topopyrone synthase was 
unsuccessfully made. By examining the activities of individual domains and perturbing 
the composition of NR-PKSs, we have made invaluable insights into the NR-PKS 
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Chapter 1: An Introduction to Polyketide Biosynthesis 
1.1. Introduction 
The polyketides are an astounding class of natural products encompassing a 
structurally and functionally diverse set of metabolites (Figure 1.1). Polyketides are 
produced by an immense array of organisms including bacteria, fungi, and plants 
occupying an incalculable number of ecological niche environments. Because of their 
structural variability, it is not surprising that they display a huge range of biological 
activities and thus represent some of the most commercially important natural products.[1] 
They serve as potent pharmaceuticals including the hugely successful cholesterol-
lowering agent lovastatin, the immunosuppressant rapamycin, the anti-cancer agent 
Figure 1.1"Representative sample of polyketide natural products. 
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daunomycin, and the antibiotic erythromycin. Many agriculturally destructive fungal 
mycotoxins are of polyketide origin including aflatoxin B1, cercosporin, patulin, and 
fumonisin B1. Still others can act as food coloring additives (e.g. curcumin) while others 
show great promise as potential therapeutic agents (e.g. dynemicin A). Understanding the 
biosynthetic origin of polyketide structural variation is of critical importance for new 
product discovery and rational engineering of polyketide pathways, especially 
considering the rapid growth of fully sequenced microbial genomes. The biosynthesis of 
polyketides has been reviewed elsewhere.[2] Here I present an abbreviated primer for 
understanding polyketide biosynthesis. 
 Despite their structural diversity and widespread source organisms, the 
polyketides share a common biosynthetic origin.[3] The carbon skeleton of all polyketide 
products derives from simple carboxylic acids and their derivatives with acetate serving 
as the standard precursor. In this way, polyketide biosynthesis is analogous to fatty acid 
biosynthesis from primary metabolism. In fact, the enzymes of polyketide biosynthesis 
are often homologous to their counterparts from fatty acid biosynthesis. As early as 1955, 
Figure 1.2"Earliest model systems for polyketide biosynthesis. (a) Collie’s synthesis of orcinol (4) from 
dehydroacetic acid (1) implied a triketone intermediate (2). (b) Using a radiolabel tracer assay, Birch 
demonstrated that 6-MSA (8) was the product of head-to-tail Claisen condensation of four acetate units. 
Dots indicate positions of radioisotope 14C incorporation. 6-MSA is converted to the phytotoxin patulin (9). 
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Arthur Birch recognized the connection between polyketide biosynthesis and fatty acid 
biosynthesis despite the limited knowledge of either pathway at the time.[4] 
 As with fatty acid biosynthesis, the central process of polyketide biosynthesis is 
carbon–carbon bond formation between acetate units. Birch hypothesized that—like fatty 
acids—repeated condensation of acetate units could generate a “poly-β-ketone,” which—
in turn—could serve as the reactive intermediate for aromatic natural products (Figure 
1.2b). Birch’s hypothesis was indeed a rediscovery of an earlier idea proposed by James 
Collie in 1893.[5] Collie was attempting to prove the structure of dehydroacetic acid (1) 
through degradation. When boiling the acid in barium hydroxide produced the aromatic 
orcinol (4), Collie happened upon a crucial finding. He proposed that orcinol production 
from dehydroacetic acid proceeded through a polyketone intermediate (2) and that such 
transformations could account for similar biological aromatic compounds—a bold claim 
for the time (Figure 1.2a). Although his contemporaries rejected this hypothesis, we now 
know it to be true and the foundation of polyketide biosynthesis. 
 Confirmation of the polyketone hypothesis was provided by Birch in an elegant 
radioisotope-labeling experiment.[4] Birch chose 6-methyl-salicylic acid (6-MSA, 8) as 
his test subject—a polyketide produced by the fungus Penicillium patulum as an 
intermediate in the biosynthesis of patulin (9).[6] By feeding the fungus acetate—the 
proposed precursor metabolite—labeled with 14C at the C1 position, the pattern of 
radioactive isotopes incorporation in 6-MSA could be used to determine the metabolite’s 
biosynthetic origin. The observed labeling pattern in 6-MSA suggested that the 
metabolite derived from the “head-to-tail” linkage of four acetate units producing a 
triketo acid (5, Figure 1.2b). Reduction of the C5 ketone of intermediate 5 followed by an 
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intramolecular aldol condensation and two dehydrations would result in 6-MSA with the 
observed labeling pattern. 
Birch’s findings were groundbreaking and radioisotope-labeled acetate feeding 
assays became the norm in the natural products community. Labeling assays became 
even more powerful with the advent of NMR and MS[7]—both techniques that 
accelerated the rate of discovery in the field. At long last, the Collie-Birch polyketide 
hypothesis gained general acceptance and not just for aromatic natural products. It was 
soon realized that the repeated condensation of acetate units accounted for the 
biosynthesis of a huge class of natural products—the polyketides. 
1.2. Polyketide Synthases 
Polyketide synthases (PKSs) are the enzymes responsible for the initial phases of 
polyketide natural product formation by setting the carbon skeleton of the eventual 
Figure 1.3"General mechanism for polyketide biosynthesis by PKSs. The central mechanism of 
polyketide biosynthesis is repeated Claisen condensations of acetate units catalyzed by the KS. The AT 
domain introduces malonyl extender units from malonyl-CoA. The ACP tethers the growing poly-!-ketone 
intermediate via a thioester linkage to a phosphopantetheine modification (16). Following each round of 
extension, the PKS can process the !-position through the action of KR, DH, and ER domains. !-position 
processing determines the catalytic program. 
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metabolite (Figure 1.3).[2a, 8] The PKSs are homologous in both form and function to the 
fatty acid synthases (FASs) of primary metabolism. Repeated acetate homologation to 
form the polyketone intermediate is the central reaction of polyketide biosynthesis and is 
the primary function of the PKSs. This reaction is accomplished through decarboxylative 
Claisen condensation between an acyl thioester and a malonyl thioester (11)—usually 
derived from malonyl-CoA. The reaction is universally catalyzed by a β-ketoacyl 
synthase (KS)—the indispensible feature of all FASs and PKSs. As with FASs, the 
malonyl extender unit and growing polyketone intermediate are covalently tethered to an 
acyl carrier protein (ACP) via a thioester linkage (12). The thioester tether is provided by 
the terminal thiol of a phosphopantetheine (PPT) post-translational modification to a 
critical Ser residue on the ACP (16). The final essential feature of most PKSs is the acyl 
transferase (AT)—an enzyme responsible for the transfer of an acyl extender unit from 
CoA to the ACP via a transient AT-linked acyl ester (10). 
 As in fatty acid biosynthesis, the PKSs can further process the nascent β-keto-
ACP thioester (12) through serial reduction at the β-ketone. Initial reduction at this 
position is catalyzed by a ketoreductase (KR), resulting in a secondary alcohol (13). 
Dehydration of this alcohol to form an α,β unsaturated thioester (14) is catalyzed by the 
dehydratase (DH). Finally, reduction of the unsaturated intermediate 14 by the 
enoylreductase (ER) generates a fully saturated thioester (15). Following reductive 
processing, transthioesterification from the ACP to the active site Cys of the KS initiates 
another round of acetate extension. Product release in the FASs is catalyzed by a 
thioesterase (TE), which catalyzes the hydrolysis of the acyl-ACP thioester to generate 
the free acid. TEs exist in PKSs where they serve the same function of product release, 
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but often with expanded chemistry. Unlike FASs, PKSs can employ any number of 
reductive steps or forego any reductive transformations to generate intermediates of great 
chemical complexity. Additionally, they can incorporate the activity of C-
methyltransferases (CMeTs) to methylate the α-position of the β-keto-ACP thioester (12). 
This unique feature of PKSs is termed programing. Programing controls not only the 
degree of reduction, but also the chain length and mechanism of product release. The 
structural basis for programing is dependent upon the type of PKS—detailed below—and 
in some cases is still unknown. 
 The FASs fall into two classes named type I and type II. The type I FASs are 
large, multifunctional enzymes in which a single protein—or pair of proteins that work in 
complex—contains all of the necessary catalytic functionalities as individual domains 
(KS-AT-DH-ER-KR-ACP-TE).[9] Type I FASs are found in both fungi and animals—
although their architectures differ. Crystal structures of both fungal[10] and animal[11] 
FASs have been solved revealing significant structural differences commensurate with 
their divergent domain architecture. The type II FASs are complexes of many single 
proteins each with its particular function.[12] The individual proteins of type II FASs work 
in trans to accomplish fatty acid biosynthesis. Type II FASs are found in bacteria and 
plants. Generally, the individual members of type II FASs are structurally similar to their 
homologous domains in type I FASs. Both type I and type II FASs function iteratively—
meaning active sites are reused during the catalytic cycle. 
 PKSs are also classified into types corresponding to the homologous FAS types. 
Type I PKSs are large, multidomain proteins where each domain catalyzes a specific 
transformation in polyketide formation.[2a, 3a] Type I PKSs can be further classified as 
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modular[2d] or iterative.[13] The modular PKSs function in a fashion analogous to an 
assembly line. Unlike type I FASs where active sites are reused during the catalytic cycle, 
in the modular PKSs a dedicated module containing the necessary functional domains 
catalyzes each individual acetate extension and subsequent β-ketone processing. The 
growing polyketide intermediate is then passed to the next module in the assembly line, 
which catalyzes its prescribed extension and β-ketone processing. In this way, each 
domain of these gigantic megasynthases is responsible for only a single reaction. The 
iterative type I PKSs are structurally simpler, but retain the more complex iterative 
functionality observed in their type I FAS homologs. Like their FAS counterparts, type II 
PKSs contain many individual proteins that work in complex to catalyze iterative 
polyketide formation.[2c, 14] A third type—type III PKSs—has no FAS homolog.[15] 
Instead, these enzymes function as stand-alone KSs without the typical AT, ACP, or TE 
functionalities. Type I PKSs are found in bacteria and fungi. Type II PKSs are only found 
in bacterial. Type III PKSs are found in bacteria, fungi, and plants. 
 David Hopwood—a venerated natural products researcher—conducted much of 
 
Figure 1.4⏐Actinorhodin is the primary model system for type II PKS biosynthesis. The central 
actinorhodin gene cluster from S. coelicolor is shown. Each member of the PKS exists as its own, stand-
alone protein. These proteins work in complex to carry out the biosynthesis of actinorhodin. 
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the early work in identifying the PKSs as the central enzymes of polyketide biosynthesis 
in the 1980s.[16] His model system was actinorhodin biosynthesis in Streptomyces 
coelicolor (Figure 1.4). Actinorhodin (21)—an antibiotic of the isochromanequinone 
class—was chosen due to its distinctive blue pigmentation. Through careful inactivation 
of specific S. coelicolor genes, Hopwood was able identify those responsible for the 
cessation of pigmentation and—therefore—actinorhodin biosynthesis. Gene 
sequencing—a challenging task at the time—identified several type II FAS homologs 
establishing the functional link between fatty acid biosynthesis and polyketide 
biosynthesis as well as identifying the first type II PKS. Three open reading frames were 
eventually identified as encoding the type II minimal PKS.[17] The protein products of 
these genes comprised a KS heterodimer and ACP—the only domains necessary for 
successful acetate extension. Downstream enzymes included a KR, aromatase (ARO), 
and cyclase (CYC), which work in tandem to catalyze regiospecific reduction and 
cyclization of the poly-β-ketone directing the intermediate toward actinorhodin.[18] It was 
later discovered that the minimal PKS is a universal feature of type II PKSs and not only 
conducts acetate extension but also controls the final chain length of the polyketide 
product. As seen with actinorhodin, downstream “tailoring” proteins—e.g. ARO, CYC, 
KR, CMeT—exert control over polyketide programming through regiospecific catalysis. 
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Following Hopwood’s success with actinorhodin, other laboratories entered the 
fray searching for still more PKSs. The groups of Peter Leadlay[19] and Leonard Katz[20] 
independently—and using complementary methods—discovered the genes responsible 
for the formation of 6-deoxyerythronolide B (6-dEB, 22)—the polyketide precursor to the 
antibiotic erythromycin A from Saccharopolyspora erythraea (Figure 1.5). To their 
surprise, the PKS was encoded in three enormous open reading frames—eryAI, eryAII, 
and eryAIII—each producing a large, multidomain protein—DEBS 1, 2, and 3, 
respectively—together called the 6-deoxyerythronolide B synthase. Individual domains 
of the DEBS proteins bore homology to FAS and putative PKS domains. Of even greater 
interest was the domain architecture of the DEBS complex. The repetitive nature of the 
domains suggested a modular, assembly-line style of biosynthesis in which each module 
provided for a single acetate extension and subsequent !-ketone processing. Indeed, it is 
now known that modular PKSs are collinear with their eventual products, making product 
prediction a simple task of deciphering the polypeptide sequence.[2d] The modular nature 
Figure 1.5"The 6-deoxyerythronolide B synthase is the model system for modular type I PKS. The 
modular type I PKSs are huge megasynthases where each domain is used only once in the production of the 
polyketide product. Sets of domains are organized into modules responsible for a single acetate extension 
and subsequent !-position processing. Biosynthesis is linear with each module passing the growing 
intermediate to the next making biosynthesis analogous to an assembly line. 
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of these PKSs also account for the programing inherent in these enzymes. DEBS remains 
the model system for type I modular PKSs and has served as the basis of significant 
engineering and structural biology efforts. 
1.3. Fungal, Iterative PKSs 
 The subset of fungal polyketides is incredibly diverse.[13] Fungal polyketides 
include some of the simplest natural products—e.g. orsellinic acid or 6-MSA—as well as 
some of the most complex metabolites—e.g. fumonisin B1 or lovastatin. Despite this 
apparent structural variety, iterative type I PKSs are responsible for the biosynthesis of 
nearly all fungal polyketides.[21] Whereas the programing inherent to the modular PKSs is 
explicit, the enzymatic control over polyketide programing is cryptic in the iterative 
PKSs. It is postulated that the catalytic program is encoded within the PKS itself; 
however, little is understood about the elements governing programing. Indeed, 
understanding catalytic programing in iterative PKSs remains one of the greatest 
unsolved challenges in natural products biosynthesis. 
 Innovative research conducted by Lazarus and Simpson helped to clarify the 
programming conundrum in fungal, iterative PKSs.[22] They categorized the fungal 
polyketides into two groups based upon their structures: nonreduced metabolites—largely 
encompassing the aromatic polyketides—and partially reduced metabolites—a group 
containing 6-MSA. Later a third category of highly reduced metabolites—an incredibly 
diverse class including metabolites such as fumonisin B1 and lovastatin—were included 
in the analysis.[23] Believing that subtle differences in protein sequence accounted for the 
structural differences in the eventual polyketide product, they compared the KS domains 
of PKS genes known at the time by preparing product class-specific degenerate KS 
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primers. Using these class-specific degenerate primers, they amplified many fungal PKS 
genes from genomic DNA. After carefully analyzing the resulting sequences, they 
discovered that indeed each class of polyketide corresponded to a family of PKSs with 
specific and distinct domain architectures. These enzymes were classified as the 
nonreducing PKSs (NR-PKSs), the partially reducing PKSs (PR-PKSs), and the highly 
reducing PKSs (HR-PKSs), respectively.[13, 21] In recent years, widespread fungal genome 
sequencing projects have revealed multiple PKSs exist in each organism. Nevertheless, 
each of these genes fall within one of the three originally identified fungal, iterative PKS 
classes. 
1.4. Non-reducing PKSs 
The NR-PKSs have become the best-understood family of fungal, iterative PKSs. 
Much of this knowledge derives from pioneering work conducted within the Townsend 
Figure 1.6"The norsolorinic acid synthase PksA is the model system for iterative type I NR-PKSs. 
Biosynthesis occurs in three stages: (i) initiation, (ii) elongation, (iii and iv) cyclization and release. The 
canonical NR-PKS domain architecture is indicated. Unique domains to NR-PKSs include the starter 
unit:ACP transacylase (SAT) and product template (PT). 
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group to elucidate the enzymatic control of polyketide programing. This work forms the 
foundation of much of the research presented in this dissertation. NR-PKSs catalyze the 
synthesis of aromatic polyketide metabolites. Because they lack any of the reductive 
domains found in either FASs or other PKSs, no change of oxidation state occurs at the 
β-position during acetate extension. In this way, the NR-PKSs form the critical poly-β-
ketone intermediate, which undergoes regiospecific cyclization/aromatization and 
release, producing aromatic metabolites (Figure 1.6). NR-PKSs share a common domain 
architecture that includes the canonical KS, AT—here more specifically named the 
malonyl-CoA:ACP transacylase (MAT) domain—and ACP domains. Unique to the NR-
PKSs are the starter-unit:ACP transacylase (SAT)[24] and product template (PT)[25] 
domains. Additionally, many NR-PKSs contain a TE domain, although these domains 
often conduct more complicated transformations than simple hydrolysis. 
 The primary model system for studying NR-PKS biochemistry is PksA from the 
destructive agricultural pathogen Aspergillus parasiticus (Figure 1.6).[26] PksA is the 
central enzyme implicated in the biosynthesis of aflatoxin B1 (27)—a potent mycotoxin 
which undergoes epoxidation in the liver activating the DNA intercalator for 
crosslinking.[27] PksA catalyzes the formation of noranthrone (25) from a hexanoyl fatty 
acid precursor[28] produced by a pair of dedicated fungal FASs—HexA and HexB[29]—
and seven malonyl-CoA extender units. Noranthrone is converted to norsolorinic acid 
(26)—the first isolable intermediate of the aflatoxin pathway—through the activity of an 
anthrone oxidase,[30] although this oxidation can occur spontaneously in aqueous solution. 
The biosynthetic pathway proceeds through a complicated series of oxidative 
rearrangements, eventually generating aflatoxin. Prolonged ingestion of aflatoxin-
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contaminated food is linked to an increased risk for hepatocellular and renal 
carcinomas.[31] 
1.4.1. Enzyme Deconstruction 
 Traditionally, limited proteolysis has been a powerful method for studying 
multidomain proteins.[32] By subjecting a multidomain protein to partial proteolysis, 
individual functional domains can be excised and assayed. Such approaches were 
invaluable in elucidating the biosynthesis of mammalian FASs.[33] The dissection-
reconstitution approach became very attractive for those wishing to understand NR-PKS 
enzymology. Townsend and coworkers sought to deconstruct the model system PksA in 
order to understand its biochemistry. Despite a herculean effort, PksA remained an 
elusive target for heterologous expression. Indeed, the NR-PKSs have been notoriously 
difficult to proteins to express and purify. Without native soluble protein, limited 
proteolysis was impossible. A new approach had to be considered. 
 That new approach came in the form of bioinformatics and the Udwary-Merski 
algorithm (UMA).[34] UMA provided a reliable and general method for determining the 
domain boundaries and linker regions of multidomain proteins. The algorithm required 
two inputs: a multiple sequence alignment of the multidomain protein of interest and 
secondary structure prediction for each member of the multiple sequence alignment. 
From this input, an UMA score would be calculated for each position in the alignment 
that reflected the degree of primary sequence homology, the degree of predicted 
secondary sequence homology, and the hydrophobicity for a given position. It was 
demonstrated that linker domains corresponded to low UMA scores due to their inherent 
primary sequence variability, low secondary structure, and low hydrophobicity. UMA 
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analysis of PksA indicated the presence of six defined domains including two previously 
unappreciated domains: an N-terminal domain bearing limited predicted secondary 
sequence homology to the AT domains of FASs and PKSs and a central domain of 
unknown function and no predicted homology. These domains were eventually classified 
as the SAT and PT domains, respectively. Indeed, it was found that these domains were 
not exclusive to PksA, but highly conserved among the NR-PKSs contributing to the 
canonical domain architecture of the subclass. 
 UMA not only helped in determining the domain architecture of the NR-PKSs, 
but also aided artificial proteolysis of PksA for mechanistic determination in vitro. Using 
contemporary cloning strategies, Townsend and coworkers were able to heterologously 
express the PksA enzyme as mono- to multidomain fragments in E. coli. Their results 
were reported in a landmark paper where—remarkably—these protein fragments retained 
their wild type activity when recombined in vitro.[26] The dissection-reconstitution 
approach has been widely adapted for a variety of NR-PKSs and has formed the 
foundation for both biochemical and structural assays. At last, a reliable method for 
studying the in vitro biochemistry of the NR-PKSs was achieved and these enigmatic 
enzymes began to reveal their secrets. 
1.4.2. The Starter Unit Effect 
 For over 60 years, a rich history of radioisotopic and later stable isotopic tracer 
assays established that—in most fungal polyketides—the fungal PKS selects a dedicated 
starter unit precursor to initiate biosynthesis.[7, 24, 35] The starter unit—usually acetyl-
CoA—is separate and distinct from the Mal-CoA extender units that are used to generate 
the crucial poly-β-ketone intermediate. This observation has become known as the 
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“starter unit effect”. In the majority of known fungal polyketides the starter unit is acetyl-
CoA; however, other products utilize far more complicated precursors. In these cases, 
dedicated upstream biosynthetic machinery—including other PKSs or FASs as is the case 
for PksA[29b, 35-36]—generates the critical starter unit. It was not until Townsend and 
coworkers utilized the in silico directed deconstruction approach that the biochemical 
basis of the starter unit effect was understood. 
 In the initial in silico analysis of PksA by UMA,[24] sequence analysis of the 
extreme N-terminal domain of unknown function led to the hypothesis that it might be 
responsible for selecting the HexA/HexB generated hexanoyl fatty acid starter unit of 
norsolorinic acid biosynthesis. In fact, the sequence analysis showed that not only was 
this domain conserved among the NR-PKSs, but it also contained a conserved GXCXG 
motif, presumptively for the tethering of the precursor metabolite as an acyl thioester. 
This observation was in contrast to the MAT domains, which contain a GHSXG motif 
where the Ser serves as the active site acyl ester tether for the malonyl extender units. On 
the basis of this analysis and subsequent biochemical assays, the mysterious domain was 
given the name starter unit:ACP transacylase (SAT). 
 Using protein deconstruction of PksA, the enigmatic SAT domain and the ACP 
domain were heterologously expressed as monodomain fragments and used in a 
radioisotope labeling transacylase assay to measure if the PksA SAT domain could 
catalyze the transfer of [1-14C]hexanoyl-CoA to the ACP domain.[24] The results of this 
assay showed that the SAT domain could not only catalyze transfer of the hexanoyl 
moiety to the ACP, but that this transfer proceeded through a hexanoyl-SAT acyl 
intermediate. The PksA SAT was also shown to be reasonably selective for hexanoyl-
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CoA.[24, 37] It is now known that in NR-PKSs utilizing complicated starter units, the SAT 
domain is selective for these unusual precursors serving as the link between the starter 
unit generator and the NR-PKSs (Figure 1.6, reaction i). In fact, this crucial link is 
believed to account for much of the incredible structural diversity of fungal polyketides. 
In the absence of a dedicated starter unit biosynthetic module, the SAT domain has been 
shown to be selective for acetyl-CoA thereby accounting for the prevalence of the acetyl-
derived starter units in NR-PKS biosynthesis. It has also been demonstrated that the PksA 
SAT domain can transfer non-native precursors so long as they are reasonably similar to 
the native hexanoyl starter unit.[37] 
 Recently, the crystal structure of the SAT from CazM was solved (Figure 1.7).[38] 
CazM is a NR-PKS from Chaetomium globosum responsible for the biosynthesis of 
chaetoviridin A and chaetomugilin A.[39] Like many fungal NR-PKSs, CazM works in 
concert with a dedicated HR-PKS—CazF—that generates a highly reduced polyketide 
 
Figure 1.7"Crystal structure of the CazM SAT domain.[38] The "/! hydrolase fold is displayed in green. 
The ferrodoxin-like subdomain is shown in blue. Hexanoyl bound to the active site Cys is displayed in 
black. Residues constituting the active site are shown as sticks. 
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starter unit. The modular separation of precursor formation from aromatic moiety 
construction is a common biosynthetic strategy among NR-PKSs observed for many 
classes including the azaphilone synthases[39-40]—the family to which CazM belongs—
and the resorcylic acid lactone synthases.[41] In all of these cases, the SAT domain serves 
as the bridge connecting the two separate modes of biosynthesis. The CazM SAT domain 
structure comprises an α/β hydrolase core and a small ferrodoxin-like subdomain with the 
active site situated at the interface of these two subdomains. The active site is 
hydrophobic presumably to stabilize the highly reduced polyketide starter unit. 
Additionally, small conformational changes to the SAT active site are observed upon 
binding of a hexanoyl thioester—a mimic of the native triketide CazM starter unit. The 
conformational change positions residues such that they can stabilize the oxyanion 
tetrahedral intermediate generated during the acyl transfer. 
1.4.3. Iterative Claisen Condensation and the Poly-β-Ketone 
 As previously stated, the central chemistry of any PKS is repeated 
decarboxylative Claisen condensation of acetate units. In the case of the bacterial type II 
PKSs, this activity is catalyzed by the so-called minimal PKS.[2c, 14b] In these systems, the 
minimal PKS is defined as a heterodimeric KS complex (KSα and KSβ) and the ACP—
the only proteins necessary to catalyze poly-β-ketone formation. A similar term for the 
minimal NR-PKSs is defined as the requisite domains for efficient acetate homologation. 
From a biological point of view, the minimal NR-PKS is an absurd classification, as NR-
PKSs by their very nature comprise all domains of the canonical domain architecture. 
The term is exclusively used to describe individual steps of NR-PKS biosynthesis and is 
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useful when discussing deconstructed NR-PKSs, where canonical domains can be 
excised. 
 The minimal NR-PKS comprises the three N-terminal domains (SAT-KS-MAT) 
and the ACP.[14a, 26] The SAT—as described—selects the starter unit and initiates 
biosynthesis whereas the MAT and KS collaborate to introduce malonyl extender units 
from malonyl-CoA and catalyze decarboxylative Claisen condensation generating the 
ACP-bound poly-β-ketone, respectively (Figure 1.6, reaction ii). Although this division 
of biosynthesis was long hypothesized, it was first biochemically demonstrated in a 
pioneering effort by the Townsend group in collaboration with the Kelleher group using 
the PksA model system.[26, 42] For the first time, the fully mature ACP-bound linear poly-
β-ketone was observed by MS/MS fragmentation analysis. Astonishingly, extension in all 
cases was complete and no intermediate poly-β-ketones could be detected. Furthermore, 
chain length was completely controlled—a feature previously observed in reactions of the 
KS, MAT, and ACP domains of Pks4, the NR-PKS from Gibberella fujikuroi implicated 
in bikaverin biosynthesis.[14a, 43] It is believed that the KS domain exerts stringent chain 
length control in the NR-PKSs as in the case of the type II PKSs. In those systems, the 
active site volume of the KS heterodimer limits chain length to the prescribed number of 
extensions.[44] Furthermore, in reactions of PksA in which non-native starter units were 
used, the number of malonyl extensions accounted for the difference favoring linear 
intermediates of the correct C20 chain length.[14a, 37] 
 In the absence of downstream cyclizing domains, the highly reactive linear poly-
β-ketone of the minimal NR-PKS undergoes spontaneous cyclization and release 
generating a thermodynamic distribution of so-called derailment products.[14a, 26] In 
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general, derailment products derive from simple intramolecular aldol and pyrone 
cyclizations, dehydrations, aromatizations, and—in some cases—decarboxylations. 
Derailment of this nature is greatly reduced when downstream domains of the NR-PKS 
are introduced and when the level of deconstruction is reduced—meaning the enzyme is 
cut in fewer places.[26] Both observations point towards a significant role for substrate 
channeling in the native enzymes as well as an inherent protective functionality in which 
the enzyme stabilizes the linear poly-β-ketone reactive intermediate. The nature of this 
stabilization is unknown, but likely involves domain-mediated restriction of 
conformational sampling by the reactive intermediate. In the bacterial type II PKSs and 
FASs, the ACP plays a protective role by sequestering bound intermediates within the 
hydrophobic core of the ACP in a mechanism similar to that of a switchblade.[45] The 
switchblade mechanism is unlikely in the type I PKSs—including the NR-PKSs. In fact, 
a solution structure of the PksA ACP showed no evidence for intermediate 
sequestration.[46] 
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1.4.4. Regiospecific Cyclization by the PT Domain 
Both bacterial type II PKSs and fungal type I NR-PKSs catalyze the formation of 
aromatic products through a linear poly-!-ketone intermediate. In either case, the PKS 
Figure 1.8"The cyclization modes of aromatic polyketides. (a) The F-mode and S-mode of cyclization 
are characteristic of fungal and bacterial polyketides, respectively. The origins of the carbons in the similar 
products viridicatumtoxin B (28) and oxytetracycline (29) are indicated to illustrate the two folding modes. 
(b) The PT domains of NR-PKS adopt three distinct cyclization regiospecificities: C2–C7 (as in YWA1, 
30), C4–C9 (as in noranthrone, 25), and C6–C11 (as in atrochrysone acid, 31). 
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system controls the regiospecificity of the cyclization/aromatization.[47] Interestingly, the 
bacterial and fungal aromatic polyketides adopt distinctive cyclization folding registers—
the S-mode and F-mode, respectively—as determined by stable isotope labeling patterns 
(Figure 1.8a).[47a, 48] The origins of the S-mode and F-mode regiospecificities lie in the 
distinct mechanisms of aromatization catalyzed by the divergent PKS systems. In the 
bacterial type II PKSs, aldol cyclization and aromatization is catalyzed by dedicated 
aromatases (AROs).[49] The AROs bind the ACP-bound linear poly-β-ketone intermediate 
in a pre-folded conformation that brings the regiospecific electrophile and nucleophile 
pair in proximity to one another, favoring the S-mode. Cyclization in the fungal type I 
NR-PKSs occurs in the product template (PT) domain by a distinct mechanism.[25-26] The 
PT domain was the final canonical NR-PKS domain to be recognized and characterized. 
It serves the crucial role of setting the aromatic scaffold of the final polyketide product. 
 The role of the PT domain in cyclization was first demonstrated in the model 
system PksA (Figure 1.6, reaction iii).[25-26, 42] When a deconstructed PT domain was 
added to reactions of the minimal PksA (SAT-KS-MAT + ACP), biosynthesis was 
redirected away from spontaneous derailment products and towards norpyrone—a 
naphthopyrone. Norpyrone adopted the predicted F-mode of folding with apparent aldol 
cyclization/aromatization occurring between C4–C9 and C2–C11 followed by O14–C1 
bond closure—a low barrier spontaneous transformation. In fact, ions corresponding to 
the ACP-bound fully elongated C20 poly-β-ketone with either one or two dehydrations 
were observed by MS/MS fragmentation in reconstitution reactions containing the PT 
domain.[26, 42] The presence of both the singly and doubly dehydrated intermediates 
suggested sequential aldol cyclization catalyzed by the PT domain. Structural analysis of 
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NR-PKS products indicated that three so-called cyclization registers exist for fungal 
aromatic polyketides: C2–C7, C4–C9, and C6–C11 (Figure 1.8b).[2b, 50] Phylogenetic 
analysis of a curated list of NR-PKSs for which products were known similarly showed 
that the PT domains separate into five distinct clades, each with a characteristic 
cyclization register.[50] Furthermore, the active site sequences of known members of each 
cyclization register are distinct, suggesting a structural basis for cyclization 
regiospecificity.[25] 
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 The current understanding of the PT cyclization mechanism is largely based upon 
a pair of crystal structures of the PksA PT domain with either palmitate (a mimic of the 
linear poly-β-ketone) or HC8 (a bicyclic mimic of the cyclized PT product) bound in the 
active site (Figure 1.9).[25] The PksA PT monodomain exists as a homodimer—both in 
 
Figure 1.9⏐The PksA PT domain structure serves as the basis for mechanistic understanding of 
regiospecific cyclizations/aromatizations in NR-PKSs. (a) The PksA PT crystal structure. The PT 
domain is a homodimer with each monomeric unit adopting the double hot dog fold. The monomers are 
displayed in green and purple, respectively. The active site cavity is displayed for one monomer with 
palmitate bound. Palmitate is displayed as black spheres. (b) The active site of the PksA PT contains three 
distinct regions: phosphopantetheine binding region (pink residues), cyclization chamber (gray and blue 
residues for the dry and wet sides, respectively), and hexanoyl binding region (green residues). The 
residues important for regiospecific aldol cyclization/aromatization are presented as sticks. (c) The 
mechanism for regiospecific aldol cyclization/aromatization requires activation of the electrophilic ketone 
through dual hydrogen bonding. 
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the crystal structure and in solution—and adopts a modified double hot dog fold.[51] The 
double hot dog fold is a common structural fold observed in the DH domains of 
mammalian FAS[11], modular PKSs,[52] and bacterial type II FAS.[53] Despite having little 
sequence homology, the PksA PT structure is similar to that of the mammalian FAS DH 
domain further underlining the similarities between the NR-PKSs and mammalian FASs. 
 The PksA PT active site is defined by the double hot dog fold and comprises three 
distinct regions: the phosphopantetheine binding region, the cyclization chamber, and the 
hexanoyl-binding region (Figure 1.9b).[25] All told, the three regions of the active site 
define a deep and narrow pocket reaching about 30 Å from the surface into the 
hydrophobic core of the protein. Electron densities for either palmitate or HC8 bound in 
the active site are well defined. There is virtually no conformational change in the protein 
structure for either the palmitate or HC8 structures. Furthermore, the palmitate binds in 
its fully extended conformation, indicating that—unlike the bacterial type II AROs—the 
linear poly-β-ketone intermediate binds in its fully extended conformation. The tail of the 
palmitate binds the narrow and hydrophobic hexanoyl-binding region, stabilizing 
palmitate’s extended conformation and suggesting a structural rationale for hexanoyl 
starter unit accommodation. Interestingly, the cyclization chamber contains clear 
orthogonal “wet” and “dry” sides. A network of crystallographic water molecules 
organized through residue-directed hydrogen bonding defines the wet side while 
hydrophobic residues compose the dry side. The HC8 compound occupies the dry side of 
the cyclization chamber. Situated at the center of the cyclization chamber is the catalytic 
His1345, activated through hydrogen bonding by its catalytic dyad partner, Asp1543. 
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 The mechanistic origin of regiospecificity is based upon in silico docking studies 
of the linear poly-β-ketone and monocyclic intermediates (Figure 1.9c).[25] It is believed 
that the linear substrate binds in an elongated conformation with a slight kink in the 
cyclization chamber, allowing for regiospecific C4–C9 and C2–C11 cyclization. This 
slightly kinked structure is stabilized through dual hydrogen bonding of the C9 ketone to 
two crystallographic waters, activating it as an electrophile.[54] The positioning of these 
waters is determined by the hydrogen bonding network of the wet side of the cyclization 
chamber. Furthermore, the polarity of the cyclization chamber likely contributes to the 
extent of enol-keto tautomerization in the poly-β-ketone. Solvent polarity has a 
determining effect on the extent of enolization of 1,3-diketones, with a more polar 
solvent favoring the diketo tautomer.[55] By projecting the C9 carbonyl into the wet side 
of the active site, the enzyme stabilizes the electrophilic keto tautomer. The catalytic 
His1345—with participation of Asp1543—removes a methylene proton at the C4 
position, generating an enzyme-stabilized enolate intermediate. Collapse of the enolate 
together with C9 electrophilic activation directs regiospecific aldol cyclization and 
aromatization. Following first-ring cyclization, translocation of the distal end of the 
monocyclic intermediate occurs, allowing for the second C2–C11 aldol cyclization to 
occur in an analogous mechanism. 
1.4.5. Product Release by the TE Domain 
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PKSs utilize a variety of methods to catalyze product release.[56] In canonical NR-
PKSs, the thioesterase (TE) domain catalyzes this activity. TE biochemistry in FASs and 
modular type I PKSs is varied and includes macrolactonization, macrolactamization, and 
hydrolysis. The TEs of NR-PKSs expand upon these functions and can also catalyze 
Claisen cyclization/Dieckmann C–C bond formation (Figure 1.6, reaction iv; Figure 
1.10).[26, 57] Expression of the wA gene from Aspergillus nidulans in the heterologous 
host Aspergillus oryzae, Ebizuka and coworkers established the first NR-PKS harboring a 
Claisen cyclase type TE (TE-CLC).[57a] The wA protein produces the spore pigment 
YWA1 (30), the product of the TE-CLC.[27a, 58] In earlier studies where the TE domain 
was mistakenly truncated, wA generated citreoisocoumarins—the products of 
spontaneous pyrone formation by C–O bond closure, a lower energy transformation.[58a] 
Since these experiments, TE-CLCs have been identified in many NR-PKSs including 
PksA[26, 57b] and Pks4.[43] 
 The crystal structure of the PksA TE monodomain[57b] reveals that it adopts the 
characteristic "/!-hydrolase fold of acyltransferases and hydrolases (Figure 1.11a).[59] 
The "/!-hydrolase fold is well characterized and found in the structures of modular type I 
Figure 1.10"Mode of release by NR-PKS TE domains. NR-PKS TE domains often catalyze 
regiospecific Claisen cyclizations. They can catalyze additional reactions including deacetylation as is the 
case for Pks1, which transforms ATHN (32) to THN (33). 
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PKSs and NRPSs, where they usually catalyze macrolactonization and 
macrolactamization, respectively. These TEs rely on a classic catalytic triad (Asp, His, 
Ser) which functions in a fashion analogous to the serine protease catalytic triad.[60] 
Unique to the α/β-hydrolase fold is a distinctive lid subdomain, which forms a portion of 
the active site and is key to substrate binding.[57b] Delivery of the penultimate 
intermediate to the TE active site occurs upon ACP docking, inducing a lid opening 
conformational change. A similar lid opening interaction is observed for the TE-peptidyl 
carrier protein (PCP)—an analog of the FAS and PKS ACP—pair of enterobactin 
biosynthesis.[61] The ACP-bound acyl intermediate is transferred to the TE active site Ser, 
where it is tethered as an enzyme acyl ester (Figure 1.11b). As the ACP disassociates 
from the acylated TE, the lid is proposed to close upon the active site sequestering the 
substrate within a hydrophobic binding pocket. The shape of this pocket imposes a strict 
conformational bias on the substrate, bringing the side chain within deprotonation 




Figure 1.11⏐The PksA TE structure and mechanism. (a) The PksA TE adopts an α/β-hydrolase fold 
(green) with a flexible lid region (purple). The lid helps define the active site cavity (cage) into which the 
final polyketide intermediate is delivered. The classic Ser-His-Asp catalytic triad is shown as sticks. (b) 
The PksA TE mechanism first requires transfer of the acyl intermediate from the ACP to the TE. As the 
phosphopantetheine of the ACP leaves the active site, it is protonated and the hexanoyl moiety flips into the 
site that it vacates. Flipping of the hexanoyl group brings the methylene position into proximity of the 
catalytic His, which facilitates Claisen cyclization. The oxyanion tetrahedral intermediate is stabilized 
through backbone interactions. 
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 As stated, the lid region is critical in forming the hydrophobic binding pocket and 
therefore catalytic specificity. The NR-PKS Pks1 from Colletotrichum lagenarium is 
implicated in melanin biosynthesis.[62] Like wA and PksA, the Pks1 TE domain catalyzes 
Claisen cyclization to generate the hexaketide product, 2-acetyl-1,3,6,8-
tetrahydroxynaphthalene (ATHN, 32, Figure 1.10). In addition to the CLC activity, the 
Pks1 TE domain also harbors a deacetylase activity and converts ATHN to 1,3,6,8-
tetrahydroxynaphthalene (THN, 33). Like Pks1, the TE-CLC domain of WdPks1 from 
Wangiella dermatitidis catalyzes the formation of ATHN from the hexaketide product.[63] 
However—unlike Pks1—WdPks1 does not contain an additional deacetylase activity. 
When the lid subdomains of Pks1 and WdPks1 were swapped, the product distribution 
between ATHN and THN was predictably altered with WdPks1 harboring the Pks1 lid 
capable of performing the deacetylation.[62] 
 In addition to its biosynthetic role, the TE domain of NR-PKSs also performs a 
critical editing function.[42] TE-mediated editing occurs when a nonproductive metabolite 
accumulates on the ACP. Because the ACP thiol tether serves as the locus of all 
biochemistry in the NR-PKSs, an improperly loaded ACP renders the entire enzyme 
inactive. In these cases, the TE domain can intercede and hydrolyze the improper acyl-
ACP species, resetting the enzyme. This effect was first observed by MS/MS 
fragmentation of PksA domain bound intermediates.[42] In reconstitution reactions where 
the TE domain was withheld, both acetyl and hexanoyl intermediates would accumulate 
on the ACP. Neither of these intermediates was observed when the TE domain was 
included. The TE domain was shown to directly hydrolyze acetyl-ACP and hexanoyl-
ACP species. Furthermore, derailment and truncation products of a minimal PksA were 
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reduced during titration of increasing amounts of PksA TE. Together these data suggest 
the critical editing role of the TE domain. The interplay between the biosynthetic and 
editing roles of the TE domain have been described as decision gating, and are predicted 
to be of crucial importance for NR-PKS engineering.[64] 
1.5. Outlook 
 Our understanding of polyketide biosynthesis has rapidly expanded in the last 
decade due in no small part to experimental advances in protein deconstruction. The 
catalytic program of the NR-PKSs—once considered an intractable black box—is now 
significantly better understood on the biosynthetic, structural, and mechanistic levels. 
Four chemical features govern the diversity of fungal aromatic polyketides: starter unit, 
chain length, cyclization register, and product release. As described above, each of these 
features is controlled by a separate domain of the NR-PKSs—SAT, KS, PT, and TE, 
respectively—allowing us to reliably predict the products of canonical NR-PKSs simply 
by investigating their primary sequences. Indeed, the individual activity of NR-PKSs 
linked to known products invariably follow the inherent, or programed, biosynthetic logic 
of their SAT, KS, PT, and TE domains (Table 1.1). 
 Despite these dramatic leaps, much is still left to learn. Although the foundations 
of catalytic programing in the NR-PKSs is well understood, it is unclear how they can be 
used to aid in NR-PKS engineering. Addressing this challenge is a central feature of this 
dissertation. While the canonical NR-PKSs are now well understood, catalytic 
programing in common NR-PKS variants is still unclear. Many NR-PKSs contain C-
methylation domains which function during elongation to methylate the α-position at 
programed stages of extension. The structural basis of the mechanism governing this 
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level of programing is completely unknown. Furthermore, little is known of the global 
structure of these enzymes or how interdomain linker regions influence catalysis. In 
addition to global structure, the nature of domain-domain interactions in NR-PKSs is a 
central question. With so many unanswered questions, it is clear that NR-PKS 
biosynthesis will remain an active area of research in the decades to come. 
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Table 1.1⏐Known products of canonical NR-PKSs. 
Species PKS Accession NR-PKS Product Final SAT KS PT TE Ref. 
Pochonia 
chlamydosporia Rdc1 ACD39770 
 





chiversii RadS2 ACM42403 Radicinol 
C10 





zeae GzPks13 ABB90282 
 





subiculosus Hpm3 ACD39762 Hypothemycin 
C12 



















































niger AdaA AEN83889 
 


















nidulans AptA XP_663604 
 





fujikuroi Pks4 CAB92399 
 
Bikaverin C2 8 C2–C7 CLC C10–C1 
[43] 
Aspergillus 
terreus ACAS XP_001217072 
 
Emodin 







nidulans mpdG XP_657754 
Prenyl 





















nicotianae CTB1 AAT69682 
 





nidulans wA Q03149 
 
Conidal Pigment C2 6 C2–C7 CLC C10–C1 
[57a] 
Aspergillus 















aethiopicum GsfA ADI24953 
 






























































[1] D. J. Newman, G. M. Cragg, J Nat Prod 2012, 75, 311-335. 
[2] (a) J. Staunton, K. J. Weissman, Nat Prod Rep 2001, 18, 380-416; (b) J. M. 
Crawford, C. A. Townsend, Nature Rev Microbiol 2010, 8, 879-889; (c) C. 
Hertweck, A. Luzhetskyy, Y. Rebets, A. Bechthold, Nat Prod Rep 2007, 24, 162-
190; (d) C. Hertweck, Trends Biochem Sci 2015, 40, 189-199. 
[3] (a) S. Smith, S. C. Tsai, Nat Prod Rep 2007, 24, 1041-1072; (b) J. E. Cronan, J. 
Thomas, Methods Enzymol 2009, 459, 395-433. 
[4] A. Birch, R. Massy-Westropp, C. Moye, Aust J Chem 1955, 8, 539-544. 
[5] N. Collie, W. S. Myers, Journal of the Chemical Society, Transactions 1893, 63, 
122-128. 
[6] O. Puel, P. Galtier, I. P. Oswald, Toxins (Basel) 2010, 2, 613-631. 
[7] T. J. Simpson, Chem Soc Rev 1987, 16, 123-160. 
[8] (a) I. Fujii, Nat Prod Rep 2009, 26, 155-169; (b) K. J. Weissman, Methods 
Enzymol 2009, 459, 3-16; (c) K. J. Weissman, Nat Chem Biol 2015, 11, 660-670. 
[9] (a) M. Leibundgut, T. Maier, S. Jenni, N. Ban, Curr Opin Struct Biol 2008, 18, 
714-725; (b) T. Maier, M. Leibundgut, D. Boehringer, N. Ban, Q Rev Biophys 
2010, 43, 373-422. 
[10] S. Jenni, M. Leibundgut, D. Boehringer, C. Frick, B. Mikolasek, N. Ban, Science 
2007, 316, 254-261. 
[11] T. Maier, M. Leibundgut, N. Ban, Science 2008, 321, 1315-1322. 
[12] C. O. Rock, J. E. Cronan, Biochim Biophys Acta 1996, 1302, 1-16. 
[13] R. J. Cox, T. J. Simpson, in Complex Enzymes in Microbial Natural Product 
Biosynthesis, Part B: Polyketides, Aminocoumarins and Carbohydrates, Vol. 459 
(Ed.: D. A. Hopwood), Elsevier Academic Press Inc, San Diego, CA, 2009, pp. 
49-78. 
[14] (a) W. J. Zhang, Y. R. Li, Y. Tang, Proc Natl Acad Sci USA 2008, 105, 20683-
20688; (b) A. Das, C. Khosla, Acc Chem Res 2009, 42, 631-639. 
[15] (a) M. B. Austin, J. P. Noel, Nat Prod Rep 2003, 20, 79-110; (b) M. B. Austin, M. 
Izumikawa, M. E. Bowman, D. W. Udwary, J. L. Ferrer, B. S. Moore, J. P. Noel, 
J Biol Chem 2004, 279, 45162-45174; (c) M. Hashimoto, T. Nonaka, I. Fujii, Nat 
Prod Rep 2014, 31, 1306-1317. 
[16] F. Malpartida, D. A. Hopwood, Nature 1984, 309, 462-464. 
Exophiala 
dermatitidis WdPks1 EHY55015 
 
Melanin C2 5 C2–C7 CLC C10–C1 
[63] 
Colletotrichum 
lagenarium Pks1 BAA18956 
 
Melanin C2 5 C2–C7 CLC C10–C1 
[62] 
Aspergillus 
oryzae AoiG XP_001827098 
 
Orthosporin 
Diaporthin C2 5 C2–C7 ? 
[84] 
Aspergillus 





















[17] R. McDaniel, S. Ebertkhosla, H. Fu, D. A. Hopwood, C. Khosla, Proc Natl Acad 
Sci USA 1994, 91, 11542-11546. 
[18] (a) R. McDaniel, C. R. Hutchinson, C. Khosla, J Am Chem Soc 1995, 117, 6805-
6810; (b) P. J. Kramer, R. J. X. Zawada, R. McDaniel, C. R. Hutchinson, D. A. 
Hopwood, C. Khosla, J Am Chem Soc 1997, 119, 635-639. 
[19] (a) J. Cortes, S. F. Haydock, G. A. Roberts, D. J. Bevitt, P. F. Leadlay, Nature 
1990, 348, 176-178; (b) D. J. Bevitt, J. Cortes, S. F. Haydock, P. F. Leadlay, Eur 
J Biochem 1992, 204, 39-49. 
[20] (a) J. S. Tuan, J. M. Weber, M. J. Staver, J. O. Leung, S. Donadio, L. Katz, Gene 
1990, 90, 21-29; (b) S. Donadio, M. J. Staver, J. B. McAlpine, S. J. Swanson, L. 
Katz, Science 1991, 252, 675-679. 
[21] R. J. Cox, Org Biomol Chem 2007, 5, 2010-2026. 
[22] L. E. Bingle, T. J. Simpson, C. M. Lazarus, Fungal Genet Biol 1999, 26, 209-223. 
[23] T. P. Nicholson, B. A. Rudd, M. Dawson, C. M. Lazarus, T. J. Simpson, R. J. 
Cox, Chem Biol 2001, 8, 157-178. 
[24] J. M. Crawford, B. C. R. Dancy, E. A. Hill, D. W. Udwary, C. A. Townsend, Proc 
Natl Acad Sci USA 2006, 103, 16728-16733. 
[25] J. M. Crawford, T. P. Korman, J. W. Labonte, A. L. Vagstad, E. A. Hill, O. 
Kamari-Bidkorpeh, S. C. Tsai, C. A. Townsend, Nature 2009, 461, 1139-U1243. 
[26] J. M. Crawford, P. M. Thomas, J. R. Scheerer, A. L. Vagstad, N. L. Kelleher, C. 
A. Townsend, Science 2008, 320, 243-246. 
[27] (a) P. K. Chang, J. W. Cary, J. Yu, D. Bhatnagar, T. E. Cleveland, Mol Gen Genet 
1995, 248, 270-277; (b) C. M. Watanabe, D. Wilson, J. E. Linz, C. A. Townsend, 
Chem Biol 1996, 3, 463-469; (c) C. M. Watanabe, C. A. Townsend, Chem Biol 
2002, 9, 981-988; (d) J. Yu, P. K. Chang, K. C. Ehrlich, J. W. Cary, D. Bhatnagar, 
T. E. Cleveland, G. A. Payne, J. E. Linz, C. P. Woloshuk, J. W. Bennett, Appl 
Environ Microbiol 2004, 70, 1253-1262; (e) K. Yabe, H. Nakajima, Appl 
Microbiol Biotechnol 2004, 64, 745-755. 
[28] C. A. Townsend, S. B. Christensen, K. Trautwein, J Am Chem Soc 1984, 106, 
3868-3869. 
[29] (a) S. W. Brobst, C. A. Townsend, Can J Chem 1994, 72, 200-207; (b) T. S. 
Hitchman, E. W. Schmidt, F. Trail, M. D. Rarick, J. E. Linz, C. A. Townsend, 
Bioorg Chem 2001, 29, 293-307. 
[30] K. C. Ehrlich, P. Li, L. Scharfenstein, P. K. Chang, Appl Environ Microbiol 2010, 
76, 3374-3377. 
[31] S. P. Hussain, J. Schwank, F. Staib, X. W. Wang, C. C. Harris, Oncogene 2007, 
26, 2166-2176. 
[32] H. Klenow, I. Henningsen, Proc Natl Acad Sci U S A 1970, 65, 168-175. 
[33] Y. Tsukamoto, H. Wong, J. S. Mattick, S. J. Wakil, J Biol Chem 1983, 258, 
15312-15322. 
[34] D. W. Udwary, M. Merski, C. A. Townsend, J Mol Biol 2002, 323, 585-598. 
[35] J. M. Crawford, A. L. Vagstad, K. R. Whitworth, K. C. Ehrlich, C. A. Townsend, 
Chembiochem 2008, 9, 1019-1023. 
[36] D. W. Brown, S. H. Lee, L. H. Kim, J. G. Ryu, S. Lee, Y. Seo, Y. H. Kim, M. 
Busman, S. H. Yun, R. H. Proctor, T. Lee, Mol Plant Microbe Interact 2014. 
 35 
[37] C. R. Huitt-Roehl, E. A. Hill, M. M. Adams, A. L. Vagstad, J. W. Li, C. A. 
Townsend, ACS Chem Biol 2015, 10, 1443-1449. 
[38] J. M. Winter, D. Cascio, D. Dietrich, M. Sato, K. Watanabe, M. R. Sawaya, J. C. 
Vederas, Y. Tang, J Am Chem Soc 2015, 137, 9885-9893. 
[39] J. M. Winter, M. Sato, S. Sugimoto, G. Chiou, N. K. Garg, Y. Tang, K. 
Watanabe, J Am Chem Soc 2012, 134, 17900-17903. 
[40] Y. M. Chiang, E. Szewczyk, A. D. Davidson, N. Keller, B. R. Oakley, C. C. 
Wang, J Am Chem Soc 2009, 131, 2965-2970. 
[41] (a) H. Zhou, J. Zhan, K. Watanabe, X. Xie, Y. Tang, Proc Natl Acad Sci U S A 
2008, 105, 6249-6254; (b) H. Zhou, K. Qiao, Z. Gao, M. J. Meehan, J. W. Li, X. 
Zhao, P. C. Dorrestein, J. C. Vederas, Y. Tang, J Am Chem Soc 2010, 132, 4530-
4531; (c) H. Zhou, K. Qiao, Z. Gao, J. C. Vederas, Y. Tang, J Biol Chem 2010, 
285, 41412-41421. 
[42] A. L. Vagstad, S. B. Bumpus, K. Belecki, N. L. Kelleher, C. A. Townsend, J Am 
Chem Soc 2012, 134, 6865-6877. 
[43] S. M. Ma, J. Zhan, K. Watanabe, X. Xie, W. Zhang, C. C. Wang, Y. Tang, J Am 
Chem Soc 2007, 129, 10642-10643. 
[44] A. T. Keatinge-Clay, D. A. Maltby, K. F. Medzihradszky, C. Khosla, R. M. 
Stroud, Nat Struct Mol Biol 2004, 11, 888-893. 
[45] (a) G. A. Zornetzer, B. G. Fox, J. L. Markley, Biochemistry 2006, 45, 5217-5227; 
(b) A. Roujeinikova, W. J. Simon, J. Gilroy, D. W. Rice, J. B. Rafferty, A. R. 
Slabas, J Mol Biol 2007, 365, 135-145; (c) M. Leibundgut, S. Jenni, C. Frick, N. 
Ban, Science 2007, 316, 288-290; (d) C. Nguyen, R. W. Haushalter, D. J. Lee, P. 
R. L. Markwick, J. Bruegger, G. Caldara-Festin, K. Finzel, D. R. Jackson, F. 
Ishikawa, B. O/'Dowd, J. A. McCammon, S. J. Opella, S.-C. Tsai, M. D. Burkart, 
Nature 2014, 505, 427-431. 
[46] P. Wattana-Amorn, C. Williams, E. Ploskon, R. J. Cox, T. J. Simpson, J. Crosby, 
M. P. Crump, Biochemistry 2010, 49, 2186-2193. 
[47] (a) R. Thomas, Chembiochem 2001, 2, 612-627; (b) H. Zhou, Y. Li, Y. Tang, Nat 
Prod Rep 2010, 27, 839-868. 
[48] G. Bringmann, T. A. M. Gulder, A. Hamm, M. Goodfellow, H.-P. Fiedler, Chem 
Commun 2009, 6810-6812. 
[49] (a) B. D. Ames, T. P. Korman, W. Zhang, P. Smith, T. Vu, Y. Tang, S.-C. Tsai, 
Proc Natl Acad Sci USA 2008, 105, 5349-5354; (b) M. Y. Lee, B. D. Ames, S. C. 
Tsai, Biochemistry 2012, 51, 3079-3091. 
[50] Y. R. Li, W. Xu, Y. Tang, J Biol Chem 2010, 285, 22762-22771. 
[51] (a) S. C. Dillon, A. Bateman, BMC Bioinformatics 2004, 5, 109; (b) J. W. 
Labonte, C. A. Townsend, Chem Rev 2013, 113, 2182-2204. 
[52] A. Keatinge-Clay, J Mol Biol 2008, 384, 941-953. 
[53] M. Leesong, B. S. Henderson, J. R. Gillig, J. M. Schwab, J. L. Smith, Structure 
1996, 4, 253-264. 
[54] F. Hibbert, J. Emsley, in Adv Phys Org Chem, Vol. Volume 26 (Ed.: D. Bethell), 
Academic Press, 1991, pp. 255-379. 
[55] S. G. Mills, P. Beak, J Org Chem 1985, 50, 1216-1224. 
[56] L. C. Du, L. L. Lou, Nat Prod Rep 2010, 27, 255-278. 
 36 
[57] (a) I. Fujii, A. Watanabe, U. Sankawa, Y. Ebizuka, Chem Biol 2001, 8, 189-197; 
(b) T. P. Korman, J. M. Crawford, J. W. Labonte, A. G. Newman, J. Wong, C. A. 
Townsend, S. C. Tsai, Proc Natl Acad Sci USA 2010, 107, 6246-6251. 
[58] (a) A. Watanabe, Y. Ono, I. Fujii, U. Sankawa, M. E. Mayorga, W. E. 
Timberlake, Y. Ebizuka, Tetrahedron Lett 1998, 39, 7733-7736; (b) A. Watanabe, 
I. Fujii, U. Sankawa, M. E. Mayorga, W. E. Timberlake, Y. Ebizuka, Tetrahedron 
Lett 1999, 40, 91-94. 
[59] D. L. Ollis, E. Cheah, M. Cygler, B. Dijkstra, F. Frolow, S. M. Franken, M. Harel, 
S. J. Remington, I. Silman, J. Schrag, J. L. Sussman, K. H. G. Verschueren, A. 
Goldman, Protein Eng 1992, 5, 197-211. 
[60] P. Carter, J. A. Wells, Nature 1988, 332, 564-568. 
[61] D. P. Frueh, H. Arthanari, A. Koglin, D. A. Vosburg, A. E. Bennett, C. T. Walsh, 
G. Wagner, Nature 2008, 454, 903-906. 
[62] A. L. Vagstad, E. A. Hill, J. W. Labonte, C. A. Townsend, Chem Biol 2012, 19, 
1525-1534. 
[63] M. H. Wheeler, D. Abramczyk, L. S. Puckhaber, M. Naruse, Y. Ebizuka, I. Fujii, 
P. J. Szaniszlo, Eukaryot Cell 2008, 7, 1699-1711. 
[64] (a) Y. Xu, T. Zhou, S. Zhang, L.-J. Xuan, J. Zhan, I. Molnar, J Am Chem Soc 
2013, 135, 10783-10791; (b) M. E. Horsman, T. P. Hari, C. N. Boddy, Nat Prod 
Rep 2015. 
[65] (a) C. D. Reeves, Z. Hu, R. Reid, J. T. Kealey, Appl Environ Microbiol 2008, 74, 
5121-5129; (b) H. Zhou, K. Qiao, Z. Gao, J. C. Vederas, Y. Tang, J Biol Chem 
2010, 285, 41412-41421. 
[66] S. Wang, Y. Xu, E. A. Maine, E. M. K. Wijeratne, P. Espinosa-Artiles, A. A. L. 
Gunatilaka, I. Molnár, Chem Biol 2008, 15, 1328-1338. 
[67] I. Gaffoor, F. Trail, Appl Environ Microbiol 2006, 72, 1793-1799. 
[68] K. Kusumoto, Y. Nogata, H. Ohta, Curr Genet 2000, 37, 104-111. 
[69] J. W. Cary, K. C. Ehrlich, S. B. Beltz, P. Harris-Coward, M. A. Klich, Mycologia 
2009, 101, 352-362. 
[70] D. M. Geiser, J. W. Dorner, B. W. Horn, J. W. Taylor, Fungal Genet Biol 2000, 
31, 169-179. 
[71] J. H. Yu, T. J. Leonard, J Bacteriol 1995, 177, 4792-4800. 
[72] R. E. Bradshaw, H. Jin, B. S. Morgan, A. Schwelm, O. R. Teddy, C. A. Young, S. 
Zhang, Mycopathologia 2006, 161, 283-294. 
[73] Y. Li, Y.-H. Chooi, Y. Sheng, J. S. Valentine, Y. Tang, J Am Chem Soc 2011, 
133, 15773-15785. 
[74] Y.-H. Chooi, R. Cacho, Y. Tang, Chem Biol 2010, 17, 483-494. 
[75] E. Szewczyk, Y. M. Chiang, C. E. Oakley, A. D. Davidson, C. C. Wang, B. R. 
Oakley, Appl Environ Microbiol 2008, 74, 7607-7612. 
[76] T. Awakawa, K. Yokota, N. Funa, F. Doi, N. Mori, H. Watanabe, S. Horinouchi, 
Chem Biol 2009, 16, 613-623. 
[77] Y.-M. Chiang, E. Szewczyk, A. D. Davidson, R. Entwistle, N. P. Keller, C. C. C. 
Wang, B. R. Oakley, Appl Environ Microbiol 2010, 76, 2067-2074. 
[78] F. Y. Lim, Y. Hou, Y. Chen, J.-H. Oh, I. Lee, T. S. Bugni, N. P. Keller, Appl 
Environ Microbiol 2012, 78, 4117-4125. 
[79] K. Throckmorton, P. Wiemann, N. P. Keller, Toxins 2015, 7, 3572-3607. 
 37 
[80] A. G. Newman, A. L. Vagstad, K. Belecki, J. R. Scheerer, C. A. Townsend, Chem 
Commun 2012, 48, 11772-11774. 
[81] H.-F. Tsai, I. Fujii, A. Watanabe, M. H. Wheeler, Y. C. Chang, Y. Yasuoka, Y. 
Ebizuka, K. J. Kwon-Chung, J Biol Chem 2001, 276, 29292-29298. 
[82] Y.-M. Chiang, K. M. Meyer, M. Praseuth, S. E. Baker, K. S. Bruno, C. C. C. 
Wang, Fungal Genet Biol 2011, 48, 430-437. 
[83] J.-E. Kim, K.-H. Han, J. Jin, H. Kim, J.-C. Kim, S.-H. Yun, Y.-W. Lee, Appl 
Environ Microbiol 2005, 71, 1701-1708. 
[84] T. Nakazawa, K. i. Ishiuchi, A. Praseuth, H. Noguchi, K. Hotta, K. Watanabe, 
ChemBioChem 2012, 13, 855-861. 
[85] J. F. Sanchez, Y. M. Chiang, E. Szewczyk, A. D. Davidson, M. Ahuja, C. E. 




Chapter 2: Analysis of the Cercosporin Polyketide Synthase 
CTB1 Reveals a New Fungal Thioesterase Function 
This chapter was adapted with permission from A. G. Newman, A. L. Vagstad, K. 
Belecki, J. R. Scheerer, C. A. Townsend, Chem. Commun. 2012, 48, 11772-11774. 
2.1. Introduction 
 Cercosporin (2, Figure 2.1) is a photoactivated phytotoxin of polyketide origin 
produced by several Cercospora species.[1] These fungal species compose destructive 
plant pathogens in which cercosporin plays a central role. The perylenequinone core of 
the molecule is essential to its toxicity. The metabolite acts as a photosensitizing agent 
upon absorption of visible light, allowing for the production of singlet oxygen (1O2) and 
superoxide radical (O2-) with impressive quantum yields.[2] Cercosporin does not have a 
known direct cellular target, but causes indiscriminate oxidative damage to cell 
membranes, proteins, lipids, and nucleic acids.[3] Other perylenequinones share this 
photosensitizing activity with cercosporin.[4] While the putative cercosporin biosynthetic 
gene cluster has been identified in the tobacco pathogen C. nicotianae, little is known 
about the metabolite’s assembly.[5] The gene cluster comprises eight proteins, including 
six enzymes believed to be responsible for the construction of the metabolite,[5-6] an MFS 
transporter,[7] and a zinc finger transcription factor that regulates expression of the 
cluster.[5b] 
 It is postulated that cercosporin biosynthesis is initiated by CTB1—an iterative, 
non-reducing polyketide synthase (NR-PKS). CTB1 comprises the characteristic basis set 
of six catalytic domains of the NR-PKS family found in fungi including a tandem acyl-
carrier protein (ACP2)—a common variant.[5a] The starter unit:ACP acyltransferase 
(SAT) domain of CTB1 initiates polyketide extension through the selective utilization of 
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acetyl-CoA,[8] which is predicted to be elongated to the heptaketide 3 by the !-ketoacyl 
synthase (KS) domain through successive decarboxylative Claisen condensations with six 
malonyl units introduced by the malonyl:ACP acyltransferase (MAT) domain. It is 
believed that the product template (PT) domain catalyzes C4–C9 and C2–C11 aldol 
cyclizations and aromatizations generating an enzyme bound bicyclic intermediate. The 
intermediate is delivered to the thioesterase (TE) domain as bicycle 4 for final product 
release.[5] 
 TE domains catalyze product release from fatty acid synthases, non-ribosomal 
peptide synthetases, and polyketide synthases. In the main, these reactions occur by 
simple hydrolysis but in the latter two protein families can take place by 
macrolactamization or macrolactonization, respectively.[9] For the subset of iterative, NR-
PKSs, TE domains play a critical “editing” role during polyketide extension[10] in 
Figure 2.1"Possible mechanisms for nor-toralactone formation by CTB1. Two mechanisms were 
considered. In pathway a, the product 1 is released by hydrolysis followed by pyrone formation. In pathway 
b, nor-toralactone (1*) is formed directly through enol lactonization. 
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addition to terminal synthetic roles in carbon–carbon bond formation 
(Claisen/Dieckmann ring formation)[11] and cleavage (deacylation).[12] 
 The anticipated product of CTB1 is carboxylic acid 5—the result of conventional 
TE-catalyzed hydrolysis. Herein we report that—contrary to expectation—the cleanly 
observed major product of CTB1 is the naphthopyrone nor-toralactone (1). The two 
simplest mechanisms (Figure 2.1) that can be proposed for nor-toralactone formation are 
(a) canonical TE-mediated hydrolysis to carboxylic acid 5, which can be visualized to 
form the pseudoacid 6 and dehydrate to 1, or (b) the TE-bound bicyclic intermediate 4 
could be directly cyclized to 1* by either rapid spontaneous enol lactonization or TE-
catalyzed pyrone formation—an unprecedented TE function. Using an enzyme 
deconstruction approach, we investigated the in vitro biochemistry of CTB1 and further 
probed the mechanism of release catalyzed by the TE domain. 
2.2. Results 
2.2.1. Deconstruction of CTB1 
 Protein deconstruction has proved to be a powerful tool for determining PKS 
activity in vitro.[11a] This method requires the identification of interdomain regions in 
multidomain proteins, which—in this instance—was achieved using bioinformatics 
methods.[13] Hexahistidine constructs of mono- and multidomain protein fragments were 
prepared for heterologous expression in E. coli and nickel-affinity purification (see 
Appendix C). The constructs used in these experiments included a SAT-KS-MAT 
tridomain and PT, ACP2, and TE monodomains (Appendix C, Table C.2). Additionally, 
S2008A and H2171Q active-site point mutants of the TE monodomain were prepared 
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(Appendix C, Table C.2). Protein purity was confirmed by 12% SDS-PAGE analysis 
(Appendix C, Figure C.1). 
2.2.2. Reconstitution of CTB1 Activity 
 Recombination of deconstructed CTB1 protein fragments to generate complete 
and partial NR-PKS systems in vitro led to reconstituted enzymatic activity and 
deduction of individual domain function. The complete set of CTB1 domains (SAT-KS-
MAT + PT + ACP2 + TE) was combined in equimolar concentrations with acetyl-CoA 
 
Figure 2.2⏐Extracted products of in vitro reconstituted CTB1 reactions. HPLC chromatograms at 280 
nm are presented of reactions of a fully reconstituted CTB1 (a), a reconstituted CTB1 lacking the TE 
domain (b), a reconstituted minimal CTB1 (SAT-KS-MAT + ACP2, c), a fully reconstituted CTB1 with 
TE-S2008A mutant (d), and a fully reconstituted CTB1 with TE-H2171Q mutant (e). For clarity, the scale 
of the y-ordinate in parts b and c are an order of magnitude less than the other chromatograms. 
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and malonyl-CoA. The major product of this reaction (Figure 2.2a) was nor-toralactone 
(1) as determined by comparison to a standard prepared by total synthesis (See Appendix 
C). In vitro reactions of CTB1 were carried out in which the TE domain was excluded 
(SAT-KS-MAT + PT + ACP2). The overall synthetic activity of CTB1 was dramatically 
reduced (ca. 50-fold) in these reactions as measured by total product output (Figure 2.2b). 
Naphthopyrone 1 was produced in small amounts while no other major product was 
observed. In keeping with this observation, a mutant TE domain in which the catalytic 
Ser2008 was replaced with Ala was similarly unproductive (Figure 2.2d). However, when 
the catalytic His2171 was mutated to Gln, the reaction proceeded at about two thirds of 
the wild type production (Figure 2.2e). 
 
Figure 2.3⏐UV-visible spectra for derailment products of minimal CTB1. UV-vis spectra are presented 
for fully (a) and partially (b) characterized derailment products. 
Table 2.1⏐HRMS–ESI-IT-TOF for derailment products of minimal CTB1. 
Peak m/z: [MH+] calcd for: found: 
7 YWA1, C14H13O6, 277.0712 277.0609 (100%) 
8 pannorin, C14H11O5, 259.0607 259.0597 (100%) 
9 triacetic acid lactone, C6H7O3, 127.0395 127.0395 (100%) 
11 C14H13O6, 277.0712 277.0703 (100%), 299.0515 (MNa+, 40.99%) 
12 C14H13O6, 277.0712 277.0705 (100%) 
13 C13H13O4, 233.0814 233.0802 (100%) 
14 C14H13O6, 277.0712 277.0703 (100%), 299.0528 (MNa+, 12.45%) 
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 A minimal CTB1 system in which both the PT and TE domains were excluded 
(SAT-KS-MAT + ACP2) was proficient in acetate polyketide extension, leading to a 
variety of "derailment" products (Figure 2.2c). These derailment products were consistent 
with full-length heptaketide intermediates as determined by LCMS (Figure 2.3, Table 
2.1). Two such products were structurally characterized to be YWA1 (7)[14] and pannorin 
(8)[15] by comparison to known chemical properties and an authentic standard, 
respectively. Additionally, triacetic acid lactone (9) was observed, a product of self-
condensation from a truncated triketide intermediate (Figure 2.3a).[16] All derailment 
products were produced in significantly lower quantities when the PT or TE was present. 
2.2.3. Selective Heavy-Isotope Incorporation into CTB1 Products 
 To investigate the CTB1 TE mechanism, an 18O heavy-isotope label was 
incorporated at the O13 position of the heptaketide linear intermediate 3. The fate of this 
oxygen could be used to distinguish between TE-catalyzed hydrolysis and enol 
lactonization (Figure 2.1). The O13 position is uniquely derived from the starter unit 
acetyl precursor, allowing for selective labeling of this position. Reconstitution reactions 
in which acetyl-CoA was withheld showed less than a quarter of the production of nor-
 
Figure 2.4⏐Demonstration of the “starter-unit effect” in CTB1. Nor-toralactone is differentially 
produced by a fully reconstituted CTB1 in vitro from acetyl-CoA and malonyl-CoA (a) or malonyl-CoA 
only (b). 
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toralactone by HPLC relative to the same reaction in which both acetyl-CoA and 
malonyl-CoA were included (Figure 2.4). 
 Reconstitution reactions were carried out as before with either unlabeled acetyl-
CoA or [18O]acetyl-CoA. [18O]Acetyl-CoA was prepared enzymatically and HPLC 
purified. Mass spectrometric analysis showed the [18O]acetyl-CoA had an exact mass 
consistent with incorporation with a single heavy-atom (m/z: [MH+] calcd for 
C23H39N7O1618OP3S, 812.1379; found 812.1328). A mass indicative of no heavy-atom 
incorporation was not detected. The products of the reconstitution reactions were 
analyzed by LCMS to measure heavy isotope content. Naphthopyrone 1 produced by the 
fully reconstituted CTB1 (SAT-KS-MAT + PT + ACP2 + TE) showed a distinct mass 
shift consistent with the incorporation of a single 18O atom (m/z: [MH+] calcd for 
 
Figure 2.5⏐Observed mass shift for nor-toralactone in CTB1 reconstitution reactions. Reactions of 
fully reconstituted CTB1 (SAT-KS-MAT + PT + ACP2 +TE) using malonyl-CoA and unlabeled (a) or 
heavy-isotope labeled (b) acetyl-CoA are indicative of heavy-isotope retention in nor-toralactone. 
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C14H11O418O 261.0649; found 261.0651 [100%]). However, a minor portion did not 
contain the heavy isotope (m/z: [MH+] calcd for C14H11O5 259.0607; found 259.0610 
[27%], Figure 2.5). 
 In the derailment products of the minimal CTB1 (SAT-KS-MAT + ACP2), 18O 
incorporation was the minor component relative to the unlabeled component. YWA1 (7) 
showed very little 18O incorporation (m/z: [MH+] calcd for C14H13O6 277.0712; found 
277.0691 [100%], 279.0725 [3%]). No 18O incorporation was observed in the derailment 
product pannorin (8, m/z: [MH+] calcd for C14H11O5 259.0607; found 259.0596 [100%]; 
m/z: [MH+] calcd for C14H11O418O 261.0649; mass not found). On the other hand, 
triacetic acid lactone (9) was substantially enriched in 18O (m/z: [MH+] calcd for 
C6H7O218O 129.0438; found 129.0430 [100%], 127.0392 [37%]). 
2.3. Discussion 
 The proposed product of CTB1 is carboxylic acid 5, making the appearance of 
nor-toralactone (1) unexpected. While it is tempting to interpret pyrone formation as 
resulting from direct enol lactonization, spontaneous intramolecular cyclization and 
dehydration of the bicyclic intermediate 4 could produce nor-toralactone without the 
intervention of the TE domain (Figure 2.1, pathway a). Indeed, enol lactonization is the 
most commonly observed spontaneous off-loading mechanism for NR-PKSs lacking a 
TE domain.[17] In the classic example of the norsolorinic acid synthase PksA from 
Aspergillus parasiticus, the product norpyrone (15) is preferentially formed over 
norsolorinic acid anthrone (16) when the TE domain is withheld (Figure 2.6).[11a, 18] In 
fact, C–O bond formation is irreversible, as PksA TE was unable to hydrolyze the pyrone 
of norpyrone to form norsolorinic acid anthrone—its native product—despite the 
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predicted stabilizing force of C–C bond formation and aromatization.[11a] We sought to 
resolve the CTB1 TE domain’s mechanistic ambiguity, given its peculiar activity relative 
to established NR-PKS chemistry. 
 As in other NR-PKSs, spontaneous pyrone formation was the predicted release 
mechanism in reactions without the TE domain. However, the low production of nor-
toralactone in reactions lacking the CTB1 TE domain indicated a slow rate of 
spontaneous release, strongly suggesting a central role for the TE domain in accelerating 
pyrone formation. In keeping with this observation, the abolishment of nor-toralactone 
production in the TE S2008A active site mutant strengthens the argument of the TE’s role 
in product evolution. The high reactivity of the H2171Q catalytic triad mutant was 
surprising. In conventional TE mechanisms, the catalytic His is believed to serve as a 
general base during the formation of the acyl-enzyme intermediate and then again to 
facilitate product-releasing nucleophilic attack of the acyl-enzyme intermediate.[9, 11b] A 
different residue may serve this role in the mutant TE thereby allowing for the increased 
residual activity. Alternatively, functionally related enzymes with the "/!-hydrolase 
family have been shown to be relatively tolerant to the His to Gln mutation.[19] It is 
Figure 2.6"Spontaneous versus TE-catalyzed release of the PksA penultimate intermediate. 
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proposed that these enzymes do not utilize the classical serine protease mechanism. 
Rather, the His-Ser dyad promotes the formation of a reactive intermediate that directly 
activates the catalytic Ser for nucleophilic attack. It is unclear if such a mechanism is at 
play in CTB1. 
Derailment products of a minimal NR-PKS lacking the PT and TE domains are to 
be expected. Without the catalytic guidance of these tailoring domains, a thermodynamic 
distribution of low-energy spontaneous aldol cyclizations and intramolecular 
transesterifications of the linear poly-!-ketone intermediate will predominate.[11a] The 
mass signatures of the observed minimal CTB1 derailment products are consistent with 
this view of derailment evolution. Specifically, YWA1 (7) and pannorin (8) can be 
envisioned as deriving from the same linear heptaketide intermediate 10 (Figure 2.7). 
Further, the uncharacterized derailment products had masses consistent with varying 
Figure 2.7"Origin of CTB1 derailment products. Spontaneous cyclization of linear heptaketide 
intermediate 10 led to the production of YWA1 (7) and pannorin (8, a). A common truncation product of 
NR-PKSs is triacetic acid lactone (9, b). The ketide unit derived from the acetyl-CoA starter unit is 
displayed in green. The 18O-labeled position is denoted with an asterisk. 
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levels of dehydration or decarboxylation of the same linear intermediate 10. All minimal 
CTB1 derailment products were produced at significantly lower quantities when the PT 
or TE was present, underscoring the central roles of these domains in both directed 
cyclization and overall catalytic efficiency. 
 Despite solidifying its overall role in catalysis, these observations did not address 
the mechanism by which the TE domain catalyzes the synthesis of nor-toralactone. As 
noted, two possible mechanisms were considered (Figure 2.1). The fate of the polyketide 
oxygen at C13 is different for each mechanism. In pathway a (hydrolysis), the oxygen 
would be lost as water, while in pathway b (enol lactonization) it would be retained as the 
endocyclic oxygen of the pyrone moiety. In NR-PKSs, the SAT domain is responsible for 
the observed “starter-unit effect” by selectively loading the ACP with a specific acyl-
thioester substrate.[8, 20] While the starter unit for CTB1 is the relatively simple acetyl-
CoA, other SATs select more distinctive starter units—usually produced by an upstream 
biosynthetic module. The results often have a profound effect on the product output of 
the given NR-PKS.[21] In the case of PksA, the starter unit is a hexanoyl thioester 
produced by a dedicated fungal fatty acid synthase.[22] In reconstitution reactions in 
which the occupancy of individual domains of PksA were assayed, it was determined that 
polyketide biosynthesis will not commence until the proper hexanoyl starter unit is 
transferred to the enzyme, underscoring the critical role the starter unit effect plays on 
overall turnover.[10] Because the O13 atom in the CTB1 linear intermediate 3 is uniquely 
derived from its starter unit acetyl-CoA, we were able to selectively label it through the 
use of [18O]acetyl-CoA. CTB1 demonstrated a significant starter unit effect with nor-
toralactone production decreased to less than 25% when acetyl-CoA was withheld. The 
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residual activity was believed to arise from acetyl-CoA contamination of malonyl-CoA 
stocks through spontaneous decarboxylation, but could also arise from PKS-mediated 
decarboxylation following malonyl loading. The strength of the starter-unit effect 
allowed for mechanistic determination by observing selective heavy-isotope 
incorporation into the CTB1 products. 
 The heavy-isotope incorporation data support pathway b and direct enol 
lactonization by the TE domain. The 18O heavy isotope was clearly incorporated into nor-
toralactone. The fraction of nor-toralactone in which the heavy isotope was not 
incorporated was estimated at about a quarter by relative mass intensity. This fraction 
was attributed to unlabeled acetyl incorporation, as the proportion was similar to the 
residual production in reactions where acetyl-CoA was withheld. Furthermore, heavy-
isotope incorporation data for the derailment products was entirely consistent with 
mechanism b. In YWA1 (7), 18O was incorporated into a very minor proportion of 
molecules as determined by relative mass intensity. As the expected labeled oxygen atom 
is part of the hemiketal moiety in YWA1, the loss of the heavy isotope as water was 
expected (Figure 2.7a). In pannorin (8), no heavy isotope was retained, because it was 
eliminated as water during the aldol cyclization/aromatization needed to access this 
scaffold (Figure 2.7a). Finally, the heavy isotope is retained as the endocyclic oxygen of 
triacetic acid lactone (9, Figure 2.7b). As with nor-toralactone, the percentage of heavy-
isotope incorporation in triacetic acid lactone roughly matches that of unlabeled acetyl-
CoA usage. 
 The isotope incorporation data are unambiguous that nor-toralactone is the direct 
product of CTB1 (pathway b). Furthermore, the strong dependence of the TE domain in 
 50 
nor-toralactone evolution eliminates the possibility of pathway b occurring 
spontaneously. The mechanism by which the TE domain of CTB1 favors pyrone 
formation over hydrolysis is not precisely known. It is likely that the thioesterase 
promotes keto/enol tautomerization in the active site thereby favoring enol lactonization. 
In contrast, TE substrates undergoing Claisen cyclization for product release contain a β-
diketone side chain, not a methyl ketone as in nor-toralactone, whose lower pKa (ca. 9 vs. 
19) doubtless plays a determining role in the catalysis of carbon–carbon bond 
formation.[11] 
2.4. Conclusions 
 The NR-PKS of cercosporin biosynthesis in C. nicotianae, CTB1, catalyzes the 
formation of the naphthopyrone nor-toralactone. The formation of nor-toralactone is 
unexpected and contrary to the proposed biosynthetic pathway for cercosporin. 
Nevertheless, direct formation of nor-toralactone by CTB1 is unambiguous, as 
demonstrated by heavy-isotope incorporation experiments. The data support pyrone 
formation through direct enol lactonization catalyzed by the TE domain—a hitherto 
unknown chemical paradigm for NR-PKS thioester domains. The underpinning 
mechanism by which enol lactonization is favored in the CTB1 TE domain remains 
unknown and warrants further investigation. The new understanding of CTB1 catalysis 
presented here must be reconciled with the currently held biosynthetic pathway for 
cercosporin. 
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2.5. Experimental Methods 
2.5.1. Reagents and Biological Strains 
 All reagents and primers were purchased from Sigma-Aldrich (St. Louis, MO, 
USA), unless otherwise specified. Magnesium chloride, sodium chloride, potassium 
phosphate monobasic, potassium phosphate dibasic, and deoxynucleotides (dNTPs) were 
purchased from Thermo Scientific (Waltham, MA, USA). Isopropyl-β-D-thiogalactoside 
(IPTG), kanamycin, and nickel (high density) agarose beads were purchased from Gold 
Biotechnology (St. Louis, MO, USA). Imidazole was purchased from Acros Organics 
(Geel, Belgium). Sodium acetate (18O, 95%) was from Cambridge Isotope Laboratories 
(Cambridge, MA, USA). Yeast extract and tryptone were purchased from Boston 
BioProducts (Ashland, MA, USA). Agar was purchased from bioWORLD (Dublin, OH, 
USA). Plasmids pET-24a(+) and pET-28a(+) were purchased from EMD Millipore 
(Darmstadt, Germany). All enzymes used for manipulation of DNA and 10 × HF Buffer 
were purchased from New England Biolabs (Ipswich, MA, USA). Bio-Rad protein assay 
dye for determining protein concentration by the Bradford assay was purchased from 
Bio-Rad laboratories (Hercules, CA, USA). Bacterial strain Escherichia coli BL21(DE3) 
was purchased from Sigma-Aldrich and made electrocompetent by standard protocols 
(Appendix B).[23] Genomic DNA purified from C. nicotianae (ATCC© 18366™) was 
provided by Dr. M. E. Daub (North Carolina State University, NC, USA). 
2.5.2. Preparation of Expression Constructs 
 DNA manipulations were carried out in accordance with standard methods 
(Appendix B).[24] Details of the expression constructs used in this study are presented in 
Table C.3 (Appendix C). Primers used for cloning are presented in Table C.1 (Appendix 
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C). All plasmids were maintained in E. coli BL21(DE3) cells stored in 20% glycerol at 
−80 °C. The SAT-KS-MAT and PT proteins had a C-terminal 6 × His tag. The ACP2 and 
TE proteins had an N-terminal 6 × His tag. All plasmids were screened for proper 
assembly by restriction enzyme digest and the complete insert was confirmed by DNA 
sequencing. All sequencing was conducted at the Sequencing and Synthesis Core 
Facility, Johns Hopkins University, School of Medicine (Baltimore, MD, USA). 
 The SAT-KS-MAT tridomain expression construct (pECTB1-NKA6) was 
generated from three separate DNA fragments that were spliced together using overlap 
extension PCR (Appendix B). The first fragment (containing the 3´ end of exon 3) was 
amplified by PCR (Appendix B) from genomic C. nicotianae DNA template with primers 
CTB1-ex3-5 and CTB1-ex3-3. The second fragment was a codon-optimized synthon 
(Appendix C) spanning exons 4 and 5 constructed through polymerase cycling assembly 
(PCA, Appendix B). The primers used in the construction of this synthon are described in 
Table C.2 (Appendix C). The third fragment (containing the 5´ end of exon 6) was 
amplified by PCR from genomic C. nicotianae DNA template with primers CTB1-ex6-5 
and CTB1-MAT6-3. Overlap extension PCR of these three fragments with outside 
primers CTB1-ex3-5 and CTB1-MAT6-3 was used to generate the SAT-KS-MAT insert. 
This product was digested with HindIII and NotI and inserted into analogous sites of 
pECTB1-SAT[8] to generate pECTB1-NKA6. 
 The PT monodomain expression construct (pECTB1-PT) was made by overlap 
extension PCR of three DNA fragments. The first fragment was amplified by PCR from 
genomic C. nicotianae DNA template with primers CTB1-PT-5 and CTB1-ex6-3. The 
second fragment was amplified by PCR from genomic C. nicotianae DNA template with 
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primers CTB1-ex7-5 and CTB1-ex7-3. The third fragment was amplified by PCR from 
genomic C. nicotianae DNA template with primers CTB1-ex8-5 and CTB1-PT-3. 
Overlap extension PCR was carried out with these three fragments with primers CTB1-
PT-5 and CTB1-PT-3 to generate the PT insert. The resulting fragment was digested with 
NdeI and NotI and inserted into corresponding restriction sites in pET-24a(+) to make 
pECTB1-PT. 
 The ACP2 monodomain expression construct (pECTB1-ACP) was made by PCR 
using C. nicotianae genomic DNA template with primers CTB1-ACP-5 and CTB1-ACP-
3s. The amplified product was digested with NdeI and NotI and inserted into the 
corresponding restriction sites in pET-28a(+) to generate pECTB1-ACP. 
 An ACP2-TE didomain expression construct (pECTB1-TA) was made through 
overlap extension PCR of two DNA fragments. The first fragment was amplified by PCR 
from C. nicotianae genomic DNA with primers CTB1-ACP-5 and CTB1-ex8-3. The 
second fragment was amplified by PCR from C. nicotianae genomic DNA with primers 
CTB1-ex9-5 and CTB1-3. Overlap extension PCR of these two fragments with primers 
CTB1-ACP-5 and CTB1-3 generated the ACP2-TE insert. This amplified product was 
digested with NdeI and NotI and inserted into the corresponding restriction sites in pET-
24a(+) to generate pECTB1-TA. 
 The TE monodomain expression construct (pECTB1-TE) was created through 
PCR amplification of pECTB1-TA template with primers CTB1-TE-5 and CTB1-3-Stop. 
The amplified product was digested with NdeI and NotI and inserted into the 
corresponding restriction sites in pET-28a(+) to generate pECTB1-TE. 
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 The TE point-mutant expression constructs (pECTB1-TE-S2008A and pECTB1-
TE-H2171Q) were generated by overlap extension PCR. The 5ʹ′ fragments were amplified 
by PCR using pECTB1-TE template with primers CTB1-TE-5 and CTB1-S2008A-3 or 
CTB1-H2171Q-3, respectively. The 3ʹ′ fragments were amplified by PCR using pECTB1-
TE template with primers CTB1-S2008A-5 or CTB1-H2171Q-5, respectively, and 
CTB1-3-Stop. Overlap extension PCR of these two fragments with primers CTB1-TE-5 
and CTB1-3-Stop generated the point-mutant insert. These amplified products were 
digested with NdeI and NotI and inserted into the corresponding sites of pET-28a(+) to 
generate pECTB1-TE-S2008A and pECTB1-TE-H2171Q, respectively. 
2.5.3. Protein Expression and Purification 
 Expression constructs were transformed into E. coli BL21(DE3) by 
electroporation (Appendix B). Proteins were prepared by heterologous expression and 
purified by nickel affinity chromatography (Appendix B). Eluted protein fractions were 
dialyzed into 100 mM potassium phosphate pH 7.0, 5% glycerol at 4 °C overnight with 
three buffer exchanges. Purified protein concentrations were determined by the Bradford 
assay using bovine serum albumin (New England Biolabs) as a standard, as described in 
Appendix B.[25] Excess protein was flash frozen in liquid nitrogen and stored at −80 °C 
until further use. 
2.5.4. [18O]Acetyl-CoA Synthesis and Purification 
 [18O]Acetyl-CoA was prepared enzymatically as follows: 5 mM CoASH, 10 mM 
sodium acetate (18O2, 95%), 10 mM ATP, 1 mM TCEP, and 0.4 unit/mL acetyl-CoA 
synthetase in 25 mM potassium phosphate pH 7.0 at 25 °C for 2 h. Protein was removed 
by filtration through an Amicon Ultra centrifugal filter unit with a 10 kDa nominal 
 55 
molecular weight limit (EMD Millipore). [18O]Acetyl-CoA was purified by HPLC on an 
Agilent 1200 (Agilent Technologies, Santa Clara, CA, USA) system fitted with a Prodigy 
5u ODS3 100Å (250 × 4.60 mm, 5 µm) column (Phenomenex, Torrance, CA, USA) 
using the following mobile phase gradient: hold at 5% solvent A, 5 min; linear gradient 
from 5% solvent A to 35% solvent A, 20 min; at a flow rate of 1 mL/min; where solvent 
A was acetonitrile + 0.1% TFA and solvent B was water + 0.1% TFA. [18O]Acetyl-CoA 
eluted at 12.2 min. Purified [18O]acetyl-CoA was lyophilized, dissolved in 100 mM 
potassium phosphate pH 7.0 to yield a 25 mM solution, and stored at −80 °C. High-
resolution mass analysis to determine heavy-isotope incorporation was conducted on a 
Shimadzu LCMS-IT-TOF (Columbia, MD, USA). 
2.5.5. In Vitro ACP Phosphopantetheinylation 
 The ACP fragment needed to be activated with 4´-phosphopantetheine prior to 
reconstitution reactions. This was accomplished in vitro using Svp, a promiscuous 
phosphopantetheinyl transferease as previously described.[11a] Briefly, the ACP activation 
reaction was as follows: 100 µM CTB1-ACP2, 2 µM Svp, 400 µM CoASH, and 20 mM 
MgCl2 in 100 mM potassium phosphate pH 7.0, 5% glycerol at 25 °C for 1 h. 
2.5.6. In Vitro Reconstitution Reactions 
 Proteins used in the reconstitution reactions were purified immediately before use. 
Reaction conditions were as follows: 10 µM each of the CTB1 protein fragments to be 
used, 0.5 mM acetyl-CoA, 2 mM malonyl-CoA, 1 mM TCEP in 100 mM potassium 
phosphate, 5% glycerol, pH 7.0. The CoA substrates were added simultaneously to 
initiate reactions. Reactions were conducted at room temperature for 4 h. To demonstrate 
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the starter unit effect, acetyl-CoA was excluded. To test the mechanism of pyrone 
formation, [18O]acetyl-CoA was used instead of the unlabeled acetyl-CoA. 
 Reactions were quenched with the addition of concentrated HCl, and the products 
were extracted thrice with 2 × reaction volume with ethyl acetate. The organic fractions 
were combined, evaporated under vacuum, and dissolved in 25% acetonitrile (aq.) to a 
final volume equivalent to the reaction volume. The extracts were filtered through 0.2 µm 
PTFE and analyzed by HPLC and LCMS-IT-TOF. 
2.5.7. Analytical Methods 
 HPLC was carried out on an Agilent 1200 fitted with a Prodigy 5u ODS3 100Å 
(250 × 4.60 mm, 5 µm) column and UV-vis diode array detector (DAD) using the 
following mobile phase gradient: 50 µL injections; into 5–85% solvent A, 40 min; at 1 
mL/min; where solvent A was acetonitrile + 0.1% formic acid and solvent B was water + 
0.1% formic acid. Polyketide products were detected by monitoring at 280 nm and the 
full UV-vis spectrum was collected for each product. 
 LCMS analysis was carried out on a Shimadzu LCMS-IT-TOF fitted with a Luna 
C18(2) 3µ (150 × 2.0 mm, 3 µm) column (Phenomenex). The mobile phase gradient for 
LC was described above, except with a flow rate of 0.2 mL/min. Mass detection was 
carried out in the positive ion mode. We thank Dr. K. L. Fiedler and Prof. R. J. Cotter of 
the Middle Atlantic Mass Spectrometry Laboratory at the Johns Hopkins School of 
Medicine (Baltimore, MD, USA) and the Mid-Atlantic Regional Office of Shimadzu 
Scientific Instruments, Inc. (Columbia, MD, USA) for use of their Shimadzu LC-IT-TOF. 
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Chapter 3: Systematic Domain-Swaps of Iterative, Non-
reducing Polyketide Synthases Provide a Mechanistic 
Understanding and Rationale for Catalytic Reprogramming 
This chapter was adapted with permission from A. G. Newman, A. L. Vagstad, P. A. 
Storm, C. A. Townsend, J. Am. Chem. Soc. 2014, 136, 7348-7362. 
3.1. Introduction 
 Polyketides are a structurally and functionally diverse family of natural products 
containing environmental toxins and pigments as well as pharmaceutical agents. Several 
drugs on the market are of polyketide origin including the antibiotics tetracycline and 
erythromycin, immunosuppressant rapamycin, anticholesterol drug lovastatin, and 
anticancer drug epothilone B.[1] The direct engineering of polyketide biosynthetic 
pathways for the production of non-native metabolites has been an attractive goal for 
those wishing to expand the potential polyketide drug pool. However, such approaches 
require a greater and nuanced understanding of the underlying mechanisms at play in 
polyketide assembly. As a consequence, the methodology of rational redirection of 
polyketide pathways is still in its infancy.[2] 
 Many of the known polyketides are assembled in a linear fashion by large, 
multidomain proteins dubbed type I polyketide synthases (PKS).[3] While the modular 
type I PKSs have been extensively studied for 20 years, the biochemistry of fungal, 
iterative, non-reducing PKSs (NR-PKS) is only now beginning to be elucidated.[4] The 
NR-PKSs are responsible for the biosynthesis of a variety of aromatic polyketide 
products and share a common domain architecture that is intrinsically linked to their 
function (Figure 3.1). The mode of biosynthesis is analogous to that of fatty acids by 
animal fatty acid synthases (FAS), but simplified.[5] The three amino-terminal domains, 
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the starter unit:acyl-carrier protein transacylase (SAT), ketosynthase (KS) and malonyl 
acyl transferase (MAT) domains are responsible for the initiation and polyketide 
elongation phases. The SAT domain selects a precursor or starter unit substrate as an acyl 
thioester while the MAT domain introduces ketide extender units from malonyl-CoA. 
The KS works in collaboration with the acyl-carrier protein (ACP) to catalyze the 
decarboxylative Claisen condensation of these substrates generating a linear, ACP-bound 
poly-!-ketone intermediate. The carboxy-terminal domains of NR-PKSs control the final 
stage of biosynthesis, which includes regiospecific aldol cyclizations/aromatizations by 
the product template (PT) domain and release through either hydrolysis,[6] Claisen 
(Dieckmann) cyclization,[7] or pyrone formation[8] by the TE. In this way, the four factors 
governing chemical diversity in aromatic polyketides are entirely controlled by the 
enzyme, with the amino-terminal half determining starter unit selection and chain length, 
and the carboxy-terminal half controlling regiospecific cyclization/aromatization and 
mechanism of product release. 
 Protein deconstruction, in which the NR-PKS is dissected into smaller mono- to 
multidomain fragments, has been a crucial tool for mechanistic understanding of these 
enzymes.[7a, 9] The method enables the rapid and selective in vitro recombination of NR-
Figure 3.1"The core domain architecture of NR-PKSs. Enzyme bound intermediates and products of 
TE-directed Claisen cyclization or spontaneous O–C bond closure are highlighted. 
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PKS activity, allowing for individual domain functions to be deduced and assayed. In 
these reactions, the enzymes work in trans, mimicking the discrete type II PKSs. The 
approach also allows for the recombination of an unnatural NR-PKS through domain-
swapping from functionally analogous domains of different NR-PKSs. Genetic domain-
swapping and the creation of chimeric modular, type I PKSs has been extensively 
examined in vivo, primarily with the DEBS PKSs of erythromycin biosynthesis.[10] These 
systems have been uniquely attractive because the domains of these canonical modular 
enzymes are only used once in an assembly line fashion. Additionally, the KS domains 
often demonstrate sufficient substrate promiscuity to allow for a degree of synthetic 
flexibility. Similarly, combinatorial studies of discrete type II PKSs have led to the 
generation of aromatic metabolite libraries.[11] Such approaches have focused on site-
specific reductions and cyclizations catalyzed by ketoreductase (KR) and 
aromatase/cyclase (ARO/CYC) proteins accepting alternative chain-length polyketide 
intermediates.[12] 
 Recently, our laboratory has explored in vitro domain-swapping as a method of 
developing non-cognate NR-PKSs.[13] We postulated that swapping N- and C-terminal 
halves of NR-PKSs could lead to the generation of novel products. In this way starter unit 
selection and chain-length control would be decoupled from the tailoring steps of late 
stage polyketide biosynthesis. Using the N-terminal SAT-KS-MAT tridomain fragment 
from the cercosporin biosynthetic NR-PKS, CTB1,[8, 14] we were able to efficiently 
complement enzymatic activity with the C-terminal half of four non-cognate NR-PKSs, 
representing a variety of cyclization and release pathways (Appendix D, Figure D.2). 
These limited data codified several proposed “rules” for efficient redirection of 
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biosynthesis, which are further tested and validated in experiments described herein. 
While the MAT and ACP domains behave consistently regardless of the parent synthase, 
the KS domain exerts stringent chain-length control, as has been demonstrated in 
multiple systems. The PT domain catalyzes cyclization using the bound 
phosphopantetheine thioester as the benchmark from which to establish regiochemistry. 
In this way, aromatization always occurs with the proper “register” (i.e. C2–C7, C4–C9, 
or C6–C11) for the given PT, even if it accepts a linear polyketide intermediate of non-
native length. This observation is in keeping with the complementation of cyclization 
register observed by Tang and coworkers with respect to the AptA and VrtA PTs.[15] 
Finally, the TE domain is crucial for catalytic turnover and will only exert its effect if a 
compatible intermediate is generated. 
 With the success of in vitro C-terminal domain-swapping with the CTB1 SAT-
KS-MAT, we wanted to systematically investigate the potential of this approach. We 
elected to study six enzymes that represent the wide span of known chemical diversity 
controlled by NR-PKSs: alkyl starter unit selection (acetyl or hexanoyl), chain-length 
control (C12 to C20), PT cyclization modes (C2–C7, C4–C9, or C6–C11), and TE release 
mechanism (hydrolysis, pyrone formation, or Claisen cyclization). The native activity of 
each enzyme investigated has been determined: Aspergillus parasiticus PksA, Giberella 
fujikuroi Pks4, Aspergillus terreus ACAS, Cercospora nicotianae CTB1, Aspergillus 
nidulans wA, and Colletotichum lagenaria Pks1 each produce norsolorinic acid anthrone 
(1, noranthrone),[7a] pre-bikaverin (2),[16] atrochrysone carboxylic acid (3),[17] nor-
toralactone (4),[8] YWA1 (5),[18] and 1,3,6,8-tetrahydroxynaphthalene (THN, 6),[19] 
respectively (Table 3.1). 
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3.2. Results 
3.2.1. Deconstruction of NR-PKSs 
The dissection of NR-PKSs into component mono- to multidomain fragments was 
patterned on the previously reported deconstruction of PksA.[7a] The percent similarity 
between the NR-PKSs used in this study ranged from 43% to 61% as calculated from 
global pairwise protein sequence alignments (Table 3.2). Equivalent cut sites for the other 
NR-PKSs used in this study were selected based on primary sequence alignments. 
Alternative cut sites were selected to optimize yields for proteins that suffered from low 
expression, insolubility or instability. SAT-KS-MAT tridomain, PT, ACPn, and TE 
Table 3.1"Native products of NR-PKSs used in this study. 






Mechanism Product Formed 
PksA Hexanoyl C20 
C4–C9 
C2–C11 C14–C1  
noranthrone, 1 
Pks4 Acetyl C18 C2–C7 C10–C1 
 
pre-bikaverin, 2 







CTB1 Acetyl C14 
C4–C9 
C2–C11 O13–C1  
nor-toralactone, 4 
wA Acetyl C14 
C4–C9 
C2–C11 C10–C1  
YWA1, 5 
Pks1 Acetyl C12 C2–C7 C10–C1b 
THN, 6 
a The TE of the ACAS system exists as a discreet !-lactamase type TE, ACTE. 
b The Pks1 TE has an additional deacetylase activity. 
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monodomain fragments were cloned as hexahistidine fusions for heterologous expression 
in E. coli followed by nickel affinity purification (Appendix D, Figure D.1). The tandem 
ACPs from CTB1, wA, and Pks1 were prepared as intact didomain fragments, here 
referred to as ACP2. The discrete β-lactamase type TE of atrochrysone biosynthesis, 
ACTE,[17] was expressed separately. SAT-KS-MAT tridomain fragments for ACAS and 
wA could not be obtained despite repeated attempts to optimize cut-site selection, fusion 
tag identity and location, and culture conditions. Details of individual protein constructs 
used in this study are presented in Table D.3 (Appendix D). All constructs were sequence 
verified. 
3.2.2. Non-cognate Minimal NR-PKS Compatibility 
 Given the successful redirection of biosynthesis in combinatorial reactions of 
CTB1,[13] we sought to systematically evaluate if non-cognate NR-PKS domains, in 
general, could predictably alter biochemistry. Combinatorial reactions were modeled on 
the in vitro reconstitution of PksA, using 10 µM protein concentrations and acyl-N-
acetylcysteamine (SNAC) thioester substrates.[7a] Extracted products from these reactions 
were analyzed by reverse phase HPLC and LC-ESI-MS. Product identification was 
accomplished by comparing UV-visible spectra and masses to those of authentic 
standards or literature values. As in the previous study,[13] selected sets of PT, ACPn, and 
Table 3.2⏐Percent identity/similarity/gaps for global pairwise alignment of NR-PKSs. Alignment 
conducted using EMBOSS Needle with default settings (http://www.ebi.ac.uk/Tools/psa/). 
 PksA ACAS Pks4 CTB1 wA 
ACAS 30.3/45.9/23.1     
Pks4 36.9/55.6/8.9 32.8/48.6/20.3    
CTB1 36.8/53.8/11.5 29.4/42.9/25.5 36.0/52.4/11.9   
wA 38.5/54.8/12.2 32.3/56.7/26.0 43.0/60.1/10.5 37.5/54.9/8.8  
Pks1 35.8/52.2/11.8 33.7/47.1/25.3 38.2/53.6/11.2 35.3/53.3/7.9 43.3/60.8/6.2 
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TE monodomains from a single parent synthase were recombined with a non-cognate 
SAT-KS-MAT tridomain. By systematically varying the SAT-KS-MAT tridomain, we 
were able to achieve 72 individual combinations, representing the complete set of two-
part non-cognate configurations. 
 We first established that all minimal NR-PKSs were active, regardless of the 
identity of the ACPn domain. We define a minimal NR-PKS as the requisite set of 
 
Figure 3.2⏐Product profiles for combinatorial minimal NR-PKSs. The 280 nm chromatograms for 
reactions of PksA SAT-KS-MAT (a), Pks4 SAT-KS-MAT (b), CTB1 SAT-KS-MAT (c), and Pks1 SAT-
KS-MAT (d) with the indicated ACPn are presented. 
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domains for proficient ketide homologation accomplished in the initial stages of 
polyketide biosynthesis. In practice, the minimal NR-PKS consists of the SAT-KS-MAT 
and ACPn domains. The combination of SAT-KS-MAT with non-cognate ACPn gave 
nearly identical product profiles in similar yields to that of the cognate reaction in all 
cases (Figure 3.2). It is noteworthy that the native ACP monodomains (PksA, Pks4 and 
ACAS) were able to efficiently complement activity with SAT-KS-MAT tridomains from 
proteins with native tandem ACPs (CTB1 and Pks1). It has been established that in wild-
type wA both ACPs are independently functional.[18] These data further strengthen the 
view that independent functionality is generally true of tandem ACPs. The role of 
multiple ACPs may then be to improve biosynthetic efficiency, as has been shown in 
polyunsaturated fatty acid synthases, which contain up to six tandem ACPs.[20] The 
complete compatibility of ACPs indicates that the recognition motifs for this domain are 
highly conserved among the NR-PKSs used in the current study. It is expected that ACP 
compatibility is a universal feature of NR-PKSs and an essential precondition of the 
planned domain-swapping experiment. 
 Overall, the products of the minimal NR-PKSs were consistent, by mass, with 
shunt products of full-length poly-!-ketones produced by the respective SAT-KS-MAT 
protein, with one exception. The major products of the minimal Pks4 are a pair of 
octaketide (C16) truncations coincident with the actinorhodin type II PKS products, SEK4 
Figure 3.3"Observed and predicted derailment products of minimal Pks4. 
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(7) and SEK4b (8, Figure 3.3).[21] Pks4 is expected to yield C18-chain-length, nonaketide 
products (9, 10, Figure 3.3), as has been observed in the reactions of 50 µM Pks4 KS-
MAT and 10 µM Pks4 ACP.[22] It should be noted that in the current study, the 
concentration of Pks4 SAT-KS-MAT is 10 µM, indicating that enzyme concentration 
might be a factor influencing chain length for deconstructed synthases. It is likely that 
Pks4 exhibits reduced processivity as the growing linear intermediate approaches the full 
chain length. The reduction in processivity is in agreement with a similar effect in PksA, 
where truncated heptaketide shunt products were observed in vitro.[23] This effect might 
be an artifact of the enzyme deconstruction approach. If the Pks4 KS domain has a 
decreased affinity for the C16-linear poly-β-ketone intermediate, the KS and ACP 
domains could freely dissociate in the deconstructed system allowing for derailing 
cyclizations and off-loading. For the intact system and perhaps for deconstructed 




Figure 3.4⏐Product analysis of combinatorial reactions with Pks4 SAT-KS-MAT. Proposed products 
of combinatorial reactions are presented (a). The chromatograms at 280 nm for products of cognate control 
reactions (b), non-cognate combinatorial reactions with the indicated PT and ACPn (c), and non-cognate 
combinatorial reactions with the indicated PT, ACPn, and TE (d) are presented. 
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3.2.3. Combinatorial Reactions of Pks4 SAT-KS-MAT 
HPLC product profiles for combinatorial reactions utilizing Pks4 SAT-KS-MAT 
are presented in Figure 3.4. Reactions for successful combinations are delineated in Table 
3.3. As has been reported, the Pks4 PT catalyzes C2–C7 aldol cyclization/aromatization 
while the Pks4 TE catalyzes C10–C1 Claisen/Dieckmann cyclization on a nonaketide 
(C18) linear intermediate to generate pre-bikaverin (2, Table 3.3).[16] The third ring (O9–













Pks4 Pks4  
 
Pks4 Pks4 Pks4 
 
Pks4 ACAS ACTE 
 
Pks4 CTB1 CTB1 
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C13) and fourth ring (C12–C17) are postulated to form spontaneously, followed by two 
dehydrations. Indeed, pre-bikaverin is observed upon complete reconstitution of a 
cognate Pks4 (Figure 3.4b). Interestingly, an additional product 11 of this reaction was 
observed to have a virtually identical UV-vis spectrum to that of YWA1 (5) suggesting 
that they share the same core architecture (Figures 3.4b and 3.5).[18] The mass of this 
product was found to correspond to a formula of C18H16O8 and there is an apparent 
complete conversion of it to pre-bikaverin with time. Given these data, we postulate that 
this product is the C18-YWA1 analog 11, in which the methyl substituent bears an 
acetoacetyl side chain extension (Table 3.3). This hypothesis would be consistent with 
proper PT and TE cyclization followed by hemi-ketal formation prior to 
cyclization/aromatization of the fourth ring. 
 Neither pre-bikaverin nor the C18-YWA1 analog 11 is detected in reactions of 
Pks4 lacking the TE. Instead, SMA93 (12)[24] is observed (Figure 2B). SMA93 arises 
from proper C2–C7 PT-catalyzed cyclization of the C18-linear intermediate followed by 
 
Figure 3.5⏐UV-vis spectra and HRMS for YWA1-core containing molecules. Product 11 converts to 
pre-bikaverin. 
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spontaneous O9–C1 closure, a common release mechanism (Table 3.3). In reactions of 
Pks4 SAT-KS-MAT with wA PT and ACP2, small quantities of SMA93 were also 
identified, indicating that wA PT directed C2–C7 cyclization (Figure 3.4c). However, wA 
TE could not complement C10–C1 cyclization, and only vanishingly small amounts of 
pre-bikaverin were observed (Figure 3.4d). 
 On the other hand, combinations with CTB1 (C14) PT, ACP2 and TE redirected 
biosynthesis towards a product of similar retention time and spectrum to that of nor-
toralactone (4), the native CTB1 product (Figure 3.4d).[8] Smaller quantities of this 
product are observed in reactions lacking the CTB1 TE domain (Figure 3.4c). The 
product has the characteristic spectrum of a naphthopyrone and can be compared to both 
nor-toralactone and norpyrone (19, Figure 3.6).[7a, 8] In keeping with these data, we 
propose a C18-nor-toralactone analog 13 arising from CTB1 PT-catalyzed C4–C9 and 
C2–C11 cyclization, followed by CTB1 TE-assisted O13–C1 pyrone formation (Table 
3.3). Because a mass for this product could not detected, the C16-nor-toralactone analog 
Figure 3.6"UV-vis spectra and HRMS for naphthopyrone-core containing molecules. 
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14 (in which the methyl group has been extended with a single acetyl substituent) cannot 
be ruled out. Two additional unique products were observed in these reactions, eluting at 
15.6 minutes and 16.1 minutes (Figure 3.4d). We did not conduct structural 
characterization of these products, but speculate that they arise from CTB1 PT- and TE-
influenced spontaneous cyclization and release. 
 ACAS (C16) was also able to complement Pks4 SAT-KS-MAT, producing a 
product with a retention time of 20.9 minutes and a molecular formula of C17H16O6 as 
determined by LC-ESI-MS (Figure 3.4d). The UV-vis spectrum for this product is in 
agreement with that for atrochrysone, the decarboxylated native product of ACAS, 
atrochrysone carboxylic acid (Table 3.1).[17, 25] If the ACAS PT domain catalyzed its 
native C6–C11 and C4–C13 cyclizations followed by ACTE-catalyzed hydrolytic release 
on the C18 linear poly-!-ketone intermediate, the resulting product, 26, would contain the 
atrochrysone core architecture (Table 3.3). We propose the structure 15, which would 
arise from decarboxylation of acid 26 and would satisfy both the mass and spectral data 
Figure 3.7"UV-vis spectra and HRMS for atrochrysone-core containing molecules. 
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(Figure 3.7). A similar decarboxylation is observed in reactions of native ACAS, with 
atrochrysone carboxylic acid decomposing spontaneously to atrochrysone.[17] 
 Notably, reactions of Pks4 SAT-KS-MAT with PksA (C20) PT, ACP and TE 
domains showed no evidence for redirection of chemistry (Figure 3.4d). This observation 
was unexpected because PksA normally processes a C20-length intermediate and could, 
therefore, easily accommodate the expected C18-length nonaketide intermediate of Pks4. 
Instead, reactions with all combinations of PksA domains showed activity similar to that 
of the minimal Pks4 alone. The inability of the PksA domains to complement activity 
with the Pks4 intermediate likely arises from the unique hexanoyl starter unit of PksA 
biosynthesis.[26] The crystal structure of PksA PT shows structurally distinct, hydrophobic 
binding pocket deep in its active site that presumably binds the hexyl moiety of the PksA 
linear poly-β-ketone.[27] It is probable that this binding pocket is incompatible with the 





Figure 3.8⏐Product analysis of combinatorial reactions with Pks1 SAT-KS-MAT. Proposed products 
of combinatorial reactions are presented (a). The chromatograms at 280 nm for products of cognate control 
reactions (b), non-cognate combinatorial reactions with the indicated PT and ACPn (c), and non-cognate 
combinatorial reactions with the indicated PT, ACPn, and TE (d) are presented. 
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3.2.4. Combinatorial Reactions of Pks1 SAT-KS-MAT 
HPLC product profiles for combinatorial reactions utilizing Pks1 SAT-KS-MAT 
are presented in Figure 3.8. Reactions for successful combinations are delineated in Table 
3.4. The native product of Pks1 is 1,3,6,8-tetrahydroxynaphthalene (THN, 6), an apparent 
pentaketide (C10) product.[19] However, as has been previously demonstrated, Pks1 in fact 
catalyzes the formation of a hexaketide (C12) intermediate from the condensation of an 
acetyl starter unit with five malonyl equivalents. The Pks1 PT domain catalyzes C2–C7 
cyclization with the TE domain catalyzing the formation of the second ring through C10–
C1 Claisen condensation cyclization, generating 2-acetyl-1,3,6,8-
tetrahydroxynaphthalene (ATHN, 16). The Pks1 TE domain has an additional, unique 
activity and will catalyze concomitant deacetylation to form THN directly. THN is 
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further auto-oxidized to the naphthoquinone flaviolin (17), which is the observed product 
of in vitro reactions (Table 3.4).[19] These activities are clearly demonstrated in the 
present Pks1 control reactions (Figure 3.8b). In reactions lacking the TE domain, the 
major product is an isocoumarin hexaketide product 18 that arises from PT-catalyzed C2–
C7 cyclization followed by spontaneous O9-C1 release (Table 3.4).[19] The fully 
reconstituted system, although inefficient, produces ATHN and flaviolin as well as the 
heptaketide product YWA1 (5). The deconstructed Pks1 shows a marked reduction in 
efficiency versus the intact or minimally deconstructed (SAT-KS-MAT-PT-ACP2 + TE) 
proteins, which produce flaviolin nearly exclusively and in high yields.[19] The 
appearance of heptaketide products in reactions with the TE is concurrent with a 
reduction of overall biosynthetic capacity (relative to reactions lacking the TE). This 
observation indicates that chain-length control, while highly regulated, is likely tied to 
overall turnover. 
 Indeed, reactions of Pks1 SAT-KS-MAT with CTB1 (C14) PT, ACP2 and TE 
produce nor-toralactone (4) as the clear major product (Figure 3.8d). Nor-toralactone is 
created by CTB1 PT-mediated C4–C9 and C2–C11 aldol cyclizations followed by CTB1 
TE-catalyzed O13–C1 bond closure of a heptaketide intermediate (Table 3.4) and is the 
native product of CTB1.[8] The generation of nor-toralactone is attended by a 
simultaneous reduction in shunt product formation indicating that both the PT and TE 
domains of CTB1 have a marked influence over chain-length control in this particular 
non-cognate PKS. It is likely that the CTB1 PT domain is capturing both hexaketide 
(native, C12) and heptaketide (native + C2, C14) linear intermediates, but only efficiently 
catalyzing cyclization of the C14 intermediate. In native CTB1, the TE domain affects a 
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dramatic enhancement of overall turnover.[8] A similar kinetic role for the CTB1 TE is 
probably at play in the present study. In reactions of Pks1 SAT-KS-MAT with CTB1 PT 
and ACP2 only, very small quantities of nor-toralactone are formed while the C12H10O5 
hexaketide shunt product is greatly enhanced (Figure 3.8c). This observation follows 
native CTB1 reactions lacking the TE domain where overall biosynthetic efficiency is 
greatly reduced.[8] We propose that after CTB1 captures and cyclizes the heptaketide 
intermediates, the resulting enzyme-bound bicyclic acyl intermediate is slowly released 
through spontaneous pyrone formation. Therefore, the only products that result in 
enzymatic turnover are the hexaketide shunt products that have a higher rate of 
spontaneous release. This effect is completely masked by the highly efficient CTB1 TE 
domain, which quickly releases the bicyclic intermediates through pyrone formation, 
effectively enriching nor-toralactone in the product pool. 
 Reactions of Pks1 SAT-KS-MAT with wA (C14) PT, ACP2, and TE domains 
stand in contrast to the results of the Pks1/CTB1 non-cognate system. While the native 
wA produces and functions on a heptaketide intermediate (as in CTB1),[18] the Pks1/wA 
non-cognate system does not alter the native Pks1 hexaketide chain-length control. 
Reactions of Pks1 SAT-KS-MAT with wA PT and ACP2 greatly enhance the production 
of the isocoumarin 18 indicating that the wA PT domain is catalyzing its expected C2–C7 
cyclization of the non-native hexaketide linear poly-β-ketone (Figure 3.8c). In reactions 
including the wA TE, the chemistry is redirected towards ATHN formation, consistent 
with catalyzed release through C10–C1 Claisen cyclization (Figure 3.8d). As with the 
Pks1/CTB1 non-cognate system, inclusion of the wA TE led to a parallel reduction in 
shunt product formation. This effect was not observed in Pks1/wA reactions lacking the 
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TE domain. As with CTB1, this finding implicates the wA TE domain in the many-fold 
enhancement of overall efficiency through kinetic competition. 
 It is evident that reactions of Pks1 SAT-KS-MAT with Pks4 (C18) PT, ACP, and 
TE redirected chemistry towards ATHN, albeit without the efficiency of the Pks1/wA 
non-cognate pair (Figure 3.8d). Reactions lacking the Pks4 TE domain produced the 
hexaketide isocoumarin 18 (Figure 3.8c). This outcome represents the expected Pks4 PT- 
and TE-catalyzed cyclizations but on a much smaller intermediate (Table 3.4). In fact, the 
hexaketide intermediate of Pks1 is a third smaller than the nonaketide intermediate of 
Pks4. This behavior is a testament to the considerable versatility of the Pks4 PT and TE 
domains, even if the redirection is inefficient. It also stands in stark contrast to the 
activity of the Pks1/CTB1 non-cognate pairs, where there is apparent chain-length 
discrimination. There is no evidence for the Pks4 domains exerting any influence over 
Pks1 KS chain-length control. 
 This result is even more remarkable when it is considered that neither PksA nor 
ACAS was able to complement Pks1 SAT-KS-MAT, with these reactions producing only 
shunt products (Figure 3.8). As with Pks4, both PksA and ACAS accept larger 
intermediates, C20 and C16, respectively.[7a, 17] The fact that both of these enzymes 
demonstrate chain-length discrimination while Pks4 PT and TE do not further confirms 
the flexibility of Pks4. Similarly, it has been previously shown that the Pks4 PT and TE 
domains also process the heptaketide intermediate produced by CTB1 SAT-KS-MAT 
(Appendix D, Figure D.2). The Pks4 PT and TE may be inherently promiscuous with 
respect to substrate selectivity. While it is known that both domains process C18 
intermediates, the exact chemical natures of these intermediates are unclear. The native 
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metabolite of Pks4 is pre-bikaverin. It is certain that the PT and TE domains set the A and 
B rings of pre-bikaverin, however the exact timing of the C and D ring formation is 
unclear (Figure 3.9). It is possible that the Pks4 PT could accept a linear C18 poly-!-
ketone 27, a monocyclic C18 intermediate 28, or both. Either one of these species could 
converge on pre-bikaverin. If it is the case that both of the species exist in the population 
of reactive intermediates and the PT domain accepts either as a substrate, it may explain 
the apparent lack of chain-length discrimination by Pks4 PT. Similarly, Pks4 TE could 
accept either a monocyclic intermediate 29, a “pre-cyclized” intermediate 30, or both, 
explaining its lack of specificity. 
 In all combinatorial reactions lacking a TE domain, an additional derailment 
product, 6-(2´,4´-dihydroxy-6´-methylphenyl)-4-hydroxy-2-pyrone (31), is observed. The 
 
Figure 3.9"Possible intermediates of the Pks4 PT and TE domains. 
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derailment arises from improper cyclization of the C12 intermediate with C-O bond closer 
release yielding the pyrone. While this product has been observed in type III PKSs, it 
occurs here from uncatalyzed cyclization.[28] Higher levels of production in reactions 
lacking a TE domain underscore the importance of the TE domain for overall catalytic 
efficiency in PKSs. Without a TE domain forcing catalytic turnover, off-loading of 
derailments like product 31 can outpace even PT-catalyzed cyclizations. Further, the TE 
domain’s editing role reduces the accumulation of this product by ensuring off-pathway 




Figure 3.10⏐Product analysis of combinatorial reactions with PksA SAT-KS-MAT. Proposed products 
of combinatorial reactions are presented (a). The chromatograms at 280 nm for products of cognate control 
reactions (b), non-cognate combinatorial reactions with the indicated PT and ACPn (c), and non-cognate 
combinatorial reactions with the indicated PT, ACPn, and TE (d) are presented. 
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3.2.5. Combinatorial Reactions of PksA SAT-KS-MAT 
HPLC product profiles for combinatorial reactions utilizing PksA SAT-KS-MAT 
are presented in Figure 3.10. Reactions for successful combinations are delineated in 
Table 3.5. Of the NR-PKSs investigated in this study, PksA is unique in that it accepts an 
abbreviated fatty acid hexanoyl starter unit.[26] As such, hexanoyl-SNAC was used as the 
starter unit in non-cognate combinations using the PksA SAT-KS-MAT tridomain. It is 
well established that PksA produces noranthrone (1), which is undetectable in the current 
assay due to low solubility, from the condensation and cyclization of hexanoyl with seven 
units of malonyl.[7a] Thus, the linear octaketide poly-!-ketone intermediate has a C20 
chain length. The PksA PT domain catalyzes C4–C9 and C2–C11 aldol cyclizations and 
the PksA TE domain catalyzes release through C14–C1 Claisen cyclization. Reactions 













PksA PksA  
 
PksA ACAS  
 
PksA ACAS ACTE 
 
 83 
lacking the PksA TE domain will make the spontaneous release product norpyrone (19, 
Table 3.5).[7a] Furthermore, the derailment products of the minimal PksA have been 
characterized as derivatives of SEK4 (7) and SEK4b (8) carrying a hexanoyl side chain 
derived from the starter unit (hex-SEK4 20, hex-SEK4b 21).[23] Control reactions 
consisting of a cognate PksA system form these expected products (Figure 3.10b). 
 Of all the non-cognate pairs with PksA SAT-KS-MAT, only ACAS (C16) was 
able to complement catalysis. Reactions of PksA SAT-KS-MAT with ACAS PT and 
ACP led to the formation of a pannorin-like molecule that we dubbed hex-pannorin (22, 
Figure 3.10c). Hex-pannorin displays the same spectral features as pannorin (23), as is to 
be expected for products sharing the same core architecture (Figure 3.11).[29] 
Interestingly, hex-pannorin arises from a chain length one extension unit shorter (C18) 
than expected from the parent PksA SAT-KS-MAT, implicating ACAS PT in some level 
of chain-length control. This product would arise from proper C6–C11 and C4–C13 aldol 
 
Figure 3.11⏐UV-vis spectra and HRMS are presented for pannorin (23) and hex-pannorin (22). 
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cyclizations by the ACAS PT domain followed by spontaneous pyrone formation with 
release from the enzyme (Table 3.5). A similar reaction occurs with the non-cognate pair 
of CTB1 SAT-KS-MAT with ACAS PT and ACP to make pannorin itself (Appendix D, 
Figure D.2).[13] Previous evidence suggests that the minimal PksA generates its linear C20 
intermediate in a highly processive fashion.[23] These data imply that the ACAS PT can 
sample maturing chain-length intermediates, particularly those approaching the full, 
native chain length, a result that is in keeping with other non-cognate pairs described 
above. The low level of production could signify a slow off-loading rate, a feature that 
could also explain the decreased amounts of hex-SEK4 and hex-SEK4b derailment 
products. Intriguingly, the addition of ACTE to the system rescued the PksA KS chain-
length control and led to the formation of a C20 product (Figure 3.10d) displaying a 
spectrum consistent with the atrochrysone core architecture (Figure 3.7).[25] Assuming 
native processing of the C20 linear intermediate by the ACAS PT and ACTE domains, the 
resulting product would be an atrochrysone carboxylic acid analog bearing a hexanoyl 
side chain (24, Table 3.5). Additionally, we observed a species 25 analogous to 
atrochrysone, likely arising from decarboxylation of acid 24 and displaying a 
characteristic spectrum for a molecule bearing the atrochrysone core architecture (Figure 
3.7 and Table 3.5). 
 It is noteworthy that combinations of PksA SAT-KS-MAT containing the PT, 
ACPn, and TE domains of either Pks4 or CTB1 led to an elimination of nearly all 
production, even shunt products (Figure 3.10d). This observation points towards the 
intrinsic editing role for all TE domains of these PKSs. As has been described for PksA, 
the TE domains of NR-PKSs not only catalyze the final release of product, but also 
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intervene when catalysis has been stalled.[23] Derailment products are expected to 
accumulate on the ACP domain of a given NR-PKS if they do not have an efficient, 
spontaneous off-loading mechanism. The TE domain can catalyze the hydrolysis of these 
products, freeing the ACP active site for another round of productive catalysis. It is likely 
that in the case of the PksA/Pks4 or PksA/CTB1 non-cognate pairs, the hexanoyl-loaded 
ACPs appear as improperly loaded, derailment products to the non-cognate TEs. Thus, 
they hydrolyze the starter unit more rapidly than extension can occur, thereby shutting 
down the catalytic cycle at the initiation stage. 
 These competing kinetic processes are complicated by reactions in which the 
ACP is held cognate with the SAT-KS-MAT tridomain. In reactions of PksA SAT-KS-
MAT and ACP with CTB1 (C14) PT and TE, production is restored (Figure 3.12). 
Remarkably, this non-cognate system is proficient in norpyrone (19) formation as well as 
enhanced in shunt production. Norpyrone would be the product of proper CTB1 PT and 
TE-mediated cyclization, but on the C20-PksA linear intermediate, a 43% longer chain 
than the native CTB1 intermediate. Although seemingly contradictory to the observed 
CTB1 TE editing of the previous reaction, this result is entirely consistent with the 
current understanding of TE editing. Editing must always be negotiated through the ACP 
 
Figure 3.12⏐Evidence for the effect of TE-mediated editing in non-cognate combinatorial reactions. 
Chromatograms at 280 nm for products of reactions of PksA SAT-KS-MAT and PksA PT, ACP, and TE 
(a); or CTB1 PT, ACP2, and TE (b); or CTB1 PT, PksA ACP, and CTB1 TE (c). 
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domain. The non-cognate PksA ACP and CTB1 TE pair likely interacts poorly relative to 
the cognate pair. Moreover, it is established that the hexanoyl-loaded PksA ACP initiates 
rapid and processive extension by the PksA SAT-KS-MAT, meaning the CTB1 TE 
cannot compete with the cognate minimal PksA. Overall, the competing interdomain 
kinetics would imply an enhanced efficiency towards extension with the CTB1 TE 
editing occurring later in the catalytic cycle after the C20 linear intermediate has been 
constructed. Thus, the editing by the CTB1 TE domain is suppressed through effective 
native substrate channeling, allowing for later stage redirection of chemistry towards 
norpyrone. 
3.2.6. Reactions of Reassembled and Chimeric NR-PKSs 
 In general, soluble full-length NR-PKSs are difficult to obtain by heterologous 
expression in E. coli, a key experimental advantage of more reliably expressed, smaller 
dissected fragments for the deconstruction approach. The rapid reconstitution of 
component parts exemplified in 72 native and non-native combinations described in this 
study is a second experimental advantage to both deduce the function of each domain and 
observe what limits are imposed by their heterocombination on product determination 
and overall flux. While not the focus of this study, we prepared intact Pks1 and a CTB1–
Pks1 chimera to assess the penalty deconstruction has on net synthetic efficiency. 
 Equivalent reactions containing either 10 µM full-length Pks1 or 10 µM each of 
Pks1 SAT-KS-MAT, PT, ACP2, and TE (4-part combination) were compared and found 
to each produce flaviolin (17) as a major product (Figure 3.13). Additionally, THN (6) 
remained the principal product for intact Pks1. Because THN oxidizes to flaviolin 
spontaneously, quantification of their relative productivity can be approximated. 
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Interestingly, ATHN (16) is not observed in the intact system, indicating that it is a more 
efficient enzyme. Derailment products 18 and YWA1 (5) are observed in comparable 
yields for both systems. Additionally, the intact Pks1 was able to produce flaviolin in 
reactions containing 1 µM of protein. At these concentrations deconstructed systems do 
not produce any detectable products. These results are in keeping with previous 
experiments with deconstructed NR-PKSs where it was shown for PksA that the extent of 
deconstruction is inversely related to overall productivity.[7a] Taken together, these 
observations suggest that at the extreme of holo-Pks1 and its 4-part reconstitution at 10 
µM a penalty of only 2- to 3-fold is exacted, but will be less as 3- or 2-part 
combinations.[7a, 19] All remain faithful in product synthesis. 
 In a further test of the penalty for deconstruction, we prepared a chimeric, full-
length NR-PKS harboring CTB1 SAT-KS-MAT and Pks1 PT-ACP2-TE. While this 
protein, dubbed M4P6, was soluble, we were hampered by low yields. Nevertheless, we 
were able to conduct in vitro reactions with 1 µM M4P6. The chimeric protein produced 
YWA1 (5) in much higher yields than the deconstructed system, which contained 10 
 
Figure 3.13⏐Comparison of deconstructed and intact Pks1 reactions. Chromatograms at 280 nm are 
presented for products of deconstructed Pks1 (a) and intact Pks1 (b). 
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times the concentration of reconstituted protein domains (Figure 3.14). The dehydration 
product of YWA1, nor-rubrofusarin (32) was the only other product observed in the 
reaction of M4P6. Assuming product yield scales linearly with enzyme concentration 
under a given set of reaction conditions and excess substrates, this outcome represents a 
ca. 20-fold increase in YWA1 production by M4P6 over the 4-part deconstructed system 
as estimated by HPLC. 
3.3. Discussion 
 The central facet of successful combinatorial biosynthesis in NR-PKSs revealed 
in this study is that production of a non-native species is contingent upon enzyme-
directed cyclization and release outpacing spontaneous reactions and TE-mediated 
 
Figure 3.14⏐Comparison of a deconstructed and a chimeric CTB1/Pks1 combinatorial NR-PKS. The 
biosynthetic logic of the CTB1 SAT-KS-MAT/Pks1 PT-ACP2-TE two-part heterocombination (a) reflects 
the activity of a the deconstructed system (CTB1 SAT-KS-MAT + Pks1 PT + ACP2 + TE (b) and the 
chimeric M4P6 (c). 
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editing. Therefore, an intimate understanding of the underlying mechanisms and relative 
rates governing the NR-PKS catalytic cycle is crucial for designing an efficient 
combinatorial enzyme. Recently, it was shown in our laboratory that fidelity of 
biosynthesis in PksA has been attributed to three main characteristics: processivity of 
extension, coordinated domain interactions leading to balanced active site occupancy, and 
TE-mediated editing of spurious intermediates.[23] The results of the current study suggest 
that these features may be generally true for the NR-PKSs, as successful 
complementation required the coordinated control of each of these mechanisms, while 
failure of just one led to the derailment of efficient redirected catalysis. 
 The complete interchangeability of ACPs in the minimal NR-PKS underscores the 
importance of the processivity of extension in these enzymes. Helix II of the ACP has 
been implicated in guiding client domain interactions.[30] While conservation of these 
recognition residues may explain some non-cognate compatibility, the uniform behavior 
of the mixed minimal systems with respect to the identity of the SAT-KS-MAT tridomain 
demonstrates the importance of rapid and complete extension. In PksA, transfer of the 
starter unit from the SAT domain to the ACP is both slow and crucial for proper 
extension.[23] It is not until the hexanoyl starter unit is delivered to the KS active site via 
the ACP that extension commences despite the MAT domain maintaining a high steady-
state level of malonyl occupancy. Indeed, when acetyl and malonyl are improperly loaded 
on the ACP, extension will not begin, a behavior rationalized as being mediated through 
negative cooperation between the SAT and KS domains. However, once the correct 
hexanoyl starter unit is loaded onto the PksA KS, extension to the full-length C20 linear 
poly-β-ketone occurs rapidly and without detectable accumulation of intermediate chain 
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lengths.[23] The non-cognate minimal NR-PKSs show similar activity. ACPs that 
normally accept acetyl starter units will accept hexanoyl starter units and vice versa. In 
either case, extension is complete and truncation products of intermediate chain lengths 
are not observed. It is fortuitous that we carried out all our reactions with an intact SAT-
KS-MAT tridomain fragment from a single parent NR-PKS, as the interaction of these 
domains govern correct extension.[23] We hypothesize that, at the very least, a matched 
SAT and KS pair is crucial in the development of a non-cognate NR-PKS. All efforts in 
our laboratory to express and purify a deconstructed SAT-KS didomain or KS 
monodomain have failed to date, making this hypothesis unverifiable by in vitro 
recombination. 
 This is not to say the KS domain exclusively controls the chain length. Early 
studies of combinatorial synthesis in bacterial type II PKS also yielded contradictory 
results.[12a] While the majority of minimal type II PKSs demonstrated complete chain-
length control,[31] the Streptomyces coelicolor spore pigment whiE minimal PKS 
produced a wide assortment of polyketide products ranging in length from 14 to 24 
carbons.[11] This observation was in contrast to the prevailing hypothesis that chain length 
in type II PKSs was controlled by the minimal PKS, consisting of a KS, a chain-length 
control factor (CLF), and an ACP.[31] In the case of whiE, an aromatase/cyclase 
(ARO/CYC) was implicated in chain-length stabilization, extending the role for 
downstream, tailoring enzymes in the central process of polyketide extension.[32] In NR-
PKSs, the PT domain may exert similar control of chain length by binding and sampling 
growing chains, especially as they near their mature “programmed” length, as has been 
suggested for the PksA PT.[7a, 23] Acyl-ACP species have been shown to negotiate client 
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domain interactions in modular PKSs and FAS.[33] Indeed, in some of the combinatorial 
reactions containing the CTB1 and ACAS PT domains, the non-cognate PT influenced 
the final chain length, directing formation of a longer or shorter intermediate, 
respectively. 
 Efficient redirection of chemistry depends on the PT domain not only capturing a 
linear intermediate but also catalyzing the correct aldol cyclization(s). The cyclization 
register in successful combinations is always set by the PT domain and determined by the 
acyl-ACP thioester benchmark, as has been previously observed.[13, 34] PT domains, with 
some exceptions (e.g. PksA PT), display a degree of substrate promiscuity and can 
proficiently accept chains with plus or minus one extension unit. This permissiveness is 
in keeping with previous investigations of NR-PKS PTs.[13, 15] Some PTs however can 
also accept linear substrates with dramatically different chain lengths. Surprisingly, this 
level of promiscuity is usually in the direction of longer intermediates implying that some 
PT active sites are unexpectedly malleable. The PksA PT active site was completely 
incompatible with any non-cognate intermediate, suggesting that the starter unit effect in 
this case is carried over to the cyclization stage of biosynthesis. The PksA PT structure 
contains a hexyl-binding region shown to be crucial for catalytic cyclization.[27] It is 
likely that acetyl-initiated linear poly-β-ketones cannot bind this site, terminating any 
catalytic redirection by the PksA PT towards these intermediates. 
  The TE domain is the most crucial of all. As has been demonstrated in multiple 
NR-PKSs, the TE domain has roles both biosynthetic and editorial.[7b, 8, 19, 23] The 
transesterification of PT-cyclized intermediates onto the TE represents a likely slow step 
in the overall catalytic cycle. However, in most cases the TE-catalyzed reaction is rapid 
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and drives the overall biosynthetic program. This factor is most evident in the reactions 
of CTB1, where the inclusion of the TE domain enhances nor-toralactone production 
about 50-fold relative to the reaction without the TE domain.[8] Without the TE domain, 
off-loading is inefficient, effectively stalling the catalytic cycle and allowing for the 
accumulation of derailment products. Furthermore, the TE domain will only process 
intermediates comprised of their native substrate’s core cyclization architecture. As has 
been recently suggested,[35] the TE domain serves as the catalytic lynchpin that 
determines success or failure in biosynthetic redirection. 
 The editing role of the TE domain of NR-PKSs has only recently been 
appreciated; however, it is essential for maintaining high catalytic turnover.[23] By 
intercepting spurious derailment products, the TE domain clears the ACP domain 
allowing for it to reenter the kinetically more productive, programmed catalytic cycle. 
Nowhere is this effect more cleanly demonstrated than with the combinatorial reactions 
of PksA and CTB1 (Figure 3.12). The CTB1 TE domain recognizes the hexanoyl loaded 
CTB1 ACP as an aberrant species and effectively hydrolyses it, thereby shutting down 
any catalysis at an early stage. The fact that changing the identity of the ACP relative to 
the TE rescues extension highlights a fundamental factor that is likely at play in all 
reactions. TE-mediated editing can effectively shut down redirection of chemistry at any 
stage in the catalytic cycle. Furthermore, a desired intermediate may be deemed 
unsuitable by the TE domain and eliminated, compromising the success of the 
combinatorial approach to the synthesis of unnatural polyketides. Thus, the kinetics of 
redirected synthesis must outpace the rate of TE editing. These interactions are difficult 
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to measure in these multistep processes, but are the theoretical factors determining 
combinatorial success and failure. 
 The deconstruction approach brings practical advantages of generally reliable 
protein over-production in E. coli and the rapid combinatorial assembly of functional 
units into reconstituted native and non-native catalytic systems. Although not assured at 
the outset, the reconstituted NR-PKSs have been found to recapitulate their wild-type 
synthetic capabilities. Similarly, heterocombination of catalytic components reassemble 
to elicit chemistry in a largely predictable fashion as we demonstrate here. While 
examples are limited, as one might intuitively expect, holo native and chimeric NR-PKSs 
show improved synthetic efficiency over their reconstituted component parts and give a 
reduced incidence of shunt and truncated products. Although only two cases are 
compared, the data suggest that these improvements will be greater for reconstituted 
heterodomains over native systems. These observations auger well for their rational 
assembly in single multidomain designed proteins for non-natural product synthesis. 
3.4. Conclusions 
 In summary, we find that non-cognate “domain-swapped” NR-PKSs will redirect 
biosynthesis to non-native products if certain underlying constraints governing NR-PKS 
programming are met. While ketide extension appears to be complete in all non-cognate 
reactions, the interplay of downstream domains (namely the PT and TE domains) 
determines catalytic turnover to non-native products. When these domains capture 
suitable intermediates and efficiently carry out their programmed catalysis, redirection of 
chemistry takes place. Effective redirection requires that these processes outpace the rate 
of spontaneous derailments and TE-mediated editing. For more effective engineered NR-
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PKSs, a greater understanding of the mechanisms and internal kinetics of the catalytic 
program is required. 
3.5. Experimental Methods 
3.5.1. Reagents and Biological Strains 
 All reagents and primers were purchased from Sigma-Aldrich (St. Louis, MO, 
USA), unless otherwise specified. Magnesium chloride, sodium chloride, potassium 
phosphate monobasic, potassium phosphate dibasic, and deoxynucleotides (dNTPs) were 
purchased from Thermo Scientific (Waltham, MA, USA). Isopropyl-β-D-thiogalactoside 
(IPTG), kanamycin, and nickel (high density) agarose beads were purchased from Gold 
Biotechnology (St. Louis, MO, USA). Imidazole was purchased from Acros Organics 
(Geel, Belgium). Sodium acetate (18O, 95%) was from Cambridge Isotope Laboratories 
(Cambridge, MA, USA). Yeast extract and tryptone were purchased from Boston 
BioProducts (Ashland, MA, USA). Agar was purchased from bioWORLD (Dublin, OH, 
USA). Plasmids pET-24a(+) and pET-28a(+) were purchased from EMD Millipore 
(Darmstadt, Germany). All enzymes used for manipulation of DNA and 10 × HF Buffer 
were purchased from New England Biolabs (Ipswich, MA, USA). Bio-Rad protein assay 
dye for determining protein concentration by the Bradford assay was purchased from 
Bio-Rad laboratories (Hercules, CA, USA). Bacterial strain Escherichia coli BL21(DE3) 
was purchased from Sigma-Aldrich and made electrocompetent by standard protocols 
(see Appendix B).[36] 
3.5.2. Preparation of Expression Constructs 
 DNA manipulations were carried out in accordance with established 
procedures.[37] Details of the expression plasmids for deconstructed NR-PKSs used in this 
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study are summarized in Table D.3 (Appendix D). Cut sites for protein deconstruction 
were guided by a variety of bioinformatics analyses including multiple sequence 
alignment, secondary structure prediction and the UMA algorithm for predicting 
interdomain regions.[9] Primers used for cloning new constructs used in this study are 
presented in Tables D.1 and D.2 (Appendix D). All expression plasmids were maintained 
in E. coli BL21(DE3) cells stored in 20% glycerol at −80 °C. 
 A C-terminal 6 × His tagged Pks4 SAT-KS-MAT construct was cloned by 
overlap extension PCR of exon fragments from genomic DNA (Appendix B). The 
resulting spliced fragment was used as template in PCR with primers Pks4-SAT-s1 and 
Pks4-NKA-3 (Appendix B). The resulting PCR product was digested with NdeI and NotI 
and ligated into pET-24a(+) to yield pEPks4-NKA-1. This plasmid was cut with NdeI 
and EcoRI and inserted into plasmid pEPks4-SATn-1[38] to yield pEPks4-NKAn. The 
resulting plasmid contains the N-terminal codon optimized sequence of pEPks4-SATn-1. 
 A full-length C-terminal 6 × His tagged CTB1 construct was cloned by overlap 
extension PCR. Overlap extension PCR DNA fragments were prepared by PCR from 
pCR-CTB1-ex #3 (a pCR®-Blunt plasmid containing CTB1 exon 3) template with 
primers CTB1-S3+1 and CTB1-ex6-3 and pCR-CTB1-ex7-9 #3 (a pCR®-Blunt plasmid 
containing CTB1 exons 7–9) template with primers CTB1-ex7-5 and CTB1-3. The 
resulting PCR products were spliced together using overlap extension PCR with outside 
primers CTB1-S3+1 and CTB1-3. The resulting overlap extension PCR product was 
digested with NheI-HF and NotI-HF and inserted into pECTB1-NKA6 to give pECTB1. 
 A C-terminal 6 × His tagged CTB1 SAT-KS-MAT/Pks1 PT-ACP2-TE chimeric 
full-length PKS was cloned using Gibson assembly cloning to give plasmid pEM4P6-
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1.[39] The crossover sites (CTB1 S1293 and Pks1 P1290) were selected to be five amino 
acids upstream of a conserved threonine at the N-terminal end of the PT domain. The 
CTB1 SAT-KS-MAT fragment was PCR amplified from pECTB1 template with T7 and 
M4P6-3 primers. The Pks1 PT-ACP2-TE fragment was PCR amplified from pEPks1alt 
template with M4P6-5 and T7 Term primers. Gibson assembly was conducted using 
these two DNA fragments and NdeI and NotI linearized pET-24a(+) in equimolar 
amounts, as described in Appendix B. 
3.5.3. Protein Expression and Purification 
 Proteins were prepared by heterologous expression in E. coli BL21(DE3) and 
purified by nickel-affinity purification as delineated in Appendix B. Eluted protein 
fractions were dialyzed at 4 °C overnight with three buffer exchanges into 100 mM 
potassium phosphate pH 7.0, 10% glycerol. Purified protein concentrations were 
determined by the Bradford assay using bovine serum albumin (New England Biolabs) as 
a standard as described in Appendix B.[40] ACP containing proteins were activated to holo 
form through the action of the promiscuous phosphopantetheinyl transferase Svp, as 
previously described (See Chapter 2.5.5.).[7a] Excess protein was flash frozen in liquid 
nitrogen and stored at −80 °C until further use. 
3.5.4. In Vitro Reactions 
 In vitro reactions were conducted using S-acyl-N-acetylcysteamine (acyl-SNAC) 
substrates in place of acyl-CoAs, as previously described.[8, 13] Acetyl- and hexanoyl-
SNACs were synthesized from the corresponding acid chlorides. The malonyl-CoA 
synthetase from Rhizobium leguminosarum, MatB, was used to produce HPLC purified 
malonyl-SNAC, as previously described.[23, 41] Purified enzyme fragments were 
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selectively recombined in vitro at 10 µM final concentration for each protein in 100 mM 
potassium phosphate pH 7.0, 1 mM tris(2-carboxyethyl)phosphine (TCEP), and 10% 
glycerol. Reactions were initiated with the simultaneous addition of either 0.5 mM 
hexanoyl-SNAC (for reactions containing PksA SAT-KS-MAT) or 0.5 mM acetyl-SNAC 
(all other reactions) and 2 mM malonyl-SNAC (all reactions) and were conducted for 4 h 
at room temperature. Reactions were quenched by acidification with HCl, and products 
were extracted into ethyl acetate. Organic fractions were combined, dried in vacuo, and 
dissolved in 20% acetonitrile (aq.) at a final volume equivalent to the initial reaction 
volume. 
3.5.5. Product Profile Analysis 
 Reactions were analyzed by reverse phase HPLC on an Agilent 1200 instrument 
(Agilent Technologies, Santa Clara, CA). Solvent A was water + 0.1% formic acid. 
Solvent B was acetonitrile + 0.1% formic acid. Purified reaction extracts were injected 
onto a linear gradient of 5% to 85% solvent B over 30 min at 1 mL/min on a Prodigy 5u 
ODS3 column (4.6 × 250 mm, 5 µm [Phenomenex, Torrence, CA, USA]). 
Chromatograms were recorded at 280 nm, 4 nm bandwidth with a background reference 
of 650 nm, 100 nm bandwidth. Mass data, unless otherwise stated, were collected on a 
Shimadzu LC-IT-TOF (Shimadzu Corporation, Kyoto, Japan) in positive ion mode fitted 
with a Luna C18(2) column (2.0 × 150 mm, 3 µm [Phenomenex]) using a linear gradient 
of 5% to 85% solvent B over 30 min at 0.2 mL/min. 
3.5.6. Polyketide Product Chemical Characterization 
 Due to low titers, product identification by NMR spectroscopy was not feasible. 
Notwithstanding, as NR-PKSs act through defined chemistry, distinct UV-vis absorption 
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profiles and high resolution MS data are sufficient for metabolite characterization. 
Unequivocal structural assignment was available for the majority of products through 
comparison to synthetic standards and literature values of fully characterized materials. 
Provisional assignments based upon available data are made for selected species for 
which unambiguous identification was not possible. A complete collection of 
characterization data for each product is presented in Appendix D. 
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Chapter 4: Attempts to Rationally Engineer a Topopyrone 
Synthase Through Domain-Swapped, Chimeric Polyketide 
Synthases 
4.1. Introduction 
 Polyketides are a large, structurally diverse family of natural products 
encompassing both pharmaceutical and toxic agents.[1] Polyketide synthases (PKS) are 
the enzymes responsible for polyketide biosynthesis. The mode of biosynthesis for most 
polyketides is through linear, assembly line construction catalyzed by large, multidomain 
type I PKSs.[2] Alternatively, in fungi, iterative, non-reducing PKSs (NR-PKS) synthesize 
aromatic polyketide products in a mode analogous to animal fatty acid synthases 
(FAS).[3] Reliable and rational engineering of PKSs has been a long-standing goal for 
those wishing to expand the pool of potential therapeutic polyketides; however, a limited 
understanding of PKS functionality has hampered engineering efforts. Recent advances 
in both NR-PKS enzymology[4] and engineering,[5] however have enabled the possibility 
of accessing custom designed NR-PKSs for the production of specific polyketide 
products. 
 NR-PKSs have a canonical domain architecture.[4] The three N-terminal 
domains—the starter unit:acyl carrier protein transacylase (SAT), ketosynthase (KS), and 
malonyl-CoA:acyl carrier protein transacylase (MAT)—together with the acyl carrier 
protein (ACP) compose a “minimal” NR-PKS that is requisite for extension of acetate 
units into an enzyme-bound poly-β-ketone.[5-6] The SAT selects a precursor (or starter 
unit) derived from an acyl-thioester[7] while the MAT introduces ketide extension units 
derived from malonyl-CoA.[6b] The KS, together with the ACP, catalyzes decarboxylative 
Claisen condensation to generate the linear, poly-β-ketone intermediate covalently bound 
 102 
to the ACP.[4, 6b] The C-terminal domains, the product template (PT) and thioester (TE), 
control the final stages of biosynthesis. The PT domain catalyzes regiospecific, 
intramolecular aldol cyclization(s)/aromatization(s) of the ACP-bound poly-β-ketone.[8] 
The TE releases the final product through one of several specific mechanisms—
Dieckmann cyclization/aromatization,[9] macrolactonization,[10] enol lactonization,[11] or 
hydrolysis.[12] Thus, individual domains of the NR-PKS order the four determining 
chemical features governing aromatic polyketide structure: starter-unit selection (SAT), 
chain-length control (KS), cyclization register (PT), and product release (TE). 
 Coordinating domain specificity is the basis of most NR-PKS engineering efforts. 
Currently, “domain-swapping” is the most successful method that has been applied 
experimentally.[5, 13] In this approach, interchanging individual homologous domains 
from different native NR-PKS imparts the swapped domain’s native catalytic specificity 
to the overall catalytic cycle. Investigating two-part heterologous combinations of a 
representative set of deconstructed NR-PKSs codified a set of rules governing catalytic 
proficiency of domain-swapped NR-PKS (see Chapter 3).[5, 13f] Any catalytically 
proficient NR-PKS must balance the rate of productive chemistry with the rate of 
spontaneous derailment and TE-mediated editing[5]—an intrinsic role of the TE 
domain.[6b] Further, individual domains retain their native specificity while displaying an 
expanded substrate selectivity—but within limits. For example, the PksA SAT domain 
from Aspergillus parasiticus, which natively accepts a hexanoyl precursor, can be made 
to select linear, aliphatic precursors;[14] or, the Pks1 PT domain from Collectotichum 
lagenarium, which natively processes a hexa-β-ketone (C12) intermediate, can catalyze 
aldol cyclization with its native regiospecificity on a hepta-β-ketone intermediate (C14).[5] 
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The off-loading TE domain is of crucial importance in any domain-swapped paradigm as 
it serves as the final, and most important, decision gate of the catalytic cycle.[5, 13d] 
 Here, we attempt to rationally engineer a NR-PKS for the production of a targeted 
polyketide scaffold topopyrone (1a–d, Figure 4.1)—a family of potent human 
topoisomerase I inhibitors.[15] This goal represents a refinement from the usual NR-PKS 
engineering efforts, which are designed to test the limits of engineering by systematically 
swapping domains and observing the resulting chemistry. In the current study, we 
preselect the final product and reverse engineered the NR-PKS to achieve the desired 
scaffold. We adopt a domain-swapping approach such that the N-terminal and C-terminal 
domains come from the native Pks4 of Gibberalla fujikuroi and PksA of A. parasiticus, 
respectively. The N-terminal SAT-KS-MAT domains from Pks4 control starter-unit 
selection and chain-length limitation while the C-terminal PT-ACP-TE domains from 
PksA control cyclization register and product release. We attempt to further optimize 
engineered catalysis through rational PT active-site alteration. To date, no such attempt to 
design a NR-PKS for the production of a specific metabolite has been successful. A long-
standing goal of the field is to use these enzymes for the fermentative production of novel 
metabolites and molecules of commercial interest. Engineering a topopyrone synthase 
would represent a significant step towards achieving that eventual goal. 
Figure 4.1"Structures of topopyrones A, B, C, D. The topopyrones are polyketide products of the fungus 
Phoma sp. BAUA2861. 
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4.2. Results 
4.2.1. Generation and In Vitro Activity of Chimeric NR-PKSs 
 To test the feasibility of chimeric NR-PKS design, two-part heterocombination 
expression constructs were prepared by fusing the N-terminal tridomain (SAT-KS-MAT) 
and C-terminal tridomain (PT-ACPn-TE) of non-cognate parent NR-PKSs. Six parent 
NR-PKS (see Appendix A) were used: PksA (Q12053, A. parasiticus), Pks4 (CAB92399, 
G. fujikuroi), ACAS (EAU31624, Aspergillus terreus), CTB1 (AAT69682, Cercospora 
nicotianae), wA (CAA46695, Aspergillus nidulans), and Pks1 (BAA18956, C. 
lagenaria). Crossover site selection was guided by a multiple sequence alignment of NR-
PKSs and the tertiary structure of PksA PT with the intent to maintain as much of the 
MAT-PT linker of the parent sequences as possible in the final chimeric construct. 
Because the N-terminus of the PT domain is better defined than the C-terminus of the 
MAT domain, the crossover site was selected to be 4 amino acids upstream of the highly 
conserved PksA Thr1309 which marks the start of the PksA PT domain (Figure E.1, 
Appendix E). Using this crossover site, the complete set of two-part heterocombination 
expression constructs was prepared. Test expressions were conducted for all 30 members 
of this library. Twenty were found to induce expression of soluble protein (Table 4.1). 
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Table 4.1"Two-part heterocombination chimeric NR-PKSs. Each cell presents the SDS-PAGE results 
of an E. coli expression test of an individual two-part NR-PKS chimera. Rows indicate the identity of the 
SAT-KS-MAT. Columns indicate the identity of the PT-ACP-TE. The lanes from each gel represent the 
uninduced, induced, and elution bands for the indicated chimeric NR-PKS, from left to right. Constructs 
that do not express protein are not shown. The name for each chimeric NR-PKS is also indicated. 
  PT-ACPn-TE 





































































Figure 4.2"In vitro reactions of two-part intact and deconstructed NR-PKS heterocombinations. 
Chromatograms at 280 nm are presented for heterocombinations of (a) M4P2 (CTB1 SAT-KS-MAT + 
Pks4 PT-ACP-TE), (b) M4P6 (CTB1 SAT-KS-MAT + Pks1 PT-ACP2-TE), and (c) M6P2 (Pks1 SAT-KS-
MAT + Pks4 PT-ACP-TE) for (i) intact, chimeric enzymes at 1 µM and (ii) deconstructed enzymes (SAT-
KS-MAT + PT + ACPn + TE) at 10 µM each proteins. 
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 Three chimeric NR-PKSs were chosen to probe the limits of protein activity. The 
three examples investigated each corresponded to a set of domains that successfully 
catalyzed non-native polyketide formation when deconstructed NR-PKSs were used. The 
chimeras tested included M4P2 (CTB1 SAT-KS-MAT + Pks4 PT-ACP-TE), M4P6 
(CTB1 SAT-KS-MAT + Pks1 PT-ACP2-TE), and M6P2 (Pks1 SAT-KS-MAT + Pks4 
PT-ACP-TE). Due to low protein yields from heterologous expressions, in vitro reactions 
of the fully intact chimeric proteins were conducted at 1 µM as opposed to the customary 
10 µM for reconstitution reactions of deconstructed NR-PKSs. Product assignments were 
based upon HPLC retention times, UV spectral profile, and MS (Figures E.2–4, 
Appendix E). All spectra were identical to literature values for these products. 
 The reaction of M4P2 (CTB1/Pks4) produced YWA1 (2) and its dehydration 
product, nor-rubrofusarin (3, Figure 4.2a). Despite the low protein concentration, yields 
of this product were dramatically improved over the analogous deconstructed 
heterocombination (CTB1 SAT-KS-MAT + Pks4 PT + ACP + TE). Assuming that 
product output scales linearly under the given reaction conditions, the production of 
YWA1 by M4P2 represented a 20–30-fold increase over the reconstituted reaction, as 
estimated by HPLC peak areas. The reaction of M4P6 (CTB1/Pks1) also produced 
YWA1 and nor-rubrofusarin (Figure 4.2b). Again yields of YWA1 were increased 20–
30-fold over the reconstituted reaction. In both cases shunt product formation was nearly 
eliminated. The reaction of M6P2 (Pks1/Pks4) produced isocoumarin 5 as its primary 
product (Figure 4.2c). This result diverged from the analogous deconstructed 
heterocombination (Pks1 SAT-KS-MAT + Pks4 PT + ACP + TE), which produced a 
variety of derailment products in addition to the anticipated redirection product—acetyl-
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tetrahydroxynaphthalene (acetyl-THN, 6)—and small amounts of isocoumarin 5—an 
anticipated spontaneously released product following PT directed cyclization. 
4.2.2. Attempts to Engineer a Topopyrone Synthase 
 Retrosynthetic analysis of topopyrones C and D (1c, d) served as the rationale for 
a designed topopyrone synthase (Figure 4.3a). Topopyrones C and D were envisioned as 
the oxidation products of anthropyrones 7a, b—here named topoketones A and B, 
respectively. Topoketones A and B were potential NR-PKS targets, arising from a 
common acetyl-primed nona-β-ketone (C18) adopting the C4–C9, C2–C11 PT-catalyzed 
cyclization pattern and C14–C1 TE-catalyzed Claisen cyclization mode. The final ring—
the pyrone moiety—could form spontaneously through hemiketal formation followed by 
dehydration. The SAT-KS-MAT from Pks4 was the only member of our parent NR-PKS 
 
Figure 4.3⏐Rationale for topopyrone synthase design. (a) The underpinning NR-PKS logic of 
topopyrone biosynthesis. (b) Native products of parent NR-PKSs used to generate topopyrone synthases. 
Bonds are color coded according to the domains that generate them. (c) The M2P1 (top) and M2P4A1 
(bottom) chassis for topopyrone synthases designed through domain-swapping. 
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library that natively produced the desired acetyl-primed linear C18-β-ketone intermediate 
(Figure 4.3b). Therefore, all designed topopyrone synthases contained the Pks4 SAT-KS-
MAT tridomain. The PT domains from both PksA and CTB1 were selected to set the 
aromatic scaffold, as their native cyclization pattern was the desired C4–C9, C2–C11 
cyclization motif (Figure 4.3b). The TE domain from PksA was the only member capable 
of performing the desired C14–C1 Claisen cyclization and was therefore used in all 
designed topopyrone synthases (Figure 4.3b). Two chimeric NR-PKS chassis were 
selected as potential topopyrone synthases: M2P1 (Pks4 SAT-KS-MAT/PksA PT-ACP-
TE) and M2P4A1 (Pks4 SAT-KS-MAT/CTB1 PT/PksA ACP-TE, Figure 4.3c). 
 Additional active site manipulation was conducted on the PT domains of both the 
M2P1 and M2P4A1 chassis. The PksA PT domain—the only PT domain for which a 
structure exists—contains an unusually deep active site comprising three distinct binding 
 
Figure 4.4⏐1.8 Å resolution crystal structure of the PksA PT domain and the hexyl-binding region.[8] 
(a) Overall structure of PksA PT monomer displaying the three distinct regions of the active site. Palmitate 
(in purple) occupies the cyclization chamber and hexyl-binding region. (b) Highlight of the hexyl-binding 
region of the PksA PT active site. Residues forming the hexyl-binding region are displayed in green. 
Residues forming the cyclization chamber are in white. The crucial catalytic dyad (His1345, Asp1543) is 
shown in red. Palmitate bound in the active site is shown in purple. The binding pocket of the hexyl-
binding region is shown as a gray cage. Gly1491 forms part of the hexyl-binding region’s wall. Mutations 
at this position would project side chain substituents into the bottom of hexyl-binding pocket. 
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subsites: the phosphopantetheine (PPT) binding region, the cyclization chamber, and the 
hexyl-binding region (Figure 4.4a). The hexyl-binding region was of particular interest in 
topopyrone synthase design. In the native protein, this site binds the hexanoyl starter-unit 
derived portion of PksA’s linear octa-β-ketone intermediate (C20, Figure 4.4b). We 
reasoned that this deep hydrophobic site would be detrimental to binding of an acetyl-
primed nona-β-ketone (C18) in the topopyrone synthases. A series of mutations was 
therefore created at the critical Gly1491 position. Gly1491 composes part of the wall of 
the hexyl-binding pocket. More sterically-demanding mutations to Gly1491 would 
project side chain substituents into the bottom of the hexyl-binding cavity, thereby 
occluding access to it. The residues that comprise the hexyl-binding region are well 
conserved among NR-PKSs with the exception of Gly1491, which is only found in 
norsolorinic acid synthases like PksA. In NR-PKSs that employ an acetyl-selective SAT, 
an aliphatic residue occupies this position. The mutations introduced side-chains of 
increasing size at this position for the M2P1 chassis (G1491A, G1491V, G1491I, and 
G1491L). The opposite approach was employed in the M2P4A1 chassis. In this case, 
Ile1468 occupies the homologous Gly1491 position. A series of mutants was generated at 
that position to further open up the bottom of the CTB1-derived PT active site for the 
M2P4A1 chassis (I1468V, I1468A, and I1468G). We rationalized that the extra space at 
the bottom of the PT active site would allow for better binding of the larger linear nona-
β-ketone intermediate (C18) as opposed to the native hepta-β-ketone intermediate (C14). 
Nine potential topopyrone synthases were generated in total: M2P1, M2P1-G1491A, 
M2P1-G1491V, M2P1-G1491I, M2P1-G1491L, M2P4A1, M2P4A1-I1468V, M2P4A1-
I1468A, and M2P4A1-I1468G. It should be noted that the numbering here does not 
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indicate the exact sequence position of the mutation in the individual chassis, but rather 
corresponds to the relative native domain sequence position. 
 Initial reactions conducted at 1 µM protein did not show any clear indication of 
either topoketone or topopyrone formation by HPLC. Nevertheless, vanishingly small 
amounts of material corresponding to the topoketone exact mass were observed by 
LCMS—a far more sensitive method of analysis. We selected the best performing 
enzyme—M2P1-G1491L—for scaled biosynthesis. Protein concentrations were 
increased to 25 µM, requiring tremendously large culture volumes for heterologous 
expression—25 L per 250 µL in vitro reaction. Overall biosynthesis was increased in the 
high concentration reactions and a minor peak, which we assigned to topoketone, was 
 
Figure 4.5⏐Reactions of the designed topopyrone synthase M2P1-G1491L. (a) 280 nm chromatograms 
for extracted products of in vitro reactions of 25 µM M2P1-G1491L: (i) extracted products and (ii) products 
sparged with air. (b) 280 nm chromatograms of extracted products of in vitro reactions of 25 µM M2P1-
G1491L control mutants: (i) M2P1P--G1491L, (ii) M2P1P--G1491L + 100 µM PksA PT-G1491L, (iii) 
M2P1P-T--G1491L , and (iv) M2P1P-T--G1491L + 100 µM each PksA PT-G1491L and PksA TE. (c) 
Metabolites of M2P1-G1491L reactions. Derailment products SEK4 (8) and SEK4b (9) coelute. 
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observed by both HPLC and LCMS (Figure 4.5a). Nevertheless, the major metabolites 
were the SEK4 (8) and SEK4b (9) derailment products. Spectral characterizations were 
positive for SEK4 and SEK4b (Figure E.5, Appendix E) and highly indicative of 
topoketone (Figure E.6, Appendix E)—although unambiguous assignment for this 
metabolite could not be made from the data collected. Several other products were 
observed corresponding to nona-β-ketone derailment products. In an attempt to generate 
topopyrone, air was bubbled through the extracted products of the M2P1-G1491L 
reaction; however, no new products were observed and there was no appreciable turnover 
of the likely topoketone peak (Figure 4.5a). Attempts to synthesize topopyrone from 
analogous deconstructed enzymes were unsuccessful. These reactions comprised 10 µM 
each protein with the compositions presented in Table 4.2. 
  
Table 4.2⏐Composition of attempted deconstructed topopyrone synthases. Control reactions lacking 
the TE or both the PT and TE were also conducted. In each case, biosynthesis of topopyrone was not 
observed by HPLC. 
Reaction SAT-KS-MAT PT ACP TE 
1 Pks4  Pks4  
2 Pks4  PksA  
3 Pks4  CTB1  
4 Pks4 PksA-G1491L Pks4  
5 Pks4 PksA-G1491L PksA  
6 Pks4 PksA-G1491L CTB1  
7 Pks4 CTB1-I1468G Pks4  
8 Pks4 CTB1-I1468G PksA  
9 Pks4 CTB1-I1468G CTB1  
10 Pks4 PksA-G1491L Pks4 PksA 
11 Pks4 PksA-G1491L PksA PksA 
12 Pks4 PksA-G1491L CTB1 PksA 
13 Pks4 CTB1-I1468G Pks4 PksA 
14 Pks4 CTB1-I1468G PksA PksA 
15 Pks4 CTB1-I1468G CTB1 PksA 
16 Pks4 PksA-G1491L PksA wA 
17 Pks4 PksA-G1491L PksA Pks4 
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 Given the small amounts of product formation, we were unsure if the observed 
topoketone was enzymatically synthesized or a product of derailed catalysis. To test for 
derailment, we generated two M2P1-G1491L control mutants. The first—M2P1P--
G1491L—corresponded to a PT null enzyme in which the catalytic His1345 of the PT 
active site was mutated to Ala. The second—M2P1P-T--G1491L—corresponded to a PT 
and TE null enzyme in which both the PT catalytic His1345 and TE catalytic Ser1937 
were mutated to Ala. We reasoned that if topoketone biosynthesis was enzymatic, it 
would be missing in the metabolite profiles of both null mutants, as the PT or TE 
domains would be inactive. Both control mutants showed the same profile of derailment 
products with evident formation of topoketone (Figure 4.5b). The overall biosynthetic 
capability was greater for M2P1P--G1491L, which produced amounts of material 
comparable to M2P1-G1491L. The biosynthetic capability of M2P1P-T--G1491L was 
 
Figure 4.6⏐Reactions of Pks1 control mutants. 280 nm chromatograms of extracted products of (a) 1 µM 
Pks1, (b) 1 µM Pks1P-, and (c) 1 µM Pks1P-T-. (d) The biosynthesis of Pks1 product. Pks1 produces a hexa-
β-ketone linear intermediate. The PT domain catalyzes C2–C7 cyclization. The TE domain catalyzes C10–
C1 Claisen cyclization generating acetyl-tetrahydroxynaphthalene (acetyl-THN, 6) as an intermediate. The 
TE domain has an additional deacetylase activity and converts acetyl-THN to tetrahydroxynaphthalene 
(THN, 10). THN spontaneously oxidizes to flaviolin (11), the primary observed product. 
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greatly reduced. The addition of 100 µM of PksA PT-G1491L or PksA TE to these 
reactions did not appreciably alter the product output (Figure 4.5b). All product formation 
was eliminated in analogous reactions of Pks1 control mutants (Pks1P- and Pks1P-T-, 
Figure 4.6). 
4.2.3. Fermentation of NR-PKS products in E. coli 
 To evaluate the ability of fungal NR-PKSs to produce polyketide products in E. 
coli, we created an E. coli BL21(DE3) strain harboring the pEPks1alt plasmid for 
inducible expression of Pks1. Six culture conditions were examined: Luria-Bertani broth 
(LB), LB supplemented with 10% glycerol, and Terrific Broth (TB) in either normal or 
baffled shake flasks. We used OD600 as a measure of cell growth and collected samples at 
various times after induction for up to 3 days (Figure 4.7a). Metabolites were extracted 
from the supernatant of collected samples and analyzed by HPLC for the presence of 
flaviolin (11), the spontaneous oxidation product of tetrahydroxynaphthalene (THN)—
the native metabolite of Pks1. The flaviolin titer (mg/mL, Figure 4.7c) was calculated and 
 
Figure 4.7⏐Flaviolin titers from E. coli fermentations. (a) Growth curves presented on a log2 scale, with 
flaviolin titers (b) normalized by cell density or (c) in mg/L. Cultures were conducted in (i) LB, (ii) LB + 
10% glycerol, and (iii) TB. 
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normalized by cell density (mg/mL/OD600, Figure 4.7b). 
 The presence or absence of baffles in the shake flask did not have an effect on cell 
growth. Cultures in LB and LB with 10% glycerol displayed similar growth curves. As 
expected, culture in TB supported higher density growth. In all cases, the stationary phase 
of growth was achieved, although the onset of this stage of growth occurred much later 
for cultures in TB. Flaviolin titers varied significantly for all culture conditions. No 
flaviolin was produced in cultures grown in LB with 10% glycerol. SDS-PAGE analysis 
indicated that Pks1 expression was not induced in these cultures. Modest titers of 
flaviolin were observed for both cultures in LB and TB reaching a maximum of 2.2 and 
2.5 mg/mL, respectively. In general, cultures grown in flasks without baffles showed 
greater flaviolin titers. The largest flaviolin titers were coincident with the onset of 
stationary phase. Titers of flaviolin were relatively stable for cultures of LB in normal 
shake flasks, while both TB conditions and LB cultures in baffled flasks displayed a 
decrease in flaviolin titer after 24 and 32 h, respectively. Higher cell densities for cultures 
in TB did not translate to higher normalized titers of flaviolin. In fact, the cultures in TB 
performed worse than those in LB with respect to cell density-normalized flaviolin titers. 
4.3. Discussion 
 The results presented herein further demonstrate the capabilities of the domain-
swapping approach for rational engineering of NR-PKSs. Previous approaches in our 
laboratory have been to use deconstructed NR-PKSs to perform generate domain-
swapped NR-PKSs.[4-5, 13f, 16] Historically, protein deconstruction has been the only 
method available to reliably access NR-PKSs and to rigorously investigate their 
biochemistry. While the approach is powerful, it is limited in its applications. Of 
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particular concern are the concentration demands of the deconstruction approach. 
Biochemical activity for a deconstructed NR-PKS is only observed above a certain 
protein concentration threshold—typically 10 µM for each protein component.[4] These 
limitations are of minor concern when investigating the in vitro chemistry of a domain-
swapped NR-PKS, but are prohibitive in many settings. For example, fermentative 
production of non-native polyketides—an eventual goal of the field—using a 
deconstructed NR-PKS would not be a viable approach. Instead, using an “intact” 
domain-swapped NR-PKS would be a much more attractive means of achieving in vivo 
polyketide production. 
 Chimeric NR-PKSs have been used previously to produce polyketide metabolites 
in fungal hosts.[13b, c] These studies however have been quite limited, investigating only a 
single domain or NR-PKS pair. The work presented here represents the first time a 
systematic library of chimeric enzymes has been generated for the specific purpose of 
heterologous protein expression and purification. Indeed, the high performance of the 
library with respect towards soluble protein production validates the structure-guided 
approach to chimeric NR-PKS generation. Furthermore, the two-part chimeric NR-PKSs 
tested for functional activity were adherent to the established “rules” of engineered NR-
PKSs (Figure 4.8).[5, 13f] For both M4P2 (CTB1/Pks4) and M4P6 (CTB1/Pks1), YWA1 
(2) is the rational metabolite arising from the acetyl-primed hepta-β-ketone intermediate 
produced by the CTB1 SAT-KS-MAT[11] followed by Pks4[17] or Pks1[18] PT and TE 
directed regiospecific cyclizations. 
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 The M6P2 (Pks1/Pks4) chimera stands in contrast to these successful enzymes. 
Although it did not produce its expected product—acetyl-THN (6)[5]—its clean 
production of isocoumarin 5 implies fidelity to the designed biosynthetic logic. Starter 
unit selection, chain length control, and cyclization pattern were all dictated by their 
associated parent domains—SAT, KS, and PT, respectively. Only the TE-catalyzed C10–
C1 Claisen cyclization failed, even though this transformation showed limited success in 
the analogous deconstructed reaction. It should be noted that the deconstructed reaction 
contained 10 times the amount of protein than the chimeric reaction. It is likely that at 
this extreme of protein concentration, the TE domain was essentially saturating allowing 
for the successful redirection of chemistry. Because the domains are covalently attached 
in the chimeric enzyme, it is expected that the effective concentration of each domain is 
quite high. In fact, the significant enhancement of turnover for the chimeric enzymes 
 
Figure 4.8⏐Mechanism for chimeric NR-PKS non-native product formation. (a) Reactions of native 
NR-PKSs: (i) Pks4, (ii) CTB1, and (iii) Pks1. (b) Reactions of chimeric NR-PKSs follow the biosynthetic 
logic proscribed by their constituent domains: (i) M4P2 (CTB1 SAT-KS-MAT/Pks4 PT-ACP-TE), (ii) 
M4P6 (CTB1 SAT-KS-MAT/Pks1 PT-ACP2-TE), and (iii) M6P2 (Pks1 SAT-KS-MAT/Pks4 PT-ACP-TE). 
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supports this notion. It was therefore surprising that the M6P2-TE domain failed. Of 
course, the intermediate presented to the TE would be quite divergent from its native 
substrate, perhaps contributing to poor catalysis. Under these conditions, it is not 
unexpected that pyrone formation—the common off-loading derailment mechanism[4]—
could outcompete TE-directed Claisen cyclization. Nevertheless, the efficiency for all of 
the chimeric enzymes over the deconstructed proteins augurs well, especially if chimeric 
enzymes are to be used for the fermentation of new products. 
 Despite the promise of the domain-swapping approach, all attempts to rationally 
engineer a topopyrone synthase failed. That is not to say that the method is without merit. 
In fact, all of the engineered enzymes are proficient in poly-β-ketone extension implying 
that many of the underlying design elements are sound. In particular, poly-β-ketone 
extension would require correct global folding of the enzymes as well as successful 
replication of crucial domain-domain interactions governing the early stages of NR-PKS 
catalysis. We attribute the failure of these enzymes to flaws in the latter half of 
biosynthesis—PT-catalyzed cyclization and TE-mediated release.  
 The designed topopyrone synthase that we explored in the most detail contained a 
PT domain derived from PksA. The PksA PT domain is the only PT for which a structure 
is known.[8] There are several features of this particular domain that make it unique. First, 
the C4–C9, C2–C11 pattern of PT-catalyzed cyclization is quite rare. To date, only two 
families of enzymes have been demonstrated to adopt this cyclization pattern: the 
norsolorinic acid synthases[8]—the family containing PksA—and the nor-toralactone 
synthases[11]—a family for which CTB1 is the only known member. The PT domains of 
different cyclization families are distinct by sequence comparison;[13a] however, it 
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remains unclear if this divergence in primary structure translates to significant difference 
in tertiary structure. Homology models of different PT cyclization family members based 
on the PksA PT structure imply an alternatively shaped active site for these domains that 
could contribute to their regiospecificity.[8] Furthermore, the hexyl-binding region of the 
PksA PT domain is a unique feature that not only accommodates the unusual hexanoyl 
starter unit but also orders the binding of the linear poly-β-ketone in the PT active site. In 
fact, the PksA PT-G1491L mutant is nonproductive for the wild type enzyme.[8] 
Previously, in reactions of domain-swapped deconstructed NR-PKSs, all reactions 
containing the PksA PT domain failed if the linear poly-β-ketone presented to it was 
primed with an acetyl starter unit.[5] Taken together, these data suggest that the PksA PT 
domain is unique and perhaps cannot be relied upon to take up the expected linear nona-
β-ketone intermediate of our designed topopyrone synthases. It was our hope that by 
mutating the critical Gly1491 some of these inherent challenges could be overcome. The 
results imply that—despite our efforts—the PT domain of the designed enzymes failed, 
thereby derailing the catalytic cycle. 
 The differential product outputs of the PT null and PT and TE null mutant 
enzymes suggest that the designed enzymes were further hampered by inherent TE 
editing. In addition to its biosynthetic role, the TE domain of NR-PKSs has a crucial 
editing function.[6b, 18] When improper intermediates occasionally are produced on the 
ACP, the TE editing mechanism intervenes to clear the ACP of the misformed 
intermediate through hydrolysis. In so doing, the TE resets the enzyme allowing it to 
enter a new catalytic cycle. Control of TE-mediated editing is a crucial feature in any 
domain-swapped paradigm, as previously described (see Chapter 3).[5] A careful balance 
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of directed biosynthesis and TE-mediated editing is of crucial importance for domain-
swapped enzymes.[5, 6b] The overall level of production in the topopyrone synthase PT 
and TE null mutant was much lower than either the native chimera or the PT null mutant. 
This result implies that—in the case of an active TE—editing plays a central function, 
clearing the enzyme allowing from greater overall production. Without this editing 
function, production by the PT and TE null mutant was stalled as intermediates occupied 
the ACP. In this way, TE editing is a double-edged sword. In clearing the ACP, it allows 
for greater turnover, but limits directed biosynthesis by removing potentially productive 
intermediates prematurely. This feature of catalysis is of particular concern for a domain-
swapped enzyme, as the structural features governing TE editing are unknown. 
 While our attempts to engineer a topopyrone synthase were unsuccessful, we 
maintain that our approach was sound and that given an expanded pool of domains, an 
engineered topopyrone synthase can be achieved. To this end, PT domains of the C4–C9, 
C2–C11 cyclization class must be identified that do not fall into the norsolorinic acid 
synthase family. Furthermore, a larger set of TE domains of the C14–C1 Claisen must be 
found. Of course, a better understanding of global NR-PKS structure is of critical 
importance for not only understanding catalysis but also for designing enzymes. To date, 
little is truly known of the global structure of these enzymes and the domain-domain 
interactions that govern their biochemistry. With a more sophisticated understanding of 
structure, we could better refine our domain-swapping approach. Finally, better 
expression conditions for NR-PKSs must be identified. The limited yields from E. coli 
BL21(DE3) expressions used for this study truly hampered our progress. If more reliable 
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conditions could be identified, a greater number of designed enzymes could be screened 
for activity. 
 The eventual goal for designed biosynthetic enzymes is to use these enzymes for 
metabolic engineering and fermentation of non-native products. Traditionally, the NR-
PKSs have been considered as quite limiting due to their relatively poor expression in 
heterologous hosts. However, the advances in heterologous production of chimeric NR-
PKSs in E. coli BL21(DE3) presented here promise a way forward. To that end, we tested 
the fermentation capabilities of E. coli BL21(DE3) with respect to a native NR-PKS. We 
chose Pks1 as our model system as its expression in E. coli BL21(DE3) is reliable and its 
in vitro product—flaviolin (11)—is easily distinguishable and quantifiable.[18] 
 Care must be taken with respect to culture conditions for high production of 
fungal polyketide products in E. coli. The cold shock conducted immediately prior to 
protein induction is of critical importance. Without this step, induction of NR-PKS 
expression does not occur. Furthermore, the composition of the culture medium must be 
considered. Cultures conducted in LB + 10% glycerol have been shown to facilitate a 
higher malonyl-CoA to acetyl-CoA ratio[19]—a crucial precursor metabolite in polyketide 
biosynthesis. In fact, cultures of the bacterial, iterative PKS CalE8—the PKS central to 
calicheamicin biosynthesis by Micromonospora echinospora[20]—in E. coli conducted in 
LB + 10% glycerol not only helped with enzymatic expression but also in identification 
of accumulated enzymatic products. However, such an approach is not feasible for the 
NR-PKSs, as cultures conducted in LB + 10% glycerol failed to induce protein 
expression. It remains unclear why the addition of glycerol would effect protein 
expression in this fashion. 
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 Flaviolin titers were highest at the onset of the stationary phase. After this point, 
titers general began to fall, especially in cultures conducted in baffled flasks. It is likely 
that changing metabolic conditions commensurate with the onset of the stationary phase 
lead to catabolism of flaviolin, decreasing its titer. Of course, this effect is to be expected 
and, generally, fermentations are not conducted in the stationary phase. While the 
flaviolin titers were modest, they represent a respectable benchmark for further 
optimization. Yields could be improved by a variety of methods. In particular, increasing 
flux through the pathway could be achieved by altering the endogenous precursor pool. 
Several metabolic engineering strategies have been adopted to improve malonyl-CoA 
pools for the express purpose of increased polyketide production.[21] Such approaches 
have been reasonably successful and could be easily adapted for the production of fungal 
polyketide products in E. coli. Additionally, both continuous product extraction and 
continuous fermentation could help improve titers. 
4.4. Conclusion 
 In summary, we find that “domain-swapped” NR-PKS chimeric enzymes are 
readably attainable and can be heterologously expressed as functional enzymes in E. coli. 
Three chimeric enzymes were tested for activity. They were found to reproduce—within 
limits—the activity of their analogous domain-swapped deconstructed NR-PKS but with 
much improved productivities and efficiencies. Together, the data suggest that the 
underlying logic of polyketide biosynthesis is maintained in chimeric enzymes. Attempts 
to design a topopyrone synthase through domain-swapping were unsuccessful. Two 
chassis were considered and PT active site manipulations were attempted. Unfortunately, 
none of the engineered enzymes produced topopyrone. They were, however, competent 
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in polyketide extension implying that the approach was sound if not successful. With a 
more diverse set of domains from which to draw, we are confident that an engineered 
topopyrone synthase can be attained. Furthermore, pilot studies into the fermentation of 
fungal polyketide products in E. coli were promising. 
4.5. Experimental Methods 
4.5.1. Reagents and Biological Strains 
 All reagents and primers were purchased from Sigma-Aldrich (St. Louis, MO, 
USA), unless otherwise stated. Magnesium chloride, sodium chloride, potassium 
phosphate monobasic, potassium phosphate dibasic, and deoxynucleotides (dNTPs) were 
purchased from Thermo Scientific (Waltham, MA, USA). Isopropyl-β-D-thiogalactoside 
(IPTG), kanamycin, and nickel (high density) agarose beads were purchased from Gold 
Biotechnology (St. Louis, MO, USA). Imidazole was purchased from Acros Organics 
(Geel, Belgium). Yeast extract and tryptone were purchased from Boston BioProducts 
(Ashland, MA, USA). Agar was purchased from bioWORLD (Dublin, OH, USA). 
Plasmids pET-24a(+) and pET-28a(+) were purchased from EMD Millipore (Darmstadt, 
Germany). All enzymes used for manipulation of DNA and 10 × HF Buffer were 
purchased from New England Biolabs (Ipswich, MA, USA). Bio-Rad protein assay dye 
for determining protein concentration by the Bradford assay was purchased from Bio-Rad 
laboratories (Hercules, CA, USA). Bacterial strain Escherichia coli BL21(DE3) was 
purchased from Sigma-Aldrich and made electrocompetent by standard protocols (see 
Appendix B).[22] 
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4.5.2. Preparation of Expression Constructs 
 DNA manipulations were carried out in accordance with established 
procedures.[23] Details of the expression plasmids used in this study are summarized in 
Tables E.6–8 (Appendix E). Gibson assembly was used to generate chimeric NR-PKS 
constructs (see Appendix B for general protocol). Touchdown PCR was used to generate 
DNA components for Gibson assembly (see Appendix B for general protocol). The 
composition of each PCR in this study is presented in Table E.1 AND E.3 (Appendix E). 
Primers used are presented in Table E.5 (Appendix E). The composition of each Gibson 
assembly reaction in this study is presented in Table E.2 AND E.4 (Appendix E). The 
plasmid DNA part for Gibson assembly was prepared by digesting pET-24(a)+ with NdeI 
and NotI. All expression plasmids were maintained in E. coli BL21(DE3) cells stored in 
20% glycerol at −80 °C. 
4.5.3. Protein Expression and Purification 
 Proteins were prepared by heterologous expression in E. coli BL21(DE3) and 
purified by nickel-affinity purification as delineated in Appendix B. Eluted protein 
fractions were exchanged into 100 mM potassium phosphate pH 7.0, 10% glycerol by 
serial dilution and passing protein fractions through an Amicon Ultracentrifuge tube, 
according to the manufacturer’s instructions. Purified protein concentrations were 
determined by the Bradford assay using bovine serum albumin (New England Biolabs) as 
a standard as described in Appendix B.[24] ACP monodomain proteins were activated to 
their holo form through the action of the promiscuous phosphopantetheinyl transferase 
Svp, as previously described.[4] Excess protein was flash frozen in liquid nitrogen and 
stored at −80 °C until further use. 
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4.5.4. In Vitro Reactions 
 In vitro reactions were conducted using acyl-CoA substrates (acetyl-CoA and 
malonyl-CoA), as previously described.[4, 8] Reactions of chimeric NR-PKSs were 
conducted at a final concentration of 1 µM in 100 mM potassium phosphate pH 7.0, 1 
mM tris(2-carboxyethyl)phosphine (TCEP), and 10% glycerol. Reactions of 
deconstructed NR-PKSs were conducted at a final concentration of 10 µM each protein in 
100 mM potassium phosphate pH 7.0, 1 mM TCEP, and 10% glycerol. In each case, 
reactions were initiated with the simultaneous addition of 0.5 mM acetyl-CoA and 2 mM 
malonyl-CoA and were conducted for either 4 h or overnight at room temperature. 
Reactions were quenched by acidification with HCl, and products were extracted into 
ethyl acetate. Organic fractions were combined, dried under vacuum, and dissolved in 
40% acetonitrile (aq.) at a final volume equivalent to the initial reaction volume. 
4.5.5. Product Profile Analysis 
 Reaction mixtures were analyzed by reverse phase HPLC on an Agilent 1200 
(Agilent Technologies, Santa Clara, CA, USA). Solvent A was water + 0.1% formic acid. 
Solvent B was acetonitrile + 0.1% formic acid. Purified reaction extracts were injected 
onto a linear gradient of 5% to 95% solvent B over 10.8 min at 1.25 mL/min on a Kinetex 
XB-C18 column (4.6 × 75 mm, 2.6 µm, Phenomenex, Torrence, CA, USA). Mass data 
were collected on a Waters Acquity/Xevo-G2 UPLC-MS system (Waters, Milford, MA, 
USA). MS and MS/MS spectra were collected in positive ion mode. UV data were 
determined from the diode array detector (DAD) signal at the maximum HPLC 
chromatogram signal. A complete collection of characterization data for each product is 
presented in Appendix E. 
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4.5.6. E. coli Fermentation of Polyketide Products 
 Pilot studies of polyketide fermentation were conducted in E. coli BL21(DE3) 
cells harboring pEPks1alt—a pET-24a(+) based plasmid harboring the Pks1 gene from C. 
lagenaria. Test media included Luria-Bertani (LB) broth, LB supplemented with 10% 
glycerol, and Terrific Broth (TB). Test vessels included shaking culture flasks with or 
without baffles. Starter cultures were prepared by inoculating 10 mL LB + 50 µg/mL 
kanamycin from a −80 °C 20% glycerol cell stock of E. coli BL21(DE3) cells harboring 
pEPks1alt. Starter cultures were incubated at 37 °C with shaking at 250 rpm, overnight. 
Test cultures were inoculated from starter cultures by diluting 1:100. Test cultures were 
incubated at 37 °C with shaking at 250 rpm. Upon achieving an OD600 of ~0.7, all 
cultures were incubated without shaking in an ice-water bath for 30 min. Immediately 
following cold shock, Pks1 expression was induced with the addition of IPTG (final 
concentration 1 mM). Cultures were incubated at 19 °C with shaking at 250 rpm for 4 
days. Aliquots (20 mL) were collected at prescribed times after IPTG induction and 
centrifuged at 4100 × g, 15 min, at 4 °C. The supernatant was decanted and acidified by 
the addition of HCl, and then stored at −80 °C until further use. 
 Total metabolite extracts from the collected supernatants were prepared through 
extraction with an equal volume of ethyl acetate, thrice. Organic fractions were 
combined, washed with brine, dried with sodium sulfate, and evaporated under vacuum 
until dry. Total metabolite extracts were dissolved in methanol, filtered through 0.2 µm 
PTFE filters, and analyzed by HPLC according to the same protocol for NR-PKS in vitro 
reactions. Titers for flaviolin were calculated from the peak areas of 280 nm 
chromatograms. A concentration standard curve was prepared from HPLC analysis of an 
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authentic flaviolin sample (Figure E.7, Appendix E). Flaviolin was generously provided 
by Dr. Eric A. Hill (Johns Hopkins University, Baltimore, MD, USA). 
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Chapter 5: Molecular Characterization of the Cercosporin 
Biosynthetic Pathway in the Fungal Plant Pathogen Cercospora 
nicotianae 
5.1. Introduction 
 The plant pathogenic Cercospora species are a widespread and destructive genus 
of ascomycetous fungi characterized by their production of the phytotoxin cercosporin (1, 
Figure 5.1b).[1] Cercosporin belongs to the perylenequinone natural product family. The 
perylenequinone metabolites share a characteristic core architecture (2) that is essential to 
 
Figure 5.1⏐The currently proposed cercosporin biosynthetic pathway. The cercosporin toxin 
biosynthetic (CTB) gene cluster has been identified in C. nicotianae (a). The proposed cercosporin 
biosynthesis hinges upon the formation of carboxylic acid 5 by the NR-PKS CTB1. The direct product of 
CTB1 is nor-toralactone (6), precluding the proposed biosynthetic scheme (b). 
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their toxicity.[2] Multiple perylenequinone natural products have been identified from 
fungal and aphidian sources.[3] Cercosporin was first isolated in 1957 from Cercospora  
kikuchii T. Matsu & Tomoyasu—a fungal pathogen of soybeans.[4] Perylenequinone 
metabolites contain the same highly oxidized conjugated pentacyclic core regardless of 
varied substituents—primarily at positions C7 and C7ʹ′—and are usually C2-symmetric. 
Notably, most perylenequinone metabolites are helically chiral, demonstrating a 
preference for one particular atropisomer despite their conjugated, sp2-hybridized carbon 
core.[5] Steric clashes between substituents in the mature perylenequinone metabolites 
account for the observed helical chirality. The biosynthetic origin of this property is 
unknown. 
 Cercosporin—like all perylenequinone metabolites—functions as a 
photosensitizing agent.[6] Upon absorption of visible light, cercosporin facilitates transfer 
of this energy to O2, leading to the production of the potent reactive oxygen species 
(ROS) singlet oxygen (1O2) and superoxide radical (O2−). These ROS cause 
indiscriminate damage to a variety of cellular targets including cell membranes, nucleic 
acids, proteins, and lipids.[7] Peroxidation of the cell membrane is particularly pernicious 
and is the primary mode of toxicity, causing ion leakage from the host organism.[7a, b] A 
direct cellular target of cercosporin has not been found and it is believed that its toxicity 
is entirely attributed to the production of the damaging ROS. As a result, cercosporin 
exerts broad toxicity to bacteria, fungi, and mice.[8] Production of cercosporin by 
Cercospora nicotianae—a fungal pathogen of tobacco—is crucial to the fungus’s 
pathogenicity and is concomitant with lesion formation on tobacco leaves.[9] Multiple 
putative resistance mechanisms have been proposed in C. nicotianae, but the primary 
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mode of resistance is through reversible reduction of the perylenequinone moiety to 
dihydrocercosporin (3)—a species with little photosensitizing activity. 
Dihydrocercopsorin is oxidized to cercosporin spontaneously upon export from the 
fungus, restoring its photoactivated toxicity.[10] 
 Cercosporin is classified as a polyketide natural product as determined from an 
early substrate-feeding assay in which the metabolite bore the characteristic alternating 
polyketide labeling pattern from acetyl and malonyl substrates.[11] Eventually, a gene 
from C. nicotianae encoding a fungal polyketide synthase—dubbed CTB1 (cercosporin 
toxin biosynthesis 1)—was identified through restriction enzyme mediated integration 
mutagenesis.[9a] CTB1 is absolutely necessary for cercosporin production and bears all 
the hallmarks of an iterative, non-reducing polyketide synthase (NR-PKS).[12] Using 







Domains and Motifs InterPro 
Annotation 
Predicted Function 
CTB1 AY649543 7036 8 2196 PKS β-ketoacyl synthase 
PKS acyl transferase 
Polyketide product template 
domain 
Acyl carrier protein-like 









CTB2 DQ991505 1439 1 461 O-methyltransferase, family 
2 
IPR001077 O-methyltransferase 










CTB4 DQ991506 1696 3 512 Major facilitator 
superfamily domain 
IPR020846 MFS transporter 




CTB6 DQ991508 1074 0 357 NAD(P)-binding domain IPR016040 NAD(P)H-
dependent ketone 
reductase 




CTB8 DQ991510 1245 1 397 Zn(2)-C6 fungal-type DNA 
binding domain 







CTB1 as a benchmark, the complete cercosporin biosynthetic gene cluster from C. 
nicotianae was determined (Figure 5.1a, Table 5.1).[13] The cluster comprises eight genes, 
six of which are believed to be responsible for cercosporin assembly (CTB1, 2, 3, 5, 6, 
and 7).[9a, c, 13-14] The zinc finger transcription factor CTB8 co-regulates expression of the 
cluster,[13] while the major facilitator superfamily (MFS) transporter CTB4 exports the 
final metabolite.[9b] In addition to the identified gene cluster, the Zn(II)Cys6 transcription 
factor CRG1 is implicated in both cercosporin production and resistance.[15] The 
Zn(II)Cys6 family of transcription factors is unique to fungi and regulates a diverse set of 
cellular processes.[16] Regulation by CRG1 is complex and poorly understood; however, 
its expression is implicated in regulation of chemical detoxification, multidrug membrane 
transport, and antioxidant biosynthesis pathways.[15c] Cercosporin production is 
completely dependent upon exposure to light and C. kikuchii grown in the dark will not 
accumulate cercosporin.[17] The regulatory mechanism governing light dependence is 
unknown. 
 On the basis of individual genetic homology of the C. nicotianae gene cluster and 
retrobiosynthetic analysis, Chen and coworkers proposed a biosynthetic pathway for 
cercosporin (Figure 5.1b).[13] The proposed pathway hinges upon the metabolite’s C2-
symmetry and the authors argued that dimerization of two identical aromatic 
intermediates 4 would lead to the perylenequinone core. They postulated that CTB1 
produces carboxylic acid 5 from which the aromatic intermediate 4 is derived. This 
pathway is reasonable and accounts for the putative activity of all the biosynthetic gene 
cluster members; nevertheless, it is likely incorrect. Using an enzyme-deconstruction 
approach, we previously characterized the in vitro activity of CTB1.[12] Surprisingly, the 
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naphthopyrone nor-toralactone (6) is the unambiguous in vitro product of CTB1 (Figure 
5.1b). The identification of this intermediate is problematic, as there is no clear member 
of the gene cluster that could presumably open the pyrone moiety—an event that must 
happen to access the perylenequinone core architecture. Herein, we present an alternative 
biosynthetic pathway bolstered by metabolites accumulated in pathway-interrupted C. 
nicotianae knockouts. Furthermore, we characterize the in vitro activity of CTB3—an 
unusual didomain protein containing O-methyltransferase and flavin-dependent 
monooxygenase domains—and implicate it in pyrone opening of nor-toralactone. 
5.2. Results 
5.2.1. Chemical Identification of Intermediates 
 C. nicotianae has been previously cultivated in liquid potato dextrose broth (PDB) 
and on solid potato dextrose agar (PDA). While functional cercosporin biosynthetic gene 
knockout strains of C. nicotianae grew in PDB, reproducible metabolite profiles could 
not be obtained. Therefore, metabolites were isolated from cultures grown on PDA under 
constant light, which provided reproducible metabolite profiles. Cultures of wild-type C. 
nicotianae resulted in a clean metabolic profile with the red-pigmented cercosporin (1) as 
the principal metabolite (Figure 5.2a). Cercosporin was absent in the metabolite profiles 
of all functional cercosporin biosynthetic gene knockout strains. Secondary metabolite 
accumulation was missing in the ΔCTB1 mutant—the knockout mutant of the central 
NR-PKS of cercosporin biosynthesis (Figure 5.2b). 
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 The structures of the major accumulated metabolites from C. nicotianae CTB 
gene cluster knockout strains were elucidated by characteristic UV spectra, exact masses, 
mass fragmentation patterns, and NMR spectra. We identified the previously 
characterized naphthopyrones nor-toralactone (6) and toralactone (7) both as metabolites 
of the ΔCTB3c mutant (Figure 5.2d). Also accumulated in the ΔCTB3c mutant was the 
oxidation product of nor-toralactone, naphthoquinone 8. Two previously unobserved 
 
Figure 5.2⏐Metabolic profiles of CTB gene cluster mutant strains. Chromatograms at 250 nm of 
extracted metabolite profiles for (a) wild-type, (b) ΔCTB1, (c) ΔCTB2, (d) ΔCTB3c, (e) ΔCTB5, (f) 
ΔCTB6, and (g) ΔCTB7 strains displayed along with images of the mycelia for each strain. The metabolites 
were prepared at a concentration of 10 cm2 colony surface area per mL in methanol. Identified cercosporin 
intermediate metabolites are displayed. 
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naphthoquinones were isolated from the ΔCTB6 and ΔCTB5 mutants, which we called 
cercoquinone A (9) and cercoquinone B (10), respectively (Figures 5.2f and 5.2e). No 
major compounds were observed in the extracted metabolite profiles for the ΔCTB2 and 
ΔCTB7 mutants (Figure 5.2c and 5.2g). The profiles for each of these mutants were 
similar to those of the ΔCTB1 mutant. 
 Structural assignments for new compounds cercoquinones A and B were bolstered 
by their 1H NMR spectra, HRMS, mass fragmentation patterns, and UV spectra. The 
aromatic CH resonances in either compound are not coupled, supporting the 1,4-quinone 
oxidation pattern. Furthermore, each compound had fragmentation ions diagnostic for 
1,4-naphthoquinones. Mass fragmentation patterns for naphthoquinone congeners have 
 
Figure 5.3⏐Mass fragmentation ions for cercoquinones A and B justify their structural assignment. 
Characteristic fragments of 1,4-napthoquinones are observed for (a) cercoquinone A and (b) cercoquinone 
B. Observed fragmentation ions are in red. 
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been previously described.[18] Protonated 2-hydroxyl-1,4-naphthoquiones have been 
shown to fragment along two predominant pathways—ring contraction with elimination 
of CO and water resulting in a carbocation or quinone ring-opening resulting in an 
oxonium ion. Fragment ions from both pathways were observed for cercoquinone A (m/z 
207, 249, and 231, Figure 5.3a), while fragmentations arising from only the first pathway 
were observed for cercoquinone B (m/z 233 and 201, Figure 5.3b). The methoxyl 
substituent at the C2 position in cercoquinone B precluded the ring-opening mechanism. 
Thus, the ion fragments confirmed the sites of O-methylation in both cercoquinones A 
and B. Both cercoquinones A and B are similar to known compounds produced by 
various Fusarium species.[19] 
5.2.2. Phenotypic Analysis of Gene Knockout Strains 
 The mycelia of wild-type C. nicotianae were blood red in color, with 
pigmentation occurring at about 4 days after inoculation (Figure 5.2a). The pigmented 
metabolites were primarily concentrated in the mycelia with a small amount exported into 
the agar surrounding individual colonies. The mycelia of each knockout strain displayed 
a different pigmentation from wild-type C. nicotianae, with pigmentation similarly 
occurring at about 4 days after inoculation. The ΔCTB1 mutant did not display any 
pigmentation (Figure 5.2b). The ΔCTB3c mutant adopted a dark yellow-brown 
coloration, with slight export of pigmented metabolites into the agar (Figure 5.2d). The 
mycelia of both ΔCTB6 and ΔCTB5 mutants turned a dark orange-red with significant 
export of colored compounds into the agar (Figures 5.2f and 5.2e). Although they did not 
accumulate any observed secondary metabolite, the mycelia of the ΔCTB2 and ΔCTB7 
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mutants both adopted a yellow-brown color with some export of pigmented compounds 
into the agar (Figures 5.2c and 5.2g). 
 In addition to the pigmentation phenotypes, the average colony diameter for each 
individual strain was distinctive after 7 days of growth (Figure 5.4b). The average colony 
diameters for the wild type, ΔCTB3c, and ΔCTB6 strains were the smallest at 15.5 ± 0.8, 
15.7 ± 1.1, and 15.9 ± 1.0 mm (average ± standard deviation, n = 37). The average colony 
diameter for the ΔCTB5 mutant was of intermediate size at 17.1 ± 1.1 mm, while the 
average colony diameters for the ΔCTB1, ΔCTB2, and ΔCTB7 mutants were the largest 
at 20.8 ± 1.3, 19.2 ± 1.4, and 18.7 ± 1.8 mm. The average colony diameter showed an 
inverse correlation with metabolite accumulation; the strains with identifiable cercosporin 
metabolites (wild-type, ΔCTB3c, ΔCTB6, and ΔCTB5) displayed smaller colony 
diameters while the strains without identifiable intermediates (ΔCTB1, ΔCTB2, and 
ΔCTB7) displayed larger colony diameters. 
 
Figure 5.4⏐Phenotypic and genetic analysis of the CTB cluster. (a) Cercosporin biosynthesis was 
complemented at the colony-colony interface of the ΔCTB1/ΔCTB3c mutant pair (top/bottom, 
respectively). The numbers indicate the distance that colonies were inoculated apart from one another in 
cm. (b) Average colony diameters of CTB disruption mutants are displayed (n = 37). Error bars represent 
the 95% confidence interval. Stars indicate statistically significant difference from wild-type (p < 0.01). (c) 
Comparison of gene clusters similar to the CTB gene cluster of C. nicotianae (top). 
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5.2.3. Cercosporin Complementation Assay 
 To test whether accumulated metabolites represented on-pathway intermediates 
we conducted a complementation assay in which pairs of CTB gene cluster knockout 
strains were grown adjacent to one another. Cercosporin biosynthetic complementation 
was indicated by red pigmentation at the colony-colony interface. The only pair that 
could successfully complement cercosporin biosynthesis was the ΔCTB1 and ΔCTB3c 
mutant pair (Figure 5.4a). Clear complementation was observed between 4 and 5 days 
after inoculation between colonies spotted approximately 0.5 cm apart. Pigmentation was 
isolated to the ΔCTB1 mutant with no clear accumulation of cercosporin in the ΔCTB3c 
mutant. We attempted to detect cercosporin extracted from agar plugs of the colony-
colony interface using a previously described spectrophotometric assay[20]; however, the 
amount of accumulated cercosporin was below the assay’s detection limit. No other 
mutant pair showed clear cercosporin complementation (Figure F.3, Appendix F). 
5.2.4. Genetic Analysis of the Cercosporin Gene Cluster 
 The antiSMASH algorithm was used to determine gene clusters homologous to 
the CTB gene cluster.[21] The top five sequences all came from fungal plant pathogens 
(Figure 5.4c). Of these sequences, only one was associated with a known natural product, 
the hypocrellin A biosynthetic cluster from Shiraia sp. slf14 responsible for the formation 
of the perylenequinone hypocrellin A (13).[22] Five homologous CTB genes were shared 
among all identified clusters: homologs of CTB1, 3, 2, 5, and 4. The CTB1 homologs 
contained the canonical NR-PKS domain architecture as determined by a BLASTp 
search. All of the homologs of CTB3 displayed the same unique didomain architecture 
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with a predicted N-terminal O-methyltransferase and a C-terminal flavin-dependent 
monooxygenase. 
5.2.5. In Vitro Analysis of CTB3 Activity 
 Predicting that it followed CTB1 on the cercosporin pathway, we investigated the 
in vitro activity of CTB3 towards nor-toralactone—the in vitro product of CTB1. 
Because of its unique didomain architecture, we deconstructed CTB3 into its constituent 
domains—the N-terminal O-methyltransferase (CTB3-MT) and the C-terminal flavin-
dependent monooxygenase (CTB3-MO)—for ease of expression and to investigate each 
domain’s activity individually (Figure F.1, Appendix F). Both CTB3 and CTB3-MO 
were purified as holo enzymes with the FAD cofactor bound to the proteins. The 
presence of FAD was confirmed by HPLC and spectrophotometric analysis (Figure F.2, 
Appendix F). Cosubstrates SAM and NADH were included in reactions of CTB3 as 
needed. SAM served as the methyl donor for CTB3-MT and NADH served as the 
reductant for CTB3-MO—transferring a hydride equivalent to FAD at the initiation of a 
catalytic cycle. 
 In vitro reactions were conducted with both nor-toralactone (6) and toralactone 
(7) as substrates. Initial reactions containing 10 µM CTB3 clearly processed these 
substrates; however, the product profiles were ambiguous. Furthermore, both potential 
substrates were processed by the CTB3-MO domain with reactions of CTB3-MO and 
nor-toralactone being converted to a host of potential products. While these species were 
not fully characterized, MS and UV data were indicative of perylenequinone-like 
products with the clear loss of a single carbon. In order to simplify the analysis of 
enzymatic reactions, significant effort went into optimizing the experimental conditions. 
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We found that lower protein concentrations (1 µM) and simplified sample preparation 
(filtration only before HPLC analysis) were necessary for reproducible and robust 
analysis. 
 Reactions of CTB3-MT showed turnover of nor-toralactone to toralactone (Figure 
5.5a). Similarly, reactions containing a low concentration of protein (0.1 µM) showed 
partial methylation of nor-toralactone to toralactone. Together, these results indicated that 
toralactone served as an intermediate of the CTB3 catalytic cycle and as the true substrate 
for the CTB3-MO domain despite its apparent activity towards nor-toralactone. 
 
Figure 5.5⏐Product profiles of in vitro reactions of CTB3. The 280 nm chromatograms of the following 
reactions are displayed: (a) CTB3-MT with nor-toralactone, (b) CTB3-MO with toralactone, (c) CTB3-MT 
and CTB3-MO with nor-toralactone, (d) CTB3-MT and CTB3-MO with nor-toralactone under reductive 
conditions, (e) CTB3-MO with toralactone under reductive conditions, and (f) CTB3 with nor-toralactone 
under reductive conditions. Peaks for nor-toralactone (6) and toralactone (7) are indicated along with peaks 
for products cercoquinone C (12) and cercoquinone D (11). A peak for DTT and other cosubstrates are 
observed, as applicable. 
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Postulating that the programming of the catalytic cycle between the MT and MO domains 
was in part kinetically controlled, we conducted reactions that were allowed to proceed 
for 60 min before quenching—significantly longer than the initial 7–10 min reactions. 
Reactions of the CTB3-MO domain with toralactone serving as the substrate resulted in 
turnover to o-naphthoquinone 12—cercoquinone C (Figure 5.5b). Cercoquinone C was 
also observed in reactions of deconstructed CTB3 with nor-toralactone as the substrate—
albeit with a coterie of other uncharacterized products (Figure 5.5c). These additional 
products were absent in reactions with toralactone. Additionally, toralactone is an 
observed intermediate of this reaction along with the off-pathway oxidation product, 
naphthoquinone 8. 
 The formation of cercoquinone C was unexpected. Presumably, this product is 
formed through its hydroquinone (14) even though that species was not directly observed. 
Assuming that oxidation was spontaneous, we postulated that conducting in vitro 
reactions under reductive conditions could have prevented the presumptive oxidation. 
Reactions under reductive conditions (1 mM DTT) resulted in the formation of a new p-
naphthoquinone 11—cercoquinone D (Figure 5.5d–f). Cercoquinone D was only 
observed when DTT was present. It was observed in either reactions of deconstructed 
CTB3 or intact CTB3 with nor-toralactone and reactions of the CTB3-MO domain with 
toralactone. Time-course experiments showed that the appearance of either cercoquinone 
C under nonreductive conditions and cercoquinone D under reductive conditions was 
coincident with the consumption of toralactone by CTB3-MO. Attempts to methylate the 
presumptive product 14 through the action of CTB2, an O-methyltransferase, were 
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unsuccessful under both normal and reductive conditions (Figure F.4, Appendix F). 
CTB2 was also unsuccessful at methylating nor-toralactone. 
 Structural assignments of cercoquinones C and D were supported by HRMS, mass 
fragmentation, and UV spectra. Insufficient amounts of material made structural analysis 
by NMR for these products unfeasible. Structural analogs of both cercoquinones C and D 
containing the same quinone cores display similar UV spectra.[23] The fragmentation data 
were highly characteristic (Figures 5.6 and 5.7). As with cercoquinones A and B, 
fragmentation ions were observed that comport with the naphthoquinone core. It should 
be noted that 1,2-naphthoquinones and 1,4-naphthoquinones each fragment in distinct 
ways.[18c] Additionally, substituents at the C3 position—the 2-oxopropyl moieties in 
 
Figure 5.6⏐Mass fragmentation ions for cercoquinone C justify its structural assignment. (a) 
Characteristic fragments of 1,2-napthoquinones are observed. (b) The 2-oxopropyl fragmentation ions 
derived from the m/z 215 ion. (c) The m/z 191 ion derived from the initial 2-oxopropyl fragment ion. 
Observed fragmentation ions are in red. 
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cercoquinones C and D—can influence the fragmentation of the quinone ring.[18] 
 The cercoquinone C m/z 151 fragmentation ion corresponded to the product of the 
known fragmentation pattern for 1,2-napthoquinones (Figure 5.6a). Interestingly, this 
fragmentation pathway established an intermediate that was primed for dehydration 
resulting in the m/z 215 ion (Figure 5.6b). The m/z 215 ion underwent further 
fragmentation producing a pair of ions—m/z 187 and 144. The parent cercoquinone C ion 
was similarly primed for the elimination of the 2-oxopropyl substituent as ketene, 
 
Figure 5.7⏐Mass fragmentation ions for cercoquinone D justify its structural assignment. (a) 
Characteristic fragments of 2-hydroxyl-1,4-napthoquinones are observed. (b) The fragmentation ions 
derived from the initial 2-oxopropyl fragment ion. Observed fragmentation ions are in red. 
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yielding a resonance-stabilized benzylic cation (m/z 219, Figure 5.6c). Although this ion 
was not observed, its ring-contracted CO-elimination ion was present (m/z 191). 
Additionally, a predominant sodiated ion for cercoquinone C was observed in the 
HRMS—a common feature of 1,2-napthoquinones.[18c] 
 The cercoquinone D fragmentation pattern was characteristic for a 2-hydroxyl-
1,4-naphthoquinone compound. The distinguishing ring-contracted ion (m/z 231) and the 
oxonium ion (m/z 151)—similar to those observed for cercoquinones A—were both 
evident (Figure 5.7a). As with cercoquinone C, the 2-oxopropyl substituent was 
fragmented and eliminated as ketene with the participation of the quinone moiety (Figure 
5.7b). The resulting resonance-stabilized ion underwent a characteristic series of 
dehydrations and CO eliminations with ring-contractions generating a collection of 
distinctive ions (m/z 235, 217, 189, and 161). 
5.3. Discussion 
 The results presented herein resolve the current ambiguity of cercosporin 
biosynthesis and suggest a common biosynthetic pathway for the perylenequinone natural 
products.[12-13] We propose a revised biosynthetic scheme for cercosporin based upon the 
accumulated metabolites of functional biosynthetic gene knockout strains (Figure 5.8). 
First, CTB1 acts according to its established in vitro chemistry producing nor-toralactone 
(6).[12] The bifunctional enzyme CTB3 methylates nor-toralactone to toralactone (7) 
before conducting an unusual oxidative aromatic ring opening producing metabolite 14. 
The O-methyltransferase CTB2 is proposed to methylate the nascent OH-6 of 
intermediate 14—blocking further oxidation at this site and yielding compound 15—
before the reductase CTB6 reduces the 2-oxopropyl ketone at position C7, giving 
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naphthalene 16. CTB5 is thought to be responsible for homodimerization of intermediate 
16 with CTB7 installing the dioxepine moiety, finally producing cercosporin (1). 
 We suggest that several of the accumulated metabolites correspond to oxidation 
products of true on-pathway intermediates. The metabolites cercoquinone A (9) and 
cercoquinone B (10) from the ΔCTB6 and ΔCTB5 mutants, respectively, fall into this 
category. Both quinone products derive from the oxidation of electron-rich naphthalene 
derivatives. The oxidation of electron-rich aromatic metabolites is common and 
spontaneous—often leading to stabilized products.[24] 1H NMR and mass fragmentation 
data comport with these structural assignments, especially with respect to the sites of 
oxidation and methylation. In fact, the observed fragmentation ions agreed with 
established fragmentation mechanisms for naphthoquinone products. The inability of 
 
Figure 5.8⏐Proposed cercosporin biosynthetic pathway. On the strength of observed pathway 
intermediates, in vitro chemistry, phenotypic, genetic, and pairwise complementation a new biosynthetic 
scheme for cercosporin is presented. 
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either %CTB6 or %CTB5 mutants to complement cercosporin activity as secretor-
converter pairs bolsters the argument that cercoquinones A and B are rapidly formed off-
pathway byproducts. 
Interestingly, cercoquinone A displays the loss of a methyl group installed earlier 
through the activity of the O-methyltransferase domain of CTB3. The loss of the methyl 
at this position is unambiguous given the metabolite’s characteristic mass fragmentation 
pattern; in particular, the retention of the methoxyl in both the ring contraction 
carbocation and the ring-opened oxonium ion confirms its structural assignment. We 
envision two possible scenarios that could account for the elimination of this moiety 
(Figure 5.9). In the first possibility, it is simply eliminated as methanol following 
oxidation to the p-quinone. Several structural features would favor addition of water at 
the methoxy position. The site of attack is vinylogous to the ketone of the quinone, which 
is—in turn—stabilized by a hydrogen bond to the peri-hydroxyl group. Collapse of the 
enolate intermediate would favor elimination of methanol resulting in cercoquinone A. In 
the second possibility, the methyl position is removed enzymatically. The methoxy at this 
position is eventually incorporated into the dioxepine functionality of the final product 
through the activity of CTB7. While the mechanism of this transformation is unknown, 
Figure 5.9"Proposed formation of cercoquinone A. Two mechanisms were considered. Addition of 
water followed by elimination of methanol (pictured) or enzymatic demethylation. Cercosporin is shown 
with a monomeric unit shown in red. CTB7 is postulated to form the dioxepine ring, a transformation that 
would require the elimination of a methyl group at the position of demethylation in cercoquinone A. 
 146 
by analogy to studies of methylenedioxy formations,[25] it would likely involve oxidative 
loss. Given the structural similarity of cercoquinone A to the monomeric unit of 
cercosporin, we suggest that CTB7 could use this metabolite as an alternative substrate 
and catalyze the elimination of the methyl in question. Cercoquinone B stands in 
opposition to both of these mechanisms. Cercoquinone B possesses the same chemical 
features that favor the addition-elimination mechanism; yet, it retains the methoxyl at the 
comparable position. Similarly, it bears structural resemblance to the cercosporin 
monomeric unit and could be envisioned as an alternative CTB7 substrate. Unique to 
cercoquinone B is a dihydrofuran moiety on the opposite side of the molecule. Perhaps 
the presence of this functionality precludes it from serving as a substrate for CTB7—a 
claim that would seem to bolster the enzymatic elimination mechanism for cercoquinone 
A. We argue that the dihydrofuran moiety of cercoquinone B arises due to intramolecular 
nucleophilic aromatic substitution with elimination of methanol after oxidation to the 
quinone. 
 The absence of any cercosporin pathway metabolites in the ΔCTB2 and ΔCTB7 
mutants is curious given that they are absolutely necessary to sustain cercosporin 
biosynthesis. Although we do not have direct evidence for degradation, we believe the 
presumptive metabolites of these knockout mutants are directed towards divergent 
pathways. Naphthoquinone secondary metabolites in fungi have been shown to inhibit 
fungal growth.[26] Both ΔCTB2 and ΔCTB7 mutant strains have more robust growth than 
either wild-type or mutant strains that accumulate significant amounts of naphthoquinone 
byproducts, suggesting that, indeed, the presumptive cercosporin pathway intermediates 
of these mutant strains are consumed. Despite their limited metabolic profiles, both 
 147 
ΔCTB2 and ΔCTB7 mutant strains appear pigmented while the ΔCTB1 mutant strain is 
colorless. The putative cercosporin pathway intermediates produced in these mutant 
strains would likely be electron-rich, hydroxylated naphthalene analogs similar to the 
components of melanin.[27] Melanin—a crucial biological pigment—is produced in fungi 
by the polymerization of polyketide-derived 1,8-dihydroxynaphthalene monomers. It is a 
critical metabolite in plant pathogens as it provides mechanical strength to cellular 
structures responsible for host invasion.[28] Furthermore, melanin is highly insoluble and 
would not contribute to the extracted metabolite profiles analyzed in the current study. 
Together, the data suggest that the metabolites of the ΔCTB2 and ΔCTB7 mutants are 
likely directed towards a melanin-like biosynthetic pathway resulting in incorporation 
into insoluble, pigmented polymers. 
 As has been shown previously, the in vitro product of CTB1—an NR-PKS—is 
naphthopyrone nor-toralactone (6).[12] The evolution of nor-toralactone by the NR-PKS 
presents an immediate problem. In order to synthesize cercosporin from nor-toralactone, 
the pyrone ring must be opened; however, there is no apparent enzyme in the CTB cluster 
that could carry out this transformation through conventional lactonase-like hydrolysis—
the common pathway for this type of reaction.[29] The accumulation of nor-toralactone in 
the ΔCTB3c mutant simultaneously confirms the importance of this metabolite while 
implicating a potential candidate in CTB3 for pyrone ring opening. Furthermore, the 
successful complementation of cercosporin biosynthesis in the ΔCTB1/ΔCTB3c mutant 
pair corroborates that nor-toralactone is an on-pathway intermediate. Nevertheless, it 
remains unclear why the pathway would proceed through a naphthopyrone intermediate 
at all. Given that downstream intermediates of the pathway are both prone to oxidation 
 148 
and putatively redirection towards other biosynthetic pathways. Perhaps production of the 
relative stable intermediate nor-toralactone ensures sufficient flux into the cercosporin 
pathway at the outset. 
 CTB3 is an unusual didomain enzyme with an O-methyltransferase domain and a 
flavin-dependent monooxygenase domain. The in vitro enzymatic reactions presented 
herein confirm that both domains work in tandem to transform the polyketide product 
nor-toralactone to the on-pathway naphthalene analog 14. Although naphthalene 14 is not 
directly observed, it is the implied shared precursor to both cercoquinone C (12) and 
cercoquinone D (11). The mass fragmentation and spectral data are in accord with the 
structural assignments for cercoquinones C and D. We observe characteristic mass 
fragments for both ortho and para quinones that confirm the positions of oxidation. The 
observed ring-contracted carbocations and ring-opened oxonium ions for both 
metabolites are the expected products of established fragmentation pathways. 
 The direct methylation of nor-toralactone to toralactone by CTB3-MT, as well as 
the appearance of toralactone in reactions of CTB3 with nor-toralactone are strong 
indicators that toralactone is a true intermediate of the CTB3 catalytic cycle. 
Furthermore, its appearance in the metabolite profile of the ΔCTB3c mutant suggests its 
biological importance. The ΔCTB3c mutant strain was produced by inserting the 
knockout cassette into the 5ʹ′-terminus of the CTB3 gene corresponding to the CTB3-MO 
domain. The sequence of the CTB3-MT domain is largely unaltered suggesting the 
possibility of a functional O-methyltransferase. We suspect that the ΔCTB3c mutant 
strain could retain some endogenous CTB3-MT activity resulting in the partial 
methylation of nor-toralactone in the disruption mutant strain. Alternatively, another O-
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methyltransferase could conceivably convert nor-toralactone to toralactone; however, this 
hypothetical O-methyltransferase could not be CTB2—the only other methyltransferase 
in the CTB cluster—as it is incapable of this transformation in vitro. 
 The CTB3-MO domain shares strong primary sequence homology to the 
canonical p-hydroxybenzoate (17) hydrolase family of flavin-dependent 
monooxygenases.[30] This is a well-studied family of enzymes with a shared catalytic 
mechanism and preference for electron-rich aromatic substrates. They are responsible for 
the hydroxylation of simple phenolic systems with a preference for the ortho and para 
positions. The reaction cycle proceeds in two halves: reductive and oxidative (Figure 
5.10a).[31] The reductive half cycle is initiated with the formation of a ternary complex of 
enzyme containing oxidized FAD (FADox, 18), NAD(P)H, and substrate. Upon formation 
 
Figure 5.10⏐Proposed mechanism for CTB3 flavin-dependent monooxygenase domain. (a) General 
mechanism of p-hydroxybenzoate (17) hydroxylase family members. (b) Proposed mechanism for CTB3 
catalyzed oxidative aromatic ring cleavage of toralactone (7). (c) Mechanism of MHPCO and 5PAO 
oxidative aromatic ring cleavage. 
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of the ternary complex, rapid reduction of FAD by NAD(P)H occurs (FADred, 19). 
Reduction is contingent on substrate binding or—in some cases—analogs of the native 
substrate. NAD(P)+ dissociation occurs at a rate similar to that of reduction. The resulting 
reduced enzyme and substrate complex has significant kinetic stability. In the oxidative 
half cycle, oxygen reacts with FADred, forming the characteristic flavin-C4a-
hydroperoxide reactive intermediate (21). The deprotonated flavin-C4a-peroxy species 
(20) has never been observed in these enzymes. Hydroxylation of the substrate occurs 
through electrophilic aromatic substitution resulting in an enzyme bound product and 
flavin-C4a-hydroxide (22) complex. Water is eliminated from the flavin species resulting 
in FADox and the product is finally released. 
 We argue that the same mechanism is at play in the CTB3-MO domain with the 
enzyme installing hydroxide at the bridgehead position of toralactone (7, Figure 5.10b). 
The hydroxylated intermediate 24 would be far more susceptible to hydrolysis due to the 
loss of conjugation and aromaticity and the favorable enolate leaving group. 
Hydrolysis—enzyme catalyzed or spontaneous—would result in acid 25. Loss of carbon 
dioxide from acid 25 to generate the o-hydroquinone 14 would likely be spontaneous and 
rapid with the reestablishment of aromaticity providing a large thermodynamic driving 
force. Alternatively, one could also consider a Baeyer-Villiger-like oxidation, with a 
flavin-C4a-peroxy nucleophile attacking the pyrone carbonyl. Ring expansion followed 
by hydrolysis and loss of carbon dioxide would generate the same product 14. We 
consider this mechanism to be unlikely. The p-hydroxybenzoate monooxygenase enzyme 
family invariably proceeds through an electrophilic flavin-C4a-hydroperoxy species 
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while flavoenzyme catalyzed Baeyer-Villiger oxidations rely on the nucleophilic flavin-
C4a-peroxy species.[32] 
 There is precedence for p-hydroxybenzoate monooxygenase family members 
participating in oxidative aromatic ring cleavage. The enzymes 2-methyl-3-
hydroxypyridine-5-carboxylic acid (MHPC, 26a) oxygenase (MHPCO) and 5-pyridoxic 
acid (5PA, 26b) oxygenase (5PAO) are flavoenzymes of the p-hydroxybenzoate 
monooxygenase family catalyzing aromatic hydroxylation and subsequent aromatic ring 
cleavage reactions (Figure 5.10c).[33] Like conventional flavin monooxygenases, these 
enzymes use the flavin-C4a-hydroperoxy reactive intermediate (21) in their initial 
electrophilic aromatic oxidation; however, they undergo a subsequent ring-opening 
reaction. The mechanism of ring opening has not been definitively established, but it is 
known that ring opening is enzyme catalyzed in MHPCO and involves the addition of 
water to the carbonyl intermediate (27a).[34] 
 Although compound 14 is not observed in vitro, it is the implied common 
intermediate of both cercosporin C and D (12 and 11, respectively). The transfer of a 
hydride equivalent from compound 14 to FADox, while not anticipated, is not entirely 
unreasonable. In the absence of a reductive environment, one could envision this 
oxidation is the dominating pathway towards cercoquinone C. Furthermore, the observed 
consumption of nor-toralactone by CTB3-MO implies an ortho-quinone intermediate. 
Ortho-quinone analogs of cercoquinone C have been used previously to access the 
perylenequinone core through simple coupling under acid conditions.[35] Assuming nor-
toralactone serves as an alternative substrate for CTB3-MO, the observed but 
uncharacterized dimeric products could likely arise through analogous couplings. 
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Under reductive conditions, cercoquinone C—upon release—would be rapidly 
reduced back to species 14. Electron rich naphthalene species such as compound 14 are 
susceptible to spontaneous oxidation. One could envision the oxidation of compound 14 
to cercoquinone D as being rapid and complete, even under reductive conditions. The 
apparent instability of intermediate 14 could explain the observed preference for 
oxidation of ortho-quinone cercosporin C. In the quinone oxidation state, this species is 
protected from subsequent oxidation, ensuring biosynthetic fidelity. 
Structural analysis of known fungal perylenequinone natural products reveals 
several common features among this family of metabolites (Figure 5.11).[35c] First, the 7, 
7# moieties are derived from 2-oxypropyl side chains. Second, the 2, 2# substituents are 
always methoxyl or—in the case of cercosporin—a derivative thereof. Third, the 6, 6# 
substituents are always methyoxy or derivatives thereof. Fourth, the perylenequinone 
core architecture remains unaltered. These core structural features suggest a common 
biosynthetic pathway for the perylenequinone metabolites. Indeed, the activities of 
Figure 5.11"Structures of known fungal perylenequinone natural products. Common architectural 
features are observed in the family. The occurrence of methyoxy at 2, 2# and 6, 6# positions are invariable. 
As is the 2-oxypropyl derivatives at 7, 7#. The formation of the perylenequinone core also appears to be 
conserved. 
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CTB1, CTB3, CTB2, and CTB5 delineated here would account for each of these features 
with CTB1 producing the common intermediate nor-toralactone, CTB3 methylating this 
intermediate at the OH-2 and opening the pyrone ring thereby installing a C6-OH, CTB2 
methylating the nascent C6-OH, and CTB5 catalyzing dimerization yielding the 
perylenequinone carbon core. Interestingly, homologs of each of these enzymes are found 
in known gene clusters most similar to the CTB cluster. Of these clusters, only one is 
linked to an observed product, hypocrellin A (13).[22] Hypocrellin A differs from 
cercosporin in three key features: the 7, 7ʹ′ substituents are retained in the 2-oxypropyl 
oxidation state and are linked through an intramolecular aldol, the 2, 2ʹ′ substituents are 
methoxyl, and the compound adopts the alternative atropisomeric conformation. 
Comparing the CTB and hypocrellin A clusters, CTB6 and CTB7 appear unique to the 
CTB cluster. Given that these enzymes presumptively reduce the 2-oxypropyl 
substituents and install the dioxepine moiety, respectively, it makes sense that they would 
be missing in the hypocrellin A cluster, where these features are not present. Altogether, 
these data imply that perylenequinone natural products proceed through a common 
biosynthetic pathway in which nor-toralactone is initially produced and further processed 
by a CTB3 didomain homolog. Given its unique activity and rarity, CTB3 and its 
homologs make appealing targets for antifungal agents. 
5.4. Conclusion 
 Here we resolve the current ambiguity of cercosporin biosynthesis and propose 
our own biosynthetic pathway. We demonstrate that the naphthoquinone nor-toralactone 
is a biologically relevant intermediate of the cercosporin pathway, further corroborating 
the previously observed in vitro activity of the NR-PKS CTB1. We also characterize the 
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activity of the unusual didomain protein CTB3, showing that its flavin-dependent 
monooxygenase domain is responsible for a unique oxidative aromatic cleavage. 
Together, these findings further not only our understanding of perylenequinone 
biosynthesis but also expand the known biochemical repertoire of flavin-dependent 
monooxygenases—an important class of enzymes in both primary and secondary 
metabolism. While addressing the initial steps of cercosporin biosynthesis, the data 
presented do not fully resolve the later portion of the biosynthetic pathway. The crucial 
perylenequinone dimerization step remains unexamined biochemically and 
enzymatically. Given the importance of cercosporin for pathogenicity, a complete 
understanding of its biosynthesis is of utmost importance. Indeed, the rare activity of 
CTB3 and its apparent conservation among perylenequinone biosynthetic gene clusters 
makes this enzyme an attractive target for Cercospora specific antifungal agents. 
5.5. Experimental Methods 
5.5.1. Reagents and Biological Strains 
 All reagents and primers were purchased from Sigma-Aldrich (St. Louis, MO, 
USA), unless otherwise specified. Magnesium chloride, sodium chloride, potassium 
phosphate monobasic, potassium phosphate dibasic, and deoxynucleotides (dNTPs) were 
purchased from ThermoFisher Scientific (Waltham, MA, USA). Isopropyl-β-D-
thiogalactoside (IPTG), kanamycin, and nickel (high density) agarose beads were 
purchased from Gold Biotechnology (St. Louis, MO, USA). Imidazole was purchased 
from Acros Organics (Geel, Belgium). Difco™ potato dextrose agar (PDA) and Difco™ 
potato dextrose broth (PDB) were purchased from Beckton, Dickson, and Company 
(Franklin Lakes, NJ, USA). Yeast extract and tryptone were purchased from Boston 
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BioProducts (Ashland, MA, USA). Agar was purchased from bioWORLD (Dublin, OH, 
USA). Plasmids pET-24a(+) and pET-28a(+) were purchased from EMD Millipore 
(Darmstadt, Germany). All enzymes used for manipulation of DNA and 10 × HF Buffer 
were purchased from New England Biolabs (Ipswich, MA, USA). Bio-Rad protein assay 
dye for determining protein concentration by the Bradford assay was purchased from 
Bio-Rad laboratories (Hercules, CA, USA). Bacterial strain Escherichia coli BL21(DE3) 
was purchased from Sigma-Aldrich and made electrocompetent by standard protocols 
(Appendix B). DNA purified from C. nicotianae (ATCC© 18366™) was provided by Dr. 
Kuang-Ren Chung (currently of National Chung Hsing University, Taichung, Taiwan). 
C. nicotianae (ATCC© 18366™) wild type strain and cercosporin gene cluster knockout 
strains previously prepared were also generously provided by Dr. Chung.[9, 13-14] 
5.5.2. Culture Conditions 
 C. nicotianae (ATCC© 18366™) and knockout strains were maintained on PDA. 
PDA plates were strictly maintained at a thickness of 3 mm. Starter cultures were 
prepared by spotting a colony from a stock plate on PDA with a sterile toothpick. The 
starter culture was allowed to grow, inverted, at 28 °C for 7 days under constant 
fluorescent light. Stock plates were prepared from fresh starter cultures that were 
wrapped in parafilm and stored at 4 °C in the dark until further use. Production cultures 
were prepared by spotting colonies from a fresh starter culture on PDA with a sterile 
toothpick. Colonies were spotted in a 2 cm grid. Mycelia were incubated, inverted, under 
constant fluorescent light at 28 °C for 7 days. 
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5.5.3. Metabolite Extraction and Purification 
 The total mass (mycelia and agar) from production cultures were collected, frozen 
in liquid nitrogen, and ground to a powder in a mortar and pestle. The powder was 
lyophilized for 12–16 h then suspended in water acidified with concentrated HCl. 
Metabolites were extracted from this slurry thrice with ethyl acetate at 4 °C. The ethyl 
acetate fractions were combined, washed with brine, dried with sodium sulfate, and 
evaporated under vacuum. The solid residue was stored at 4 °C until further use. 
 The extracted metabolites were dissolved in methanol and filtered through 0.4 µm 
PTFE filters. Metabolites were separated on a Sephadex LH-20 column (GE Healthcare, 
Little Chalfont, UK) using methanol as a mobile phase with a flow rate of 1.3 mL/min 
and injecting 1.2 mL aliquots. Fractions were collected every 5 min. Fractions were 
screened for metabolites of interest by reverse phase HPLC on an Agilent 1200 (Agilent 
Technologies, Santa Clara, CA, USA). Solvent A was water + 0.1% formic acid. Solvent 
B was acetonitrile + 0.1% formic acid. Fractions were injected onto a linear gradient of 
5–95% solvent B over 10.8 min at 1.25 mL/min on a Kinetex XB-C18 column (4.6 mm × 
75 mm, 2.6 µm, Phenomenex, Torrence, CA, USA). Typical injection volumes were 10–
15 µL. Chromatograms at 250 and 280 nm were recorded. 
 Fractions containing metabolites of interest were combined, concentrated under 
vacuum, and purified by reverse phase HPLC on an Agilent 1100 instrument (Agilent 
Technologies). Solvent A was water + 0.1% formic acid. Solvent B was acetonitrile + 
0.1% formic acid. Fractions were injected onto a linear gradient of 5–95% solvent B over 
45 min at 4.726 mL/min on a Prodigy 5u ODS3 column (10 mm × 250 mm, 5 µm, 
Phenomenex). Injection volumes were typically 500–1000 µL. Chromatograms at the 
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expected λmax for the metabolite of interest were recorded. Metabolites were manually 
collected as they eluted and the fractions from serial injections were combined. 
Acetonitrile and formic acid were removed from these samples by evaporation under 
vacuum in a rotary evaporator. The remaining aqueous solution was frozen in liquid 
nitrogen and lyophilized until dry. Purified samples were stored at 4 °C until further use. 
5.5.4. Complementation Assays 
 Cercosporin biosynthesis functional knockouts were plated adjacent to one 
another to assay for cercosporin production complementation. Colonies were spotted with 
a sterile toothpick from a fresh starter culture on 3 mm thick PDA plates. The complete 
set of pairwise combinations of cercosporin biosynthetic functional knockouts was 
assayed. Colonies from different strains were spotted 0.5, 0.7, 1.0, 1.5, and 2.0 cm apart 
from one another. The cultures were incubated, inverted, under constant fluorescent light 
at 28 °C for 7 days. The appearance of red pigmentation at the boundary between two 
mycelia was determined to represent cercosporin production complementation. Evidence 
of complementation was monitored daily. 
5.5.5. Preparation of Expression Constructs 
 DNA manipulations were carried out in accordance with established 
procedures.[36] Protocols for PCR and overlap extension PCR are found in Appendix B. 
Details of the expression plasmids used in this study are summarized in Table F.2 
(Appendix F). Cut sites for protein deconstruction were guided by a variety of 
bioinformatics analyses including multiple sequence alignment, secondary structure 
prediction and the UMA algorithm for predicting interdomain regions.[37] Primer 
sequences used for cloning new constructs used in this study are presented in Tables F.1 
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(Appendix F). All expression plasmids were maintained in E. coli BL21(DE3) cells 
stored in 20% glycerol at −80 °C. 
 The complete CTB3 ORF was cloned into a pCR®-Blunt vector (ThermoFisher 
Scientific) for easier genetic manipulation. The insert was prepared by PCR using C. 
nicotianae (ATCC© 18366™) genomic DNA template with primers CTB3-5 and CTB3-3. 
The product was ligated into pCR®-Blunt using the Zero Blunt® PCR Cloning Kit 
(ThermoFisher Scientific) according to the manufacturer’s instructions, yielding pCR-
CTB3. 
 Two full-length CTB3 expression constructs were prepared. The first had a C-
terminal 6 × His tag (pECTB3) and the second had an N-terminal 6 × His tag (p28CTB3). 
The CTB3 ORF contains three exons that were synthetically spliced using overlap 
extension PCR. Overlap extension PCR DNA fragments were prepared by PCR from 
pCR-CTB3 template. The exon 1 fragment was prepared with primers CTB3-AseI-5 and 
CTB3-ex1-3. The exon 2 fragment was prepared with primers CTB3-ex2-5 and CTB3-
ex2-3. Two exon 3 fragments were prepared with primers CTB3-ex3-5 and CTB3-NotI-3 
or CTB3-Stop-3, for fragments without and with a stop codon, respectively. The resulting 
PCR products were spliced together using overlap extension PCR with outside primers 
CTB3-AseI-5 and CTB3-NotI-3 or CTB3-Stop-3 for inserts without and with a stop 
codon, respectively. The inserts were digested with AseI and NotI-HF. The insert without 
a stop codon was ligated in NdeI and NotI-HF digested pET-24a(+) yielding pECTB3. 
The insert with a stop codon was ligated in NdeI and NotI-HF digested pET-28a(+) 
yielding p28CTB3. 
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 Two CTB3 O-methyltransferase monodomain expression constructs were 
prepared by PCR. The first had a C-terminal 6 × His tag (pECTB3-MT1) and the second 
had an N-terminal 6 × His tag (p28CTB3-MT1). The inserts were prepared by PCR using 
pECTB3 template with primers CTB3-AseI-5 and CTB3-MT1-3 or CTB3-MT1-Stop-3 
for inserts without or with a stop codon, respectively. The inserts were digested with AseI 
and NotI-HF. The insert without a stop codon was ligated into NdeI and NotI-HF 
digested pET-24a(+) yielding pECTB3-MT1. The insert with a stop codon was ligated 
into NdeI and NotI-HF digested pET-28a(+) yielding p28CTB3-MT1. 
 Two CTB3 flavin-dependent monooxygenase monodomain expression constructs 
were prepared by PCR. The first had a C-terminal 6 × His tag (pECTB3-MO3) and the 
second had an N-terminal 6 × His tag (p28CTB3-MO3). The inserts were prepared by 
PCR using pECTB3 template with primers CTB3-MO3-5 and CTB3-NotI-3 or CTB3-
Stop-3 for inserts without or with a stop codon, respectively. The inserts were digested 
with NdeI and NotI-HF. The insert without a stop codon was ligated into NdeI and NotI-
HF digested pET-24a(+) yielding pECTB3-MO3. The insert with a stop codon was 
ligated into NdeI and NotI-HF digested pET-28a(+) yielding p28CTB3-MO3. 
 The complete CTB2 ORF was cloned into a pCR®-Blunt vector for easier genetic 
manipulation. The insert was prepared by PCR using C. nicotianae (ATCC© 18366™) 
genomic DNA template with primers CTB2-5 and CTB2-3. The product was ligated into 
pCR®-Blunt using the Zero Blunt® PCR Cloning Kit according to the manufacturer’s 
instructions, yielding pCR-CTB2. 
 Two CTB2 expression constructs were prepared. The first had a C-terminal 6 × 
His tag (pECTB2) and the second had an N-terminal 6 × His tag (p28CTB2). The CTB2 
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ORF contains two exons that were synthetically spliced using overlap extension PCR. 
Overlap extension PCR DNA fragments were prepared by PCR from pCR-CTB2 
template. The exon 1 fragment was prepared with primers CTB2-NdeI-5 and CTB2-ex1-
3. Two exon 2 fragments were prepared with primers CTB2-ex2-5 and CTB2-NotI-3 or 
CTB2-Stop-3, for fragments without and with a stop codon, respectively. The resulting 
PCR products were spliced together using overlap extension PCR with outside primers 
CTB2-NdeI-5 and CTB2-NotI-3 or CTB2-Stop-3 for inserts without and with a stop 
codon, respectively. The inserts were digested with NdeI and NotI-HF. The insert without 
a stop codon was ligated in NdeI and NotI-HF digested pET-24a(+) yielding pECTB2. 
The insert with a stop codon was ligated in NdeI and NotI-HF digested pET-28a(+) 
yielding p28CTB2. 
5.5.6. Protein Expression and Purification 
 Proteins were prepared by heterologous expression in E. coli BL21(DE3) and 
purified by nickel-affinity purification as delineated in Appendix B. Cultures used for the 
expression of protein constructs containing the CTB3 flavin-dependent monooxygenase 
domain were supplemented with 1 µM riboflavin added immediately prior to inoculation. 
Eluted protein fractions were dialyzed at 4 °C overnight with three buffer switches into 
100 mM potassium phosphate pH 7.0, 10% glycerol. Purified protein concentrations were 
determined by the Bradford assay using bovine serum albumin (New England Biolabs) as 
a standard as described in Appendix B.[38] Excess protein was flash frozen in liquid 
nitrogen and stored at −80 °C until further use. 
 The CTB3-MO monodomain was assayed for flavin identity and content by 
cofactor release through heat denaturation.[39] A 10 µM solution of CTB3-MO was 
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incubated in a boiling water bath for 10 min. The heat-denatured sample was cooled on 
ice, centrifuged (14500 × g at 4 °C for 10 min), and the supernatant was retained 
(containing free cofactor). The supernatant was also analyzed by HPLC on an Agilent 
1200 fitted with a Prodigy 5u ODS3 column (4.6 × 250 mm, 5 µm, Phenomenex) using a 
linear gradient of 85–25% solvent A over 20 min at a flow rate of 1.0 mL/min. Solvent A 
was 5 mM ammonium acetate pH 6.5. Solvent B was methanol. The elution profile of 
released cofactor was compared to that of an authentic standard of FAD. 
5.5.7. In Vitro Reactions of CTB3 
 Nor-toralactone and toralactone purified from the ΔCTB3c mutant strain were 
used as substrates for in vitro reactions of CTB3. Stock solutions of the substrates (2 
mM) were prepared in 90% DMSO [aq.] and stored at −80 °C until use. NADH stock 
solutions (50 mM) were prepared immediately before use in 100 mM potassium 
phosphate pH 7.0, 10% glycerol. DTT and SAM stock solutions (100 mM and 50 mM, 
respectively) were prepared in 100 mM potassium phosphate pH 7.0, 10% glycerol and 
stored at −20 °C until use. Reactions were prepared in potassium phosphate pH 7.0, 10% 
glycerol. Reactions were prepared by diluting CTB3 (intact, CTB3-MT, CTB3-MO, or 
CTB2, 1.0 µM final concentration) in buffer followed by the addition of cosubstrates 
(NADH or SAM, as needed; 1 mM final concentration), followed by the addition of 
DTT, as needed (1 mM final concentration). Reactions were initiated with the addition of 
naphthopyrone substrate (0.1 mM final concentration, 4.5% DMSO final concentration) 
and immediately mixed by gentle agitation. Reactions were allowed to proceed at room 
temperature for 1 h, and then were quenched with the addition of 5 N HCl (5 µL to 250 
µL reaction). The reaction mixtures were filtered through 0.2 µm PTFE filters and 
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analyzed by HPLC. HPLC was conducted on an Agilent 1200 system fitted with a diode 
array detector (DAD) and a Kinetex XB-C18 column (4.6 × 75 mm, 2.6 µm). The 
gradient method was as follows: 5–95% acetonitrile + 0.1% formic acid, over 10.8 min, 
at a flow rate of 1.25 mL/min. 
5.5.8. Chemical Characterization of Cercosporin Pathway Products 
 1H NMR data were collected on a 400 MHz Bruker Avance spectrometer (Bruker, 
Billerica, MA, USA). HRMS data were collected on a Waters Acquity/Xevo-G2 UPLC-
MS system (Waters, Milford, MA, USA). MS and MS/MS spectra were collected in 
positive ion mode. HPLC was conducted on an Agilent 1200 system fitted with a DAD 
and a Kinetex XB-C18 column (4.6 × 75 mm, 2.6 µm). UV data were determined from 
the DAD signal at the maximum HPLC chromatograph signal. Spectra are presented in 
Appendix F (Figures F.5–18). 
5,12-dihydroxy-8,9-bis((R)-2-hydroxypropyl)-7,10-dimethoxyperyleno[1,12-
def][1,3]dioxepine-6,11-dione (cercosporin, 1) 
 Cercosporin was purified from wild type C. nicotianae (ATCC© 18366™) as a red 
powder. 1H NMR (400 MHz, CCl3D, δ): 7.07 (s, 2H), 5.74 (s, 2H), 4.21 (s, 6H), 3.59 (dd, 
J = 12.8, 6.8 Hz, 2H), 3.39 (m, 2H), 2.90 (dd, J = 12.8, 6.0 Hz, 2H), 0.65 (d, J = 6.0 Hz, 
6H); HRMS–ESI/ACPI-TOF (m/z): [MH+] calcd for C29H27O10, 535.1604; found, 
535.1599 (100); UV (acetonitrile [aq.]) λmax, nm: 224, 260, 272, 324, 470, 566; HPLC 
(Kinetex XB-C18, 1.25 mL/min, 5–95% acetonitrile + 0.1% formic acid, 10.8 min) tR = 




7,9,10-trihydroxy-3-methyl-1H-benzo[g]isochromen-1-one (nor-toralactone, 6) 
 Nor-toralactone was purified from C. nicotianae ΔCTB3c as a yellow powder. 1H 
NMR (400 MHz, CCl3D, δ): 13.61 (s, 1H), 9.50 (s, 1H), 6.92 (s, 1H), 6.61 (d, J = 2.4 Hz, 
1H), 6.48 (d, J = 2.4 Hz, 1H), 6.23 (s, 1H), 2.27 (s, 3H); HRMS–ESI/ACPI-TOF (m/z): 
[MH+] calcd for C14H11O5, 259.0607; found, 259.0606 (100); UV (acetonitrile [aq.]) λmax, 
nm:  268, 278, 292, 390; HPLC (Kinetex XB-C18, 1.25 mL/min, 5–95% acetonitrile + 
0.1% formic acid, 10.8 min) tR = 6.83 min. These data are in agreement with literature 
values for nor-toralactone.[12] 
9,10-dihydroxy-7-methoxy-3-methyl-1H-benzo[g]isochromen-1-one (toralactone, 7) 
 Toralactone was purified from C. nicotianae ΔCTB3c as a yellow powder. 1H 
NMR (400 MHz, CCl3D, δ): 13.55 (s, 1H), 9.42 (s, 1H), 6.98 (s, 1H), 6.62 (d, J = 2.4 Hz, 
1H), 6.54 (d, J = 2.4 Hz, 1H), 6.24 (s, 1H), 3.90 (s, 3H), 2.27 (s, 3H); HRMS–ESI/ACPI-
TOF (m/z): [MH+] calcd for C15H13O5, 273.0763; found, 273.0764 (100); UV 
(acetonitrile [aq.]) λmax, nm: 268, 278, 292, 390; HPLC (Kinetex XB-C18, 1.25 mL/min, 
5–95% acetonitrile + 0.1% formic acid, 10.8 min) tR = 8.51 min. These data are in 
agreement with literature values for toralactone.[40] 
7,9-dihydroxy-3-methyl-5-(λ3-oxidanylidene)-1H-benzo[g]isochromene-1,10(5H)-
dione (8) 
 Product 8 was purified from C. nicotianae ΔCTB3c as a red powder. This product 
was also observed as an oxidation product of nor-toralactone in in vitro CTB3 reactions. 
HRMS–ESI/ACPI-TOF (m/z): [MH+] calcd for C14H9O6, 273.0399; found, 273.0388 
(100); UV (acetonitrile [aq.]) λmax, nm:  248, 270sh, 296sh, 474; HPLC (Kinetex XB-
C18, 1.25 mL/min, 5–95% acetonitrile + 0.1% formic acid, 10.8 min) tR = 4.92 min. 
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2,5-dihydroxy-6-methoxy-7-(2-oxopropyl)naphthalene-1,4-dione (cercoquinone A, 9) 
 Metabolite 9 was purified from C. nicotianae ΔCTB6 as an orange powder. 1H 
NMR (400 MHz, CCl3D, δ): 12.76 (s, 1H), 7.49 (s, 1H), 6.26 (s, 1H), 4.05 (s, 3H), 3.80 
(s, 2H), 2.27 (s, 3H); HRMS–ESI/ACPI-TOF (m/z): [MH+] calcd for C14H13O6, 
277.0712; found, 277.0711 (100); HRMS/MS–ESI/ACPI-TOF (m/z): [MH+ –CO] calcd 
for C13H13O5, 249.0763; found, 249.0756 (15); [MH+ –CO –H2O] calcd for C13H11O4, 
231.0657; found, 231.0649 (17); [MH+ –C3H5O] calcd for C11H8O5, 220.0372; found, 
220.0369 (54); [MH+ –C2H5O2] calcd for C12H8O4, 216.0423; found, 216.0415 (30); 
[MH+ –CO –H2C=C=O] calcd for C11H11O4, 207.0657; found, 207.0655 (100); [MH+ –
C3H4O2] calcd for C11H9O4, 205.0501; found, 205.0494 (42); [MH+ –C4H5O2] calcd for 
C10H8O4, 192.0423; found, 192.0414 (57); [MH+ –C4H6O2] calcd for C10H7O4, 191.0344; 
found, 191.0343 (43); [MH+ –C3H4O3] calcd for C11H9O3, 189.0552; found, 189.0546 
(63); [MH+ –C4H4O3] calcd for C10H9O3, 177.0552; found, 177.0543 (35); [MH+ –
C4H6O3] calcd for C10H7O3, 175.0395; found, 175.0390 (79); [MH+ –C4H4O4] calcd for 
C10H9O2, 161.0603; found, 161.0594 (47); [MH+ –C6H6O3] calcd for C8H7O3, 151.0395; 
found, 151.0388 (21); UV (acetonitrile [aq.]) λmax, nm: 248, 300, 422; HPLC (Kinetex 
XB-C18, 1.25 mL/min, 5–95% acetonitrile + 0.1% formic acid, 10.8 min) tR = 5.42 min. 
9-hydroxy-6-methoxy-2-methyl-2,3-dihydronaphtho[2,3-b]furan-5,8-dione 
(cercoquinone B, 10) 
 Metabolite 10 was purified from C. nicotianae ΔCTB5 as a red-orange powder. 
1H NMR (400 MHz, CD3CN, δ): 7.55 (s, 1H), 6.19 (s, 1H), 3.97 (s, 3H), 2.78 (m, 2H), 
1.16 (d, J = 6.4 Hz, 3H); HRMS–ESI/ACPI-TOF (m/z): [MH+] calcd for C14H13O5, 
261.0763; found, 261.0761 (100); HRMS/MS–ESI/ACPI-TOF (m/z): [MH+ –CH3] calcd 
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for C13H10O5, 246.0528; found, 246.0529 (36); [MH+ –CO] calcd for C13H13O4, 
233.0814; found, 233.0812 (37); [MH+ –2CH3] calcd for C12H7O5, 231.0293; found, 
231.0295 (37); [MH+ –CH3 –H2O] calcd for C13H8O4, 228.0423; found, 228.0419 (22); 
[MH+ –C3H4O] calcd for C11H9O4, 205.0501; found, 205.0499 (46); [MH+ –C3H6O] calcd 
for C11H7O4, 203.0344; found, 203.0345 (100); [MH+ –CO –CH3OH] calcd for C12H9O3, 
201.0551; found, 201.0531 (26); [MH+ –C2H5O2] calcd for C12H8O3, 200.0473; found, 
200.0474 (68); [MH+ –C3H5O3] calcd for C11H8O2, 172.0534; found, 172.0523 (25); UV 
(acetonitrile [aq.]) λmax, nm: 250, 302, 426; HPLC (Kinetex XB-C18, 1.25 mL/min, 5–
95% acetonitrile + 0.1% formic acid, 10.8 min) tR = 5.07 min. 
3,5-dihydroxy-7-methoxy-2-(2-oxopropyl)naphthalene-1,4-dione (cercoquinone D, 
11) 
 1,4-Naphthoquinone 11 was analyzed from in vitro reactions of CTB3 against 
nor-toralactone or toralactone as a pale yellow residue. Limited yields hindered 1H NMR 
analysis of this product. HRMS–ESI/ACPI-TOF (m/z): [MH+] calcd for C14H13O6, 
277.0712; found, 277.0717 (100); HRMS/MS–ESI/ACPI-TOF (m/z): [MH+ –H2C=C=O] 
calcd C12H11O5, 235.0607; found, 235.0615 (100); [MH+ –CO –H2O] calcd C13H11O4, 
231.0657; found, 231.0656 (24); [MH+ –H2C=C=O –H2O] calcd C12H9O4, 217.0501; 
found, 217.0502 (65); [MH+ –H2C=C=O –H2O –CO] calcd C11H9O3, 189.0551; found, 
189.0558 (51); [MH+ –H2C=C=O –H2O –2CO] calcd C10H9O2, 161.0602; found, 
161.0611 (42); [MH+ –CO –C5H6O2] calcd C8H7O3, 151.0395; found, 151.0401 (46); UV 
(acetonitrile [aq.]) λmax, nm: 260, 320sh, 380sh; HPLC (Kinetex XB-C18, 1.25 mL/min, 
5–95% acetonitrile + 0.1% formic acid, 10.8 min) tR = 4.65 min. 
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8-hydroxy-6-methoxy-3-(2-oxopropyl)naphthalene-1,2-dione (cercoquinone C, 12) 
 1,2-Naphthoquinone 12 was analyzed from reactions of CTB3 under non-
reductive conditions. Limited yields hindered 1H NMR analysis of this product. HRMS–
ESI/ACPI-TOF (m/z): [MH+] calcd for C14H13O5, 261.0763; found, 261.0767 (100); 
[MNa+] calcd for C14H12O5Na, 283.0582; found, 283.0582 (76); HRMS/MS–ESI/ACPI-
TOF (m/z): [MH+ –CO –H2O] calcd C13H11O3, 215.0708; found, 215.0709 (100); [MH+ –
H2C=C=O –CO] calcd C11H11O3, 191.0708; found, 191.0708 (91); [MH+ –2CO –H2O] 
calcd C12H11O2, 187.0759; found, 187.0757 (92); [MH+ –2CO –H2O –CH3] calcd 
C11H8O2, 172.0524; found, 172.0522 (56); [MH+ –H2C=C=O –2CO] calcd C10H11O2, 
163.0759; found, 163.0758 (31); [MH+ –CO –C5H6O] calcd C8H7O3, 151.0395; found, 
151.0399 (28); [MH+ –H2C=C=O –2CO –H2O] calcd C10H9O, 144.0653; found, 
144.0576 (77); UV (acetonitrile [aq.]) λmax, nm: 216, 286, 306sh, 386, 504; HPLC 
(Kinetex XB-C18, 1.25 mL/min, 5–95% acetonitrile + 0.1% formic acid, 10.8 min) tR = 
6.39 min. 
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Appendix A: NR-PKS Sequences 
A.1. Native NR-PKS 
 Six native fungal NR-PKSs were investigated in this dissertation. Expression 
constructs of all of these proteins were prepared in pET-24a(+) vectors for IPTG 
inducible expression in E. coli. The resulting native proteins contained C-terminal 6 × 
His tags. In some cases, the NR-PKSs were codon optimized in portions of the genes—
typically the N-terminus—to enhance expression in E. coli. The sequences of these genes 
and their resulting proteins are presented in this section. Underlined sequences are codon 
optimized. Bold sequences are from the 6 × His tags. 
Appendix Table A.1⏐Details of full-length NR-PKS expression constructs. 
Protein Source Organism Accessesion Plasmid Vector Tag MW (kDa) 
PksA Aspergillus parasiticus Q12053 pEPksA pET-24a(+) C-His 232.0 
Pks4 Giberella fujikouroi CAB92399 pEPks4 pET-24a(+) C-His 222.7 
ACAS Aspergillus terreus EAU31624 pEACAS pET-24a(+) C-His 195.4 
CTB1 Cercospora nicotianae AAT69682 pECTB1 pET-24a(+) C-His 238.0 
wA Aspergillus nidulans CAA46695 pEwA pET-24a(+) C-His 236.9 
Pks1 Colletotichum lagenaria BAA18956 pEPks1alt pET-24a(+) C-His 238.1 
 
A.1.1. PksA 











































































































































































































































































































































































































































































































































































































































































































































































A.2. NR-PKS Protein Sequence Alignments 
 Protein alignments for individual NR-PKS domains were conducted in ClustalX 
using the BLOSUM60 scoring matrix.[1] Individual domains were aligned with sequences 
with known crystal or solution structures. Display files were created using the ENDscript 





Appendix Figure A.1"Alignment of NR-PKS SAT domains. NR-PKS sequences are aligned with the 
fabD MAT domain of both fatty acid and polyketide biosynthesis in Streptomyces coelicolor. The 







Appendix Figure A.2⏐Alignment of NR-PKS KS-MAT didomains. NR-PKS sequences are aligned 
with the module 5 KS-AT didomain of 6-deoxyerythronolide B synthase (DEBS) from Saccharopolyspora 




Appendix Figure A.3"Alignment of NR-PKS PT domains. The secondary structure is from a crystal 
structure of PksA PT domain (PDB: 3HRQ).[5] 
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Appendix Figure A.4"Alignment of NR-PKS ACP domains. Individual tandem ACPs are aligned, 




Appendix Figure A.5"Alignment of NR-PKS TE domains. The secondary structure is from a crystal 
structure of PksA TE domain (PDB: 3ILS).[7] 
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Appendix B: General Experimental Methods 
B.1. Transformation of E. coli by Electroporation 
 Electroporation was used to transform E. coli BL21(DE3) with expression 
constructs. E. coli BL21(DE3) cells were made electrocompetent by standard protocols.[1] 
E. coli BL21(DE3) cells were grown in 1 L LB broth in a baffled flask at 37 °C with 
constant shaking at 250 rpm until OD600 0.5 was achieved. The cells were immediately 
chilled on ice and harvested by centrifugation at 4000 × g, for 20 min at 4 °C. The 
pelleted cells were washed with 1 L of sterile, ice-cold ddH2O, centrifuged as above, 
suspended in 0.5 L of sterile, ice-cold ddH2O, centrifuged as above, suspended in 20 mL 
of sterile, ice-cold 10% glycerol, centrifuged as above, and suspended in 2–3 mL of 
sterile, ice-cold 10% glycerol. The resulting suspension was divided into 80 µL aliquots, 
flash frozen in an ethanol and dry-ice bath, and stored at −80 °C, until further use. 
 Electrocompetent cells were thawed on ice and 18 µL cell suspension was mixed 
with 2 µL of plasmid DNA for transformation. The resulting mixture was placed between 
the electrodes of an ice-cold Potter cuvette and pulsed with a 9–10 kV/cm electric field 
for 10 ms, at 4 °C. The mixture was inoculated into 180 µL LB broth and incubated at 37 
°C with constant shaking at 250 rpm for 1 h. The resulting inoculum was streaked on an 
LB agar plate containing the appropriate antibiotic and incubated, inverted, at 37 °C, 
overnight. 
B.2. Heterologous Expression of Proteins in E. coli 
 All proteins were expressed in E. coli BL21(DE3) unless otherwise stated. Most 
protein expression constructs in this study were prepared with a T7 promoter and the lac 
operon for IPTG inducible expression. Overnight starter cultures were inoculated from 
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−80 °C 20% glycerol cell stocks into LB broth supplemented with 50 µg/mL kanamycin 
and incubated at 37 °C with shaking at 250 rpm. Starter cultures were used to inoculate 
LB broth supplemented with 50 µg/mL kanamycin in baffled flasks by a 1:100 dilution. 
Cultures were incubated at 37 °C with shaking at 250 rpm until OD600 nm 0.7 was 
achieved (roughly 2.5 h). The cultures were immediately submerged in ice water for 30 
min. Protein expression was induced with the addition of 1 mM IPTG from a 1 M stock. 
Induction was carried out at 19 °C with shaking at 250 rpm for 16 h. Cells were harvested 
by centrifugation at 4100 × g at 4 °C for 20 min. Cell pellets were flash frozen in liquid 
nitrogen and stored at −80 °C until further use. 
B.3. Nickel Affinity Protein Purification 
 In the main, proteins in these studies were purified from frozen cell pellets and 
harbored 6 × His tags for nickel affinity purification. Cell pellets were suspended in lysis 
buffer to a final concentration of 0.25 g/mL at 4 °C. Lysis buffer was composed of 50 
mM potassium phosphate pH 8.0, 300 mM NaCl, 10 mM imidazole, and 10% glycerol. 
The cell suspension was lysed by sonication (50% duty cycle, 10 s pulses over 3.33 min) 
on ice. The lysate was immediately separated by centrifugation at 25000 × g at 4 °C for 
20 min. High density nickel agarose beads were added to the decanted lysate and allowed 
to incubate at 4 °C with gentle mixing for 1 h. The nickel beads were packed into a 
column under gravity and washed three times with 10 column volumes of lysis buffer and 
two times with 10 column volumes of wash buffer at 4 °C. Wash buffer was composed of 
50 mM potassium phosphate pH 8.0, 200 mM NaCl, 50 mM imidazole, and 10% 
glycerol. Recombinant proteins were eluted in 4 column volumes of elution buffer at 4 
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°C. Elution buffer was composed of 50 mM potassium phosphate pH 8.0, 300 mM NaCl, 
250 mM imidazole, and 10% glycerol. 
B.4. Protein Concentration Determination by the Bradford Assay 
The Bradford assay was used to determine protein concentration for in vitro 
reactions of purified proteins.[2] A calibration curve was prepared using bovine serum 
albumin as a standard (Figure B.1). A second order polynomial regression was used to 
generate a standard curve for calculating protein concentration from the absorbance at 
595 nm (Equation B.1). A 1 # Bio-Rad protein assay dye was prepared by diluting a 5 # 
stock solution in water. Purified protein was diluted to a final volume of 100 µL in water. 
To this dilution, 5 mL of 1 # Bio-Rad protein assay dye was added and the solution was 
mixed by inversion thrice. The absorbance at 595 nm was recorded and Equation B.1 was 
used to calculate the purified protein concentration accounting for the initial dilution. 
 
Appendix Figure B.1"Bradford assay calibration curve for determining protein concentration. The 
calibration curve calculated in Equation B.1 is displayed. 
!!!!"! !!"!!!!! ! !!!!"! !!"!!!! ! !!!!"! !!"!! ! !!!!!!!!!!!!!"#$%&'(!!! !! 
where x is the protein concentration in µg/mL and y is the absorbance at 595 nm in AU. 
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B.5. Touchdown Polymerase Chain Reaction for DNA Amplification 
 Standard PCR reactions were conducted using the touchdown PCR protocol.[3] 
Touchdown PCR reactions were prepared as 50 µL solutions of 1 × HF Buffer, 3% 
dimethyl sulfoxide (DMSO), 0.2 mM each dNTP, 0.2 µM each primer, 30 ng DNA 
template, and 1 U Phusion polymerase (New England Biolabs, Ipswich, MA, USA). The 
template DNA contained the target sequence for amplification. The primers flanked the 
target template sequence. Touchdown PCR reactions were cycled as follows: 98 °C for 
30 s; followed by 10 cycles of 98 °C for 10 s, 68 °C decreasing by 1 °C each cycle for 30 
s, and 72 °C for 15 s/kbp target sequence; followed by twenty cycles of 98 °C for 10 s, 58 
°C for 30 s, and 72 °C for 15 s/kbp target sequence; followed by 72 °C for 300 s, then 
held at 4 °C until further use. Touchdown PCR products were run on a 1.1% agarose gel 
in their totality.[4] Correctly sized products were purified using a GeneJET gel extraction 
kit (Thermo Scientific, Waltham, MA, USA) according to the manufacturer’s 
instructions. Purified products were stored at −20 °C until further use. 
B.6. Overlap Extension PCR and Polymerase Chain Assembly 
 Overlap extension PCR was used to synthetically splice individual exons during 
expression construct assembly. Overlap extension PCR reactions were prepared as 50 µL 
solutions of 1 × HF Buffer, 3% dimethyl sulfoxide (DMSO), 0.2 mM each dNTP, 0.2 µM 
each outside primer, 30 ng each internal DNA fragment, and 1 U Phusion polymerase 
(New England Biolabs, Ipswich, MA, USA). The internal DNA fragments contained a 
20–30 bp overlap sequence at the desired splicing site. The outside primers flanked the 
desired total DNA target for amplification. Overlap extension PCR reactions were cycled 
as follows: 98 °C for 30 s; followed by 30 cycles of 98 °C for 10 s, 58 °C for 30 s, and 72 
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°C for 15 s/kbp target sequence; followed by 72 °C for 300 s, then held at 4 °C until 
further use. Overlap extension PCR products were run on a 1.1% agarose gel in their 
totality.[4] Correctly sized products were purified using a GeneJET gel extraction kit 
(Thermo Scientific, Waltham, MA, USA) according to the manufacturer’s instructions. 
Purified products were stored at −20 °C until further use. Polymerase chain assembly 
(PCA) was used to generate entirely synthetic exons (synthons) to be used in overlap 
extension PCR. PCA was conducted in the same manner as overlap extension PCR with 
40 bp oligonucleotides containing nesting 20 bp overlaps and no outside primers. 
B.7. Gibson Assembly for Plasmid Construction 
 Gibson assembly was used to produce chimeric NR-PKS expression constructs 
according to established protocols.[5] Gibson assembly reaction were prepared as 20 µL 
solutions of equimolar DNA fragments (between 10 and 100 ng), 1 × ISO Buffer, 0.08 U 
T4 exonuclease, 0.5 U Phusion polymerase, and 80 U Taq DNA ligase. The DNA 
fragments contained 20–40 bp overlaps at their termini and were the necessary pieces 
generate the desired plasmid. A 5 × ISO Buffer solution was prepared according to 
established protocols[5] and consisted of 25% (w/w) poly(ethylene glycol) average 
molecular weight 8000 Da (PEG-8000), 500 mM Tris-HCl pH 7.5, 50 mM MgCl2, 50 
mM DTT, 1 mM each dNTP, and 5 mM NAD+. Gibson assembly reactions were 
incubated at 50 °C for 1 h followed by dilution with 80 µL of water. The resulting 
dilution was transformed into E. coli BL21(DE3) cells by electroporation, plated on LB 
agar supplemented with 50 µg/mL kanamycin, and incubated at 37 °C for 16 h. Resulting 
colonies were inoculated into LB broth supplemented with 50 µg/mL kanamycin and 
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incubated at 37 °C with shaking at 250 rpm for 16 h. Plasmids from the resulting colonies 
were purified using the GeneJET Miniprep plasmid kit. 
B.8. Standard Culture Recipes 
 Luria-Bertani (LB) broth was prepared by dissolving 10 g tryptone, 5 g yeast 
extract, and 10 g NaCl in 1 L of ddH2O. The solution was adjusted to pH 7.0 and 
autoclaved for 25 min. 
 LB agar was prepared by dissolving 10 g tryptone, 5 g yeast extract, 10 g NaCl, 
and 7.5 g agar in 1 L of ddH2O. The solution was adjusted to pH 7.0 and autoclaved for 
25 min. The mixture was allowed to cool with constant stirring. Once the solution had 
reached a manageable temperature (about 45-50 °C), the appropriate antibiotic(s) were 
added to achieve the desired concentration and the LB agar was poured into Petri dishes. 
The LB agar was allowed to set overnight and the resulting plates were stored at 4 °C, 
inverted, until further use. Plates were dried, inverted, in as sterile hood immediately 
prior to use. 
 Potato Dextrose Agar (PDA) was prepared by dissolving 38 g of Difco™ potato 
dextrose agar in 1 L of ddH2O with gentle heating. The solution was autoclaved for 25 
min and allowed to cool with constant stirring. Once the solution had read a manageable 
temperature (about 45-50 °C), the PDA was poured in a sterile hood into Petri dishes to 
yield a bed thickness of about 3 mm. The PDA was to set for 1 h and the resulting plates 
were stored at 4 °C, inverted, until further use. Plates were dried, inverted, in a sterile 
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Appendix C: Supplementary Material to Chapter 2 
C.1. Deconstructed CTB1 Expression Construct Cloning Details 
 CTB1 was deconstructed into mono- to multidomain fragments for ease of 
expression as detailed in Chapter 2. Specific sequence information relevant to cloning 
deconstructed CTB1 expression constructs are detailed in this section. 
C.1.1. Primer Sequences 
Appendix Table C.1⏐Primers used to clone deconstructed CTB1 expression constructs. Bold 

























C.1.2. Synthon of CTB1 Exons 4 and 5 
 Exons 4 and 5 of CTB1 comprise 67 codons of the final protein. Due to their 
small sizes, a codon-optimized synthon of exons 4 and 5 was prepared by polymerase 
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chain assembly (PCA), as described in Chapter 2. The sequences of the synthon and the 
primers used to prepare it are as follows: 





Synthon Protein Sequence: 
PREAPQVDPAQRLALLTATEALEQAGVVPNRTSSTQKNRVGVWYGATSNDWMETNSAQNVDTYFIPG 













C.2. Deconstructed CTB1 Proteins 
 Deconstructed CTB1 mono- to multidomain fragments were expressed and 
purified as described in Chapter 2. Specific characteristics of these proteins are presented 
in this section. 
Appendix Table C.3⏐Details of deconstructed CTB1 expression constructs. 
Protein Encodes Plasmid Vector Tag MW (kDa) 
CTB1 SAT-KS-MAT M1-S1293 pECTB1-NKA6 pET-24a(+) C-His 140.1 
CTB1 PT S1293-I1654 pECTB1-PT pET-24a(+) C-His 41.2 
CTB1 ACP2 S1637-K1909 pECTB1-ACP pET-28a(+) N-His 31.7 
CTB1 TE R1910-S2196 pECTB1-TE pET-28a(+) N-His 33.6 
CTB1 TE-S2008A R1910-S2196 pECTB1-TE-S2008A pET-28a(+) N-His 33.6 




Appendix Figure C.1"12% SDS-PAGE of deconstructed CTB1 protein fragments. Benchmark Protein 
ladder (Invitrogen, M), CTB1 SAT-KS-MAT (1), CTB1 PT (2), CTB1 ACP2 (3), CTB1 TE (4), CTB1 TE-
S2008A (5), and CTB1 TE-H2171Q (6). 
C.3. Nor-toralactone Synthesis 
A synthetic standard of nor-toralactone was prepared by Dr. Jonathan R. Scheerer 
(Johns Hopkins University, Baltimore, MD, USA) as follows: 
 
Ethyl 2,4-bis(methoxymethoxy)-6-((6-methyl-2-oxo-2H-pyran-4-yl)methyl)benzoate. 
A colorless solution of ethyl 2,4-bis(methoxymethoxy)-6-methylbenzoate[1] (100 
mg, 0.35 mmol) in THF (0.7 mL) was added dropwise to a freshly prepared $78 °C 
solution of LDA in THF (0.5 M, 1.54 mL, 0.77 mmol). After allowing the resulting deep 
red solution to equilibrate at $78 °C for 20 min, a solution of 4-methoxy-6-methyl-2H-
pyran-2-one[1] (50 mg, 0.35 mmol) in THF (0.7 mL) was added slowly. The resulting 
orange solution was allowed to react at $78 °C for 1 h, quenched (sat. NH4Cl, 10 mL), 
diluted (Et2O, 30 mL), washed (3 # sat. NH4Cl), concentrated and purified by flash 
chromatography (4:1 hexane:EtOAc % 3:1 hexane:EtOAc); yielding a colorless oil (99 
mg, 72%). 1H NMR (400 MHz, CDCl3, '): 6.77 (d, J = 2.0 Hz, 1H), 6.48 (d, J = 2.0 Hz, 
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1H), 5.89 (s, 1H), 5.87 (s, 1H), 5.17 (s, 2H), 5.15 (s, 2H), 4.30 (q, J = 7.2 Hz, 2H), 3.66 
(s, 2H), 3.47 (s, 3H), 3.44 (s, 3H), 2.17 (s, 3H), 1.29 (t, J = 7.2 Hz, 3H). 
 
10-hydroxy-7,9-bis(methoxymethoxy)-3-methyl-1H-benzo[g]isochromen-1-one. 
 To a 0 °C colorless solution of the ester above (117 mg, 0.30 mmol) in THF (5 
mL), LiHMDS (1 M solution in hexane, 0.66 mL, 0.66 mmol) was added. The resulting 
dark brown solution was allowed to warm to room temperature over 3 h, quenched (sat. 
NH4Cl), diluted (Et2O), washed (3 # sat. NH4Cl), concentrated and purified by flash 
chromatography on silica gel (4:1 hexane:EtOAc, Rf 0.4) to afford the tricyclic pyrone as 
a colorless solid (69 mg, 67 %). 1H NMR (400 MHz, CDCl3, '): 12.99 (s, 1H), 6.94 (s, 
1H), 6.92 (d, J = 2.4 Hz, 1H), 6.77 (d, J = 2.4 Hz, 1H), 6.20 (s, 1H), 5.36 (s, 2H), 5.28 (s, 




 The di-MOM protected pyrone above (69 mg, 0.20 mmol) was dissolved in a 
solution of MeOH (10 mL) and conc. HCl (0.4 mL), and allowed to react at room 
temperature, under Ar for 4 h.  The reaction mixture was diluted (EtOAc), washed (3 # 
sat. NH4Cl), dried (MgSO4) and concentrated to a light yellow solid (45 mg, 87%). 1H 
NMR (400 MHz, d6-acetone, ') 7.07 (s, 1H), 6.73 (d, J = 2.2 Hz, 1H), 6.49 (d, J = 2.2 
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Hz, 1H), 2.26 (s, 3H); HRMS–ESI-IT-TOF (m/z): [MH+] calcd for C14H11O5 259.061; 
found 259.060. 
C.4. References 
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Appendix D: Supplementary Material to Chapter 3 
D.1. Deconstructed NR-PKS Expression Construct Cloning Details 
 The NR-PKSs used in this study were deconstructed into SAT-KS-MAT 
tridomain fragments and PT, ACPn, and TE monodomain fragments for ease of selective 
domain-swapping as detailed in Chapter 3. Specific sequence information relevant to 
cloning deconstructed NR-PKSs and the CTB1/Pks1 chimeric NR-PKS expression 
constructs are detailed in this section. 
D.1.1. Primer Sequences 









D.1.2. Primers for Gibson Assembly of Chimeric NR-PKS 





T7 Term GCTAGTTATTGCTCAGCGG 
 
D.2. Deconstructed NR-PKSs Used in This Study 
 Deconstructed NR-PKS fragments were expressed and purified as described in 
Chapter 3. Specific characteristics of these proteins are presented in this section. 
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Appendix Table D.3⏐Protein constructs used in this study. Experimental cloning details are provided in 
the given references. Asterisks indicate revised sequence numbering described in the given reference. 
Protein Encodes Plasmid Vector Tag MW (kDa) Ref. 
PksA SAT-KS-MAT M1-S1294 pENKA4 pET24a C-His 143.7 [1] 
PksA PT E1305-I1677 pEPT2 pET24a C-His 42.4 [1] 
PksA ACP I1677-S1839 pEACP41 pET28a N-His 20.6 [2] 
PksA TE D1812-A2109 pETE2 pET28a N-His 36.4 [1] 
ACAS PT S1318-A1669 pEACAS-PT2 pET24a C-His 40.0 [3] 
ACAS ACP A1668-S1771 pEACAS-ACP2 pET28a N-His 13.3 [3] 
ACTE Full protein pEACTE pET28a N-His 37.5 [3] 
Pks4 SAT-KS-MAT M1-A1283*[4] pEPks4-NKAn pET24a C-His 140.8 This study 
Pks4 PT R1284-P1631*[4] pEPks4-PT pET24a C-His 39.6 [3] 
Pks4 ACP P1631-K1764*[4] pEPks4-ACP pET28a N-His 16.2 [3] 
Pks4 TE P1765-N2036*[4] pEPks4-TE pET28a N-His 32.2 [3] 
CTB1 SAT-KS-MAT M1-S1293 pECTB1-NKA6 pET24a C-His 140.1 [5] 
CTB1 PT S1293-I1654 pECTB1-PT pET24a C-His 41.2 [5] 
CTB1 ACP2 S1637-K1909 pECTB1-ACP pET28a N-His 31.7 [5] 
CTB1 TE R1910-S2196 pECTB1-TE pET28a N-His 33.6 [5] 
CTB1 full-length Full protein pECTB1 pET24a C-His 238.0 This study 
wA PT T1287-P1619 pEwA-PT pET24a C-His 38.5 [3] 
wA ACP2 P1619-H1879 pEwA-ACP pET28a N-His 30.4 [3] 
wA TE L1859-V2157 pEwA-TE2 pET28a N-His 34.9 [3] 
Pks1 SAT-KS-MAT M1-K1291*[6] pEPks1-NKA pET24a C-His 141.3 [4] 
Pks1 PT K1291-P1640*[6] pEPks1-PT pET24a C-His 39.4 [3] 
Pks1 ACP2 P1640-K1908*[6] pEPks1-ACP pET28a N-His 30.9 [3] 
Pks1 TE P1881-E2183*[6] pEPks1-TEalt pET28a N-His 35.7 [6] 











Appendix Figure D.1⏐Purified proteins used in this study separated by SDS-PAGE. BenchMark 
Protein Ladder was used as a molecular weight standard (indicated in kDa). A) 10% SDS-PAGE of SAT-
KS-MAT proteins, B) 15% SDS-PAGE of PT proteins, C) 15% SDS-PAGE of ACPn proteins, D) 15% 
SDS-PAGE of TE proteins, and E) 12% SDS-PAGE of full-length PKS. 
 
D.3. Combinatorial Reactions of CTB1 SAT-KS-MAT 
 Previously, we conducted and reported combinatorial reactions including CTB1 
SAT-KS-MAT.[3] The results of these reactions are presented in Figure D.2. 
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Appendix Figure D.2⏐Product analysis of combinatorial reactions with CTB1 SAT-KS-MAT. 
Proposed products of combinatorial reactions are presented (a). The chromatograms at 280 nm for products 
of cognate control reactions (b), non-cognate combinatorial reactions with the indicated PT and ACPn (c), 
and non-cognate combinatorial reactions with the indicated PT, ACPn, and TE (d) are presented. 
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D.4. Polyketide Product Chemical Characterization 
All mass data unless otherwise stated was collected on a Shimadzu LC-IT-TOF 
(Shimadzu Corporation, Kyoto, Japan) in positive ion mode fitted with a Luna C18(2) 
column (2.0 $ 150 mm, 3 µm [Phenomenex, Torrence, CA]) using a linear gradient of 5% 
to 85% solvent B over 30 min at 0.2 mL/min. HPLC retention times are reported for a 
Prodigy 5u ODS3 column (4.6 # 250 mm, 5 µm [Phenomenex]) using a linear gradient of 
5% to 85% solvent B over 30 min at 1 mL/min. Solvent A was water + 0.1% formic acid 
and solvent B was acetonitrile + 0.1% formic acid in both cases. The &  for each 
compound was recorded for the HPLC peak maximum at 280 nm. 
 
3,8,10,11-tetrahydroxy-1-methyl-12H-benzo[b]xanthen-12-one (pre-bikaverin, 2). 
UV (acetonitrile [aq.]) !max, nm: 226, 254, 276, 302, 332, 348, 428. HPLC retention time: 
33.0 min. HRMS–ESI-IT-TOF (m/z): [MH+] calcd for C18H13O6, 325.0712; found, 
325.0703. These data are in complete agreement with literature values for 2.[7] 
 
7,9,10-trihydroxy-3-methyl-1H-benzo[g]isochromen-1-one (nor-toralactone, 4). 
UV (acetonitrile [aq.]) !max, nm: 268, 278, 394. HPLC retention time: 28.7 min. HRMS–
ESI-IT-TOF (m/z): [MH+] calcd for C14H11O5, 259.0607; found, 259.0606. These data are 
in complete agreement with literature values for 4.[5] 
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2,5,6,8-tetrahydroxy-2-methyl-2,3-dihydro-4H-benzo[g]chromen-4-one (YWA1, 5). 
UV (acetonitrile [aq.]) λmax, nm: 228, 280, 324, 334, 408. HPLC retention time: 21.6 min. 
HRMS–ESI-IT-TOF (m/z): [MH+] calcd for C14H13O6, 277.0712; found, 277.0670. These 
data are in complete agreement with literature values for 5.[8] 
 
naphthalene-1,3,6,8-tetraol (THN, 6). 
UV (acetonitrile [aq.]) λmax, nm: 266, 300. HPLC retention time: 14.2 min. HRMS–
ESI/APCI-TOF (m/z): [MH+] calcd for C10H9O4, 193.0501; found, 193.0494. MS data 
was collected on a Waters Acquity/Xeno-G2 UPLC-MS in positive ion mode. These data 
are in complete agreement with literature values for 6.[6] 
 
6-((3,6-dihydroxy-6-methyl-8-oxo-5,6,7,8-tetrahydronaphthalen-1-yl)methyl)-4-
hydroxy-2H-pyran-2-one (SEK4, 7). 
UV (acetonitrile [aq.]) λmax, nm: 280. HPLC retention time: 15.9 min. HRMS–ESI-IT-
TOF (m/z): [MH+] calcd for C16H15O7 319.0818; found, 319.0806. SEK4 coelutes with its 



















UV (acetonitrile [aq.]) λmax, nm: 280. HPLC retention time: 15.9 min. HRMS–ESI-IT-
TOF (m/z): [MH+] calcd for C16H15O7, 319.0818; found, 319.0806. SEK4b coelutes with 




UV (acetonitrile [aq.]) λmax, nm: 230, 284, 326, 338, 416. HPLC retention time: 17.6 min. 
HRMS–ESI/APCI-TOF (m/z): [MH+] calcd for C18H17O8, 361.0923; found, 361.0913; 
[MH+-H2O] calcd for C18H15O7, 343.0818; found, 343.0808. MS data was collected on a 
Waters Acquity/Xeno-G2 UPLC-MS in positive ion mode. The λmax and shape of the UV-
vis spectrum for this molecule are similar to those for YWA1 (5) with which it likely 
shares the same core architecture (see Figures 3.5, D.3).[8] This peak converts to pre-
bikaverin (2) with time. Taken together, these data support the proposed structural 
















one (SMA93, 12). 
UV (acetonitrile [aq.]) λmax, nm: 244, 278, 328. HPLC retention time: 20.0 min. HRMS–
ESI-IT-TOF (m/z): [MH+] calcd for C12H11O5, 235.0607; found, 235.0603. These data are 
in complete agreement with literature values for 12.[11] 
 
1-(7,9,10-trihydroxy-1-oxo-1H-benzo[g]isochromen-3-yl)pentane-2,4-dione (13) or 
7,9,10-trihydroxy-3-(2-oxopropyl)-1H-benzo[g]isochromen-1-one (14). 
UV (acetonitrile [aq.]) λmax, nm: 270, 280, 392. HPLC retention time: 24.8 min. HRMS–
ESI-IT-TOF (m/z): [MH+] calcd for C18H15O7 (13), 345.0818; mass not found; [MH+] 
calcd for C16H13O6 (14), 301.0712; mass not found. The λmax and shape of the UV-vis 
spectrum for this molecule are similar to those for nor-toralactone (4) and norpyrone (19), 
suggesting a shared core architecture (see Figures 3.6, D.3).[1, 5] Because a mass for this 
peak could not be found, we propose structures 13 and 14 as the most reasonable 












R = CH2COCH2COCH3, 13




UV (acetonitrile [aq.]) λmax, nm: 226, 272, 398. HPLC retention time: 20.9 min. HRMS–
ESI-IT-TOF (m/z): [MH+] calcd for C17H17O6, 317.1025; found, 317.1015. The λmax and 
shape of the UV-vis spectrum for this molecule are similar to those for atrochrysone, 
suggesting a shared core architecture (see Figures 3.7, D.3).[12] Taken together, these data 
support the proposed structural assignment. This assignment is in agreement with 
polyketide cyclization logic. 
 
1-(1,3,6,8-tetrahydroxynaphthalen-2-yl)ethan-1-one (ATHN, 16). 
UV (acetonitrile [aq.]) λmax, nm: 230, 280, 320, 330, 404. HPLC retention time: 24.9 min. 
HRMS–ESI-IT-TOF (m/z): [MH+] calcd for C12H11O5, 235.0607; found, 235.1326. These 
data are in complete agreement with literature values for 16.[6] 
 
2,5,7-trihydroxynaphthalene-1,4-dione (flaviolin, 17). 
UV (acetonitrile [aq.]) λmax, nm: 216, 262, 306, 446. HPLC retention time: 18.5 min. 













data was collected on a Waters Acquity/Xeno-G2 UPLC-MS in positive ion mode. These 
data are in complete agreement with literature values for 17.[6] 
 
6,8-dihydroxy-3-(2-oxopropyl)-1H-isochromen-1-one (18). 
UV (acetonitrile [aq.]) λmax, nm: 244, 278, 328. HPLC retention time: 20.0 min. HRMS–
ESI-IT-TOF (m/z): [MH+] calcd for C12H11O5, 235.0607; found, 235.0603. These data are 
in complete agreement with literature values for 18.[6] 
 
7,9,10-trihydroxy-3-(2-oxoheptyl)-1H-benzo[g]isochromen-1-one (norpyrone, 19). 
UV (acetonitrile [aq.]) λmax, nm: 272, 280, 390. HPLC retention time: 35.1 min. HRMS–
ESI-IT-TOF (m/z): [MH+] calcd for C20H21O6, 357.1338; found, 357.1340. These data are 




















UV (acetonitrile [aq.]) λmax, nm: 232, 278. HPLC retention time: 24.7 min. HRMS–ESI-
IT-TOF (m/z): [MH+] calcd for C20H23O7, 375.1444; found, 375.1441. Hex-SEK4 coelutes 
with its isomer Hex-SEK4b, 21. These data are in complete agreement with literature 




UV (acetonitrile [aq.]) λmax, nm: 232, 278. HPLC retention time: 24.7 min. HRMS–ESI-
IT-TOF (m/z): [MH+] calcd for C20H23O7, 375.1444; found, 375.1441. Hex-SEK4b 
coelutes with its isomer Hex-SEK4, 20. These data are in complete agreement with 
literature values for 21.[3] 
 
4,8,10-trihydroxy-5-pentyl-2H-benzo[h]chromen-2-one (Hex-pannorin, 22). 
UV (acetonitrile [aq.]) λmax, nm: 232, 278, 288, 322, 368. HPLC retention time: 28.5 min. 
HRMS–ESI-IT-TOF (m/z): [MH+] calcd for C18H19O5, 315.1233; found, 315.1220. The 
λmax and shape of the UV-vis spectrum for this molecule are similar to those for pannorin 













these data support the proposed structural assignment. This assignment is in agreement 
with polyketide cyclization logic. 
 
4,8,10-trihydroxy-5-methyl-2H-benzo[h]chromen-2-one (pannorin, 23). 
UV (acetonitrile [aq.]) λmax, nm: 230, 276, 288, 320, 364. HPLC retention time: 20.1 min. 
HRMS–ESI-IT-TOF (m/z): calcd for C14H11O5 [MH+], 259.0607; found, 259.0606. These 
data are in complete agreement with literature values for 23.[5, 14] 
 
3,6,8,9-tetrahydroxy-1-oxo-3-pentyl-1,2,3,4-tetrahydroanthracene-2-carboxylic acid 
(Hex-atrochrysone carboxylic acid, 24). 
UV (acetonitrile [aq.]) λmax, nm: 224, 268, 318, 378. HPLC retention time: 29.0 min. 
HRMS–ESI-IT-TOF (m/z): [MH+], calcd for C20H23O7, 375.1444; found, 375.1440. The 
λmax and shape of the UV-vis spectrum for this molecule are similar to those for 
atrochrysone, suggesting a shared core architecture (see Figures 3.7, D.5).[12] Taken 
together, these data support the proposed structural assignment. This assignment is in 















UV (acetonitrile [aq.]) λmax, nm: 228, 272, 320, 294. HPLC retention time: 32.6 min. 
HRMS–ESI-IT-TOF (m/z): [MH+] calcd for C19H23O5, 331.1546; found, 331.1535. The 
λmax and shape of the UV-vis spectrum for this molecule are similar to those for 
atrochrysone, suggesting a shared core architecture (see Figures 3.7, D.5).[12] Taken 
together, these data support the proposed structural assignment. This assignment is in 
agreement with polyketide cyclization logic. 
 
6-(2,4-dihydroxy-6-methylphenyl)-4-hydroxy-2H-pyran-2-one (31). 
UV (acetonitrile [aq.]) λmax, nm: 304. HPLC retention time: 14.3 min. HRMS–ESI/APCI-
TOF (m/z): [MH+] calcd for C12H11O5, 235.0607; found, 235.0604. MS data was collected 
on a Waters Acquity/Xeno-G2 UPLC-MS in positive ion mode. A synthetic standard of 
this material was provided by Dr. Ikuro Abe. HPLC chromatogram for this product is 
presented in Figure D.7. These data are in complete agreement with the standard.[9c, 15] 
 













UV (acetonitrile [aq.]) λmax, nm: 224, 278, 328, 412. HPLC retention time: 27.0 min. 
HRMS–ESI/APCI-TOF (m/z): [MH+] calcd for C14H11O5, 259.0607; found, 259.0599. MS 
data was collected on a Waters Acquity/Xeno-G2 UPLC-MS in positive ion mode. These 
data are in complete agreement with literature values for 32.[16] 
 
 
Appendix Figure D.3⏐Proposed structures, HRMS data, UV-vis spectra, and retention times for 
products of combinatorial reactions with Pks4 SAT-KS-MAT. Previously characterized species include 




Appendix Figure D.4⏐Proposed structures, HRMS data, UV-vis spectra, and retention times for 
products of combinatorial reactions with Pks1 SAT-KS-MAT. Previously characterized species include 
6-(2,4-dihydroxy-6-methylphenyl)-4-hydroxy-2-pyrone (31), isocoumarin 18,[6] ATHN (16),[6] THN (6), 
flaviolin (17),[6] YWA1 (5),[17] and nor-toralactone (4).[5] 
 
 
Appendix Figure D.5⏐Proposed structures, HRMS data, UV-vis spectra, and retention times for 
products of combinatorial reactions with PksA SAT-KS-MAT. Previously characterized species include 








Appendix Figure D.7⏐HRMS, UV-vis, and retention time data for nor-rubrofusarin (32). Data is in 
accord with literature values.[16] 
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Appendix E: Supplementary Material to Chapter 4 
E.1. Cloning of Chimeric NR-PKS 
 
Appendix Figure E.1⏐Multiple sequence alignment of NR-PKSs for the MAT-PT linker region. NR-
PKS sequences used in this alignment correspond to known polyketide products. Accession numbers for 
each sequence are indicated. Stars indicate sequences used in this study (PksA from A. parasiticus, Pks4 
from G. fujikuroi, ACAS from A. terreus, CTB1 from C. nicotianae, wA from A. nidulans, and Pks1 from 
C. lagenaria). The secondary structure at the N-terminus of the PksA PT domain is shown. The crossover 
site for two-part heterocombinations is shown as a red line. It was selected to be 4–5 amino acids upstream 
of the conserved Thr at the N-terminal boundary of the PT. This figure was prepared using the ENDscript 
server.[1] 
 
E.1.1. Gibson Assembly of Chimeric NR-PKS Constructs 
Appendix Table E.1⏐PCR reagents used to generate DNA parts for Gibson assembly of two-part 
NR-PKS chimeras. 
PCR Product Template Forward Primer Reverse Primer 
M1P2-N pEPksA T7 M1P2-3 
M1P3-N pEPksA T7 M1P3-3 
M1P4-N pEPksA T7 M1P4-3 
M1*P5-N pEPksA T7 M1*P5-3 
M1*P6-N pEPksA T7 M1*P6-3 
M2P1-N pEPks4 T7 M2P1-3 
M2P3-N pEPks4 T7 M2P3-3 
M2P4-N pEPks4 T7 M2P4-3 
M2P5-N pEPks4 T7 M2P5-3 
M2P6-N pEPks4 T7 M2P6-3 
M3P1-N pEACAS T7 M3P1-3 
M3P2-N pEACAS T7 M3P2-3 
M3P4-N pEACAS T7 M3P4-3 
M3P5-N pEACAS T7 M3P5-3 
M3P6-N pEACAS T7 M3P6-3 
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M4P1-N pECTB1 T7 M4P1-3 
M4P2-N pECTB1 T7 M4P2-3 
M4P3-N pECTB1 T7 M4P3-3 
M4P5-N pECTB1 T7 M4P5-3 
M4P6-N pECTB1 T7 M4P6-3 
M5P1-N pEwANKA2 T7 M5P1-3 
M5P2-N pEwANKA2 T7 M5P2-3 
M5P3-N pEwANKA2 T7 M5P3-3 
M5P4-N pEwANKA2 T7 M5P4-3 
M5P6-N pEwANKA2 T7 M5P6-3 
M6P1-N pEPks1alt T7 M6P1-3 
M6P2-N pEPks1alt T7 M6P2-3 
M6P3-N pEPks1alt T7 M6P3-3 
M6P4-N pEPks1alt T7 M6P4-3 
M6P5-N pEPks1alt T7 M6P5-3 
M1P2-C pEPks4 M1P2-5 T7 term 
M1P3-C pEACAS M1P3-5 T7 term 
M1P4-C pECTB1 M1P4-5 T7 term 
M1*P5-C pEwa-PTA M1*P5-5 T7 term 
M1*P6-C pEPks1alt M1*P6-5 T7 term 
M2P1-C pEPksA M2P1-5 T7 term 
M2P3-C pEACAS M2P3-5 T7 term 
M2P4-C pECTB1 M2P4-5 T7 term 
M2P5-C pEwa-PTA M2P5-5 T7 term 
M2P6-C pEPks1alt M2P6-5 T7 term 
M3P1-C pEPksA M3P1-5 T7 term 
M3P2-C pEPks4 M3P2-5 T7 term 
M3P4-C pECTB1 M3P4-5 T7 term 
M3P5-C pEwa-PTA M3P5-5 T7 term 
M3P6-C pEPks1alt M3P6-5 T7 term 
M4P1-C pEPksA M4P1-5 T7 term 
M4P2-C pEPks4 M4P2-5 T7 term 
M4P3-C pEACAS M4P3-5 T7 term 
M4P5-C pEwa-PTA M4P5-5 T7 term 
M4P6-C pEPks1alt M4P6-5 T7 term 
M5P1-C pEPksA M5P1-5 T7 term 
M5P2-C pEPks4 M5P2-5 T7 term 
M5P3-C pEACAS M5P3-5 T7 term 
M5P4-C pECTB1 M5P4-5 T7 term 
M5P6-C pEPks1alt M5P6-5 T7 term 
M6P1-C pEPksA M6P1-5 T7 term 
M6P2-C pEPks4 M6P2-5 T7 term 
M6P3-C pEACAS M6P3-5 T7 term 
M6P4-C pECTB1 M6P4-5 T7 term 
M6P5-C pEwA-PTA M6P5-5 T7 term 
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Appendix Table E.2⏐DNA components used in Gibson assembly reactions of two-part NR-PKS 
chimeras. 
Plasmid Part 1 Part 2 Part 3 
pEM1P2-2 M1P2-N M1P2-C pET-24a(+)-NdeI-NotI 
pEM1P3-2 M1P3-N M1P3-C pET-24a(+)-NdeI-NotI 
pEM1P4-1 M1P4-N M1P4-C pET-24a(+)-NdeI-NotI 
pEM1*P5-1a M1*P5-Na M1*P5-Ca pET-24a(+)-NdeI-NotI 
pEM1*P6-2a M1*P6-Na M1*P6-Ca pET-24a(+)-NdeI-NotI 
pEM2P1-3 M2P1-N M2P1-C pET-24a(+)-NdeI-NotI 
pEM2P3-2 M2P3-N M2P3-C pET-24a(+)-NdeI-NotI 
pEM2P4-4 M2P4-N M2P4-C pET-24a(+)-NdeI-NotI 
pEM2P5-2 M2P5-N M2P5-C pET-24a(+)-NdeI-NotI 
pEM2P6-3 M2P6-N M2P6-C pET-24a(+)-NdeI-NotI 
pEM3P1-4 M3P1-N M3P1-C pET-24a(+)-NdeI-NotI 
pEM3P2-1 M3P2-N M3P2-C pET-24a(+)-NdeI-NotI 
pEM3P4-2 M3P4-N M3P4-C pET-24a(+)-NdeI-NotI 
pEM3P5-1 M3P5-N M3P5-C pET-24a(+)-NdeI-NotI 
pEM3P6-3 M3P6-N M3P6-C pET-24a(+)-NdeI-NotI 
pEM4P1-7 M4P1-N M4P1-C pET-24a(+)-NdeI-NotI 
pEM4P2-3 M4P2-N M4P2-C pET-24a(+)-NdeI-NotI 
pEM4P3-8 M4P3-N M4P3-C pET-24a(+)-NdeI-NotI 
pEM4P5-1 M4P5-N M4P5-C pET-24a(+)-NdeI-NotI 
pEM4P6-1 M4P6-N M4P6-C pET-24a(+)-NdeI-NotI 
pEM5P1-1 M5P1-N M5P1-C pET-24a(+)-NdeI-NotI 
pEM5P2-1 M5P2-N M5P2-C pET-24a(+)-NdeI-NotI 
pEM5P3-1 M5P3-N M5P3-C pET-24a(+)-NdeI-NotI 
pEM5P4-1 M5P4-N M5P4-C pET-24a(+)-NdeI-NotI 
pEM5P6-1 M5P6-N M5P6-C pET-24a(+)-NdeI-NotI 
pEM6P1-1 M6P1-N M6P1-C pET-24a(+)-NdeI-NotI 
pEM6P2-2 M6P2-N M6P2-C pET-24a(+)-NdeI-NotI 
pEM6P3-1 M6P3-N M6P3-C pET-24a(+)-NdeI-NotI 
pEM6P4-2 M6P4-N M6P4-C pET-24a(+)-NdeI-NotI 
pEM6P5-1 M6P5-N M6P5-C pET-24a(+)-NdeI-NotI 
a A silent mutation is introduced at the crossover site to make synthesis of these constructs easier. 
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E.1.2. Gibson Assembly of Engineered Topopyrone Synthases 
Appendix Table E.3⏐PCR reagents used to generate DNA parts for Gibson assembly of topopyrone 
synthases. 
PCR Product Template Forward Primer Reverse Primer 
M2P4A1-N pEM2P4-4 T7 P4A1-3 
M2P1-G1491L-N pEM2P1-3 T7 P1-G1491L-40-3 
M2P1-G1491I-N pEM2P1-3 T7 P1-G1491I-40-3 
M2P1-G1491V-N pEM2P1-3 T7 P1-G1491V-3 
M2P1-G1491A-N pEM2P1-3 T7 P1-G1491A-3 
M2P4A1-I1468V-N pEM2P4A1 T7 P4-I1468V-40-3 
M2P4A1-I1468A-N pEM2P4A1 T7 P4-I1468V-40-3 
M2P4A1-I1468G-N pEM2P4A1 T7 P4-I1468V-40-3 
M2P1P--G1491L-N pEM2P1-GL T7 P1-H1345A-3 
Pks1P--N pEPks1alt T7 P6-H1330A-3 
M2P4A1-C pEPksA P4A1-5 T7 term 
M2P1-G1491L-C pEM2P1-3 P1-G1491L-40-5 T7 term 
M2P1-G1491I-C pEM2P1-3 P1-G1491I-40-5 T7 term 
M2P1-G1491V-C pEM2P1-3 P1-G1491V-5 T7 term 
M2P1-G1491A-C pEM2P1-3 P1-G1491A-5 T7 term 
M2P4A1-I1468V-C pEM2P4A1 P4-I1468V-40-5 T7 term 
M2P4A1-I1468A-C pEM2P4A1 P4-I1468A-40-5 T7 term 
M2P4A1-I1468G-C pEM2P4A1 P4-I1468G-40-5 T7 term 
M2P1P--G1491L-C pEM2P1-GL P1-H1345A-5 T7 term 
M2P1P-T--G1491L-C1 pEM2P1-GL P1-H1345A-5 T1-S1937A-3 
M2P1P-T--G1491L-C2 pEM2P1-GL T1-S1937A-5 T7 term 
Pks1P--C pEPks1alt P6-H1330S-5 T7 term 
Pks1P-T--C1 pEPks1alt P6-H1330S-5 T6-S2009A-3 




Appendix Table E.4⏐DNA components used in Gibson assembly reactions of topopyrone synthases. 
Plasmid Part 1 Part 2 Part 3 Part 4 
pEM2P4A1 M2P4A1-N M2P4A1-C pET-24a(+)-NdeI-NotI  
pEM2P1-GL M2P1-G1491L-N M2P1-G1491L-C pET-24a(+)-NdeI-NotI  
pEM2P1-GI M2P1-G1491I-N M2P1-G1491I-C pET-24a(+)-NdeI-NotI  
pEM2P1-GV M2P1-G1491V-N M2P1-G1491V-C pET-24a(+)-NdeI-NotI  
pEM2P1-GA M2P1-G1491A-N M2P1-G1491A-C pET-24a(+)-NdeI-NotI  
pEM2P4A1-IV M2P4A1-I1468V-N M2P4A1-I1468V-C pET-24a(+)-NdeI-NotI  
pEM2P4A1-IA M2P4A1-I1468A-N M2P4A1-I1468A-C pET-24a(+)-NdeI-NotI  
pEM2P4A1-IG M2P4A1-I1468G-N M2P4A1-I1468G-C pET-24a(+)-NdeI-NotI  
pEM2P1P--GL M2P1P--G1491L-N M2P1P--G1491L-C pET-24a(+)-NdeI-NotI  





pEPks1P- Pks1P--N Pks1P--C pET-24a(+)-NdeI-NotI  




E.1.3. Primer Sequences 




























































































E.1.4. Protein Expression Constructs 
Appendix Table E.6⏐Details of chimeric NR-PKS expression constructs used in this study. 
Protein 
Encodes 
Plasmid Vector Tag 
MW 
SAT-KS-MAT PT-ACP-TE (kDa) 
M1P2 PksA (M1–P1304) Pks4 (A1285–N2036) pEM1P2-2 pET-24a(+) C-His 226.6 
M1P3 PksA (M1–P1304) ACAS (S1318–S1771) pEM1P3-2 pET-24a(+) C-His 194.3 
M1P4 PksA (M1–P1304) CTB1 (N1294–S2196) pEM1P4-1 pET-24a(+) C-His 242.6 
M1P5 PksA (M1–P1304) wA (P1286–V2157) pEM1*P5-1 pET-24a(+) C-His 240.2 
M1P6 PksA (M1–P1304) Pks1 (P1290–E2183) pEM1*P6-2 pET-24a(+) C-His 241.8 
M2P1 Pks4 (M1–R1284) PksA (E1305–A2109) pEM2P1-3 pET-24a(+) C-His 228.2 
M2P3 Pks4 (M1–R1284) ACAS (S1318–S1771) pEM2P3-2 pET-24a(+) C-His 190.5 
M2P4 Pks4 (M1–R1284) CTB1 (N1294–S2196) pEM2P4-4 pET-24a(+) C-His 238.8 
M2P5 Pks4 (M1–R1284) wA (P1286–V2157) pEM2P5-2 pET-24a(+) C-His 236.4 
M2P6 Pks4 (M1–R1284) Pks1 (P1290–E2183) pEM2P6-3 pET-24a(+) C-His 238.0 
M3P1 ACAS (M1–P1317) PksA (E1305–A2109) pEM3P1-4 pET-24a(+) C-His 233.1 
M3P2 ACAS (M1–P1317) Pks4 (A1285–N2036) pEM3P2-1 pET-24a(+) C-His 227.7 
M3P4 ACAS (M1–P1317) CTB1 (N1294–S2196) pEM3P4-2 pET-24a(+) C-His 243.7 
M3P5 ACAS (M1–P1317) wA (P1286–V2157) pEM3P5-1 pET-24a(+) C-His 241.3 
M3P6 ACAS (M1–P1317) Pks1 (P1290–E2183) pEM3P6-3 pET-24a(+) C-His 242.9 
M4P1 CTB1 (M1–S1293) PksA (E1305–A2109) pEM4P1-7 pET-24a(+) C-His 227.3 
M4P2 CTB1 (M1–S1293) Pks4 (A1285–N2036) pEM4P2-3 pET-24a(+) C-His 221.9 
M4P3 CTB1 (M1–S1293) ACAS (S1318–S1771) pEM4P3-8 pET-24a(+) C-His 189.6 
M4P5 CTB1 (M1–S1293) wA (P1286–V2157) pEM4P5-1 pET-24a(+) C-His 235.6 
M4P6 CTB1 (M1–S1293) Pks1 (P1290–E2183) pEM4P6-1 pET-24a(+) C-His 237.1 
M5P1 wA (M1–Q1285) PksA (E1305–A2109) pEM5P1-1 pET-24a(+) C-His 228.6 
M5P2 wA (M1–Q1285) Pks4 (A1285–N2036) pEM5P2-1 pET-24a(+) C-His 223.2 
M5P3 wA (M1–Q1285) ACAS (S1318–S1771) pEM5P3-1 pET-24a(+) C-His 190.9 
M5P4 wA (M1–Q1285) CTB1 (N1294–S2196) pEM5P4-1 pET-24a(+) C-His 239.3 
M5P6 wA (M1–Q1285) Pks1 (P1290–E2183) pEM5P6-1 pET-24a(+) C-His 238.4 
M6P1 Pks1 (M1–R1289) PksA (E1305–A2109) pEM6P1-1 pET-24a(+) C-His 228.3 
M6P2 Pks1 (M1–R1289) Pks4 (A1285–N2036) pEM6P2-2 pET-24a(+) C-His 222.9 
M6P3 Pks1 (M1–R1289) ACAS (S1318–S1771) pEM6P3-1 pET-24a(+) C-His 190.6 
M6P4 Pks1 (M1–R1289) CTB1 (N1294–S2196) pEM6P4-2 pET-24a(+) C-His 238.9 




Appendix Table E.7⏐Details of potential topopyrone synthase expression constructs used in this 
study. PT or TE null control constructs for Pks1 are also included. The numbering for point mutations are 
derived from the parent sequence’s numbering scheme and do not reflect the true position of mutation in 
the final chimeric sequence.  
Protein 
Encodes 
Plasmid Vector Tag 
MW 
SKMa Pb AnTc (kDa) 
M2P1 Pks4 PksA PksA pEM2P1-3 pET-24a(+) C-His 228.2 
M2P1-GL Pks4 PksA G1491L PksA pEM2P1-GL pET-24a(+) C-His 228.2 
M2P1-GI Pks4 PksA G1491I PksA pEM2P1-GI pET-24a(+) C-His 228.2 
M2P1-GV Pks4 PksA G1491V PksA pEM2P1-GV pET-24a(+) C-His 228.2 











PksA pEM2P1P--GL pET-24a(+) C-His 228.1 
M2P4A1 Pks4 CTB1 PksA pEM2P4A1 pET-24a(+) C-His 224.8 
M2P4A1-IV Pks4 CTB1 I1468V PksA pEM2P4A1-IV pET-24a(+) C-His 224.8 
M2P4A1-IA Pks4 CTB1 I1468A PksA pEM2P4A1-IA pET-24a(+) C-His 224.7 
M2P4A1-IG Pks4 CTB1 I1468G PksA pEM2P4A1-IG pET-24a(+) C-His 224.7 





Pks1 pEPks1P-T- pET-24a(+) C-His 238.0 
Pks1P- Pks1 Pks1 H1330A Pks1 pEPks1
P- pET-24a(+) C-His 238.0 
a SAT-KS-MAT (SKM) fraction encodes native Pks4 M1–R1284. 
b PT (P) fraction encodes native PksA E1305–A1704 or CTB1 N1294–K1666. 




Appendix Table E.8⏐Details of deconstructed NR-PKS constructs used in this study. Revised 
sequencing number is used for constructs with asterisks. References for the revised sequences are given. 
Protein Encodes Plasmid Vector Tag MW (kDa) 
Pks4 SAT-KS-MAT M1-A1283*[2] pEPks4-NKAn pET-24a(+) C-His 140.8 
PksA PT-G1491L E1305-I1677 pEPT-G1491L pET-24a(+) C-His 42.4 
CTB1 PT-I1468G S1293-I1654 pECTB1-PT-I1468G pET-24a(+) C-His 40.4 
PksA ACP I1677-S1839 pEACP41 pET-28a(+) N-His 20.6 
Pks4 ACP P1631–K1764*[2] pEPks4-ACP pET-28a(+) N-His 16.2 
CTB1 ACP2 S1637–K1909 PECTB1-ACP pET-28a(+) N-His 31.7 
PksA TE D1812-A2109 pETE2 pET-28a(+) N-His 36.4 
Pks4 TE P1765-N2036*[2] pEPks4-TE pET-28a(+) N-His 32.2 
wA TE L1859-V2157 pEwA-TE pET-28a(+) N-His 34.9 
 
E.2. Chemical Characterization of Polyketide Products 
 
Appendix Figure E.2⏐Spectral characterization of YWA1. (a) Extracted ion chromatogram for m/z 





Appendix Figure E.3⏐Spectral characterization of nor-rubrofusarin. (a) Extracted ion chromatogram 
for m/z 259.0607. (b) MS for nor-rubrofusarin. (c) UV spectrum for nor-rubrofusarin. These data are 
consistent with literature values.[3d] 
 
 
Appendix Figure E.4⏐Spectral characterization of isocoumarin 5. (a) Extracted ion chromatogram for 
m/z 235.0607. (b) MS for isocoumarin 5. (c) UV spectrum for isocoumarin 5. These data are consistent 




Appendix Figure E.5⏐Spectral characterization of derailment products SEK4 and SEK4b. (a) 
Extracted ion chromatogram for m/z 319.0818. (b) MS for products SEK4 and SEK4b. (c) UV spectrum for 
products SEK4 and SEK4b. These data are consistent with literature values.[3d] 
 
 
Appendix Figure E.6⏐Spectral characterization of topoketone. (a) Extracted ion chromatogram for m/z 
325.0712. (b) MS for topoketone. (c) UV spectrum for topoketone. 
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E.3. Flaviolin Standard Curve 
 An authentic sample of flaviolin was prepared by Dr. Eric A. Hill (Johns Hopkins 
University, Baltimore, MD, 21218).[4] The area under the 280 nm chromatogram peak for 
flaviolin was used to generate a standard curve for determining flaviolin titers by 
producing strains (Figure E.7). 
 
Appendix Figure E.7⏐Flaviolin standard curve. (a) HPLC 280 nm chromatogram of synthetic flaviolin. 
(b) UV spectrum of synthetic flaviolin. (c) Standard curve for flaviolin. Area under the flaviolin peak from 
280 nm chromatograms are plotted against amount of flaviolin injected. Error bars are the standard 
deviation (n = 3). 
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Appendix F: Supplementary Material to Chapter 5 
F.1. Cloning CTB3 and CTB2 
 Expression constructs were prepared from CTB3 and CTB2. CTB3 was 
deconstructed into monodomain fragments for ease of expression as detailed in Chapter 
5. Specific sequence information relevant to cloning expression constructs for CTB3 and 
CTB2 are detailed in this section. 
F.1.1. Primer Sequences 
Appendix Table F.1⏐Primers used to clone new constructs in this study. Underlined sequence aligns to 
adjacent exon. Bold sequences are introduced restriction enzyme cut sites. Italicized sequences are 






















F.2. Protein Expression Constructs 
 Proteins were expressed and purified as described in Chapter 5. Specific 
characteristics of these proteins are presented in this section. We report here the corrected 
CTB3 sequence. Five corrections were made in the CTB3 nucleotide sequence: A292G, 
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C2038A, G2075A, G2550A, and G2679A. These changes resulted in three in the CTB3 
protein sequence: D635N, G793D, G836E. Large sections of the CTB2 nucleotide 
sequence were corrected. These corrections led to a corrected CTB2 protein sequence 
with a new numbering scheme. The corrected CTB2 sequence showed greater alignment 
with other O-methyltransferases as determined by BLAST. 
Edited CTB3 Nucleotide Sequence from C. nicotianae 
Changes in sequence are in boldface. Changes resulting in changes to 







































Edited CTB3 Protein Sequence from C. nicotianae 

















Edited CTB2 Nucleotide Sequence from C. nicotianae 
Changes in sequence are in boldface. Changes resulting in changes to 






















Edited CTB2 Nucleotide Sequence from C. nicotianae 








Appendix Table F.2⏐Details of expression constructs used in this study. 
Protein Encodes Plasmid Vector Tag MW (kDa) 
CTB3 M1–F871a p28CTB3-3 pET-28a(+) N-His 98.2 
CTB3-MT M1–S433 p28CTB3-MT3-3 pET-28a(+) N-His 50.7 
CTB3-MO D454–F871a pECTB3-MO1-3 pET-24a(+) C-His 47.0 
CTB2 M1–Q462b pECTB2-1 pET-24a(+) C-His 51.8 
a New CTB3 protein sequence as described above. 




Appendix Figure F.1⏐12% SDS-PAGE analysis of proteins used in this study. Lane M: Ladder; 1: 
CTB3; 2: CTB3-MT; 3: CTB3-MO; 4: CTB2. 
 
 
Appendix Figure F.2⏐Analysis of FAD content of CTB3-MO. (a) HPLC analysis of FAD released from 
heat denatured CTB3-MO. (b) HPLC analysis of FAD standard. (c) UV-vis spectra of CTB3-MO (black), 
FAD released from heat denatured CTB3-MO (red), and free FAD (green). 
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F.3. Cercosporin Complementation Assays 
 
Appendix Figure F.3⏐Pairwise complementation assay of C. nicotianae cercosporin biosynthetic gene 
knockout strains. Labels for each row indicate the identity of the top colony on each plate. Labels for each 
column indicate the identity of the bottom colony on each plate. Cercosporin complementation is indicated 
by the presence of a red pigment at the colony–colony interface. Colonies are spaced 0.5, 0.7, and 1.0 cm 
apart, from left to right. 
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F.4. In Vitro Analysis of CTB2 Activity 
 
Appendix Figure F.4⏐Product profiles of in vitro reactions of CTB3 and CTB2. The 280 nm 
chromatograms of the following reactions are displayed: (a) CTB3-MT, CTB3-MO, CTB2 with nor-
toralactone, (b) CTB3-MT, CTB3-MO with nor-toralactone, (c) CTB2 with nor-toralactone, (d) CTB3-MT, 
CTB3-MO, CTB2 with nor-toralactone under reductive conditions, (e) CTB3-MT, CTB3-MO with nor-
toralactone under reductive conditions, (f) CTB2 with nor-toralactone under reductive conditions. 
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F.5. Chemical Characterization of Cercosporin Metabolites 
F.5.1. 1H NMR 
Appendix Figure F.5"1H NMR (400 MHz, CCl3D) of cercosporin (1) purified from C. nicotianae 
(ATCC© 18366™). 
242
Appendix Figure F.6"1H NMR (400 MHz, CCl3D) of nor-toralactone (6) purified from C. nicotianae 
"CTB3c. 
243
Appendix Figure F.7"1H NMR (400 MHz, CCl3D) of toralactone (7) purified from C. nicotianae 
"CTB3c. 
244









Appendix Figure F.10⏐HRMS spectra for cercosporin (1). (a) Extracted ion chromatogram for m/z 
535.1604, and (b) MS, (c) MS/MS for cercosporin. 
 
 
Appendix Figure F.11⏐HRMS spectra for nor-toralactone (6). (a) Extracted ion chromatogram for m/z 
259.0607, and (b) MS, (c) MS/MS for nor-toralactone. 
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Appendix Figure F.12⏐HRMS spectra for toralactone (7). (a) Extracted ion chromatogram for m/z 
273.0763, and (b) MS, (c) MS/MS for toralactone. 
 
 
Appendix Figure F.13⏐HRMS spectra for compound 8. (a) Extracted ion chromatogram for m/z 




Appendix Figure F.14⏐HRMS spectra for cercoquinone A (9). (a) Extracted ion chromatogram for m/z 
277.0712, and (b) MS, (c) MS/MS for cercoquinone A. 
 
 
Appendix Figure F.15⏐HRMS spectra for cercoquinone B (10). (a) Extracted ion chromatogram for m/z 




Appendix Figure F.16⏐HRMS spectra for cercoquinone C (12). (a) Extracted ion chromatogram for m/z 
261.0763, and (b) MS, (c) MS/MS for cercoquinone C. 
 
 
Appendix Figure F.17⏐HRMS spectra for cercoquinone D (11). (a) Extracted ion chromatogram for m/z 





Appendix Figure F.18⏐UV-visible spectra for cercosporin metabolites. The spectra for cercosporin 
(1),[1] nor-toralactone (6),[2] toralactone (7)[3] match those in the literature for these molecules. 
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